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Chapter 1 | Introduction
1Exploring new ways to improve treatment outcome of colorectal liver metastases by studying the behavior of the biological clock in cancer cells and the effects of dietary 
restriction.
Dysregulation of the circadian clock in cancer cells
The biological functions of many organisms display a rhythm with a periodicity of 
approximately 24-hours, called the circadian rhythm. These rhythms are controlled 
by circadian clocks (1). Circadian clocks are present in almost all life forms on earth, 
ranging from single cellular organisms like bacteria and yeast to multicellular organ-
isms like plants, animals and humans. In a simple way, the mammalian circadian clock 
is composed of three components: a master clock (an internal oscillator located in the 
neurons of the suprachiasmatic nuclei, SCN), an input (keeping the clock in phase with 
environmental cues, the light-dark cycle), and an output (coupling the circadian clock to 
different biological processes) (2, 3). Circadian (Latin for “about one day”) rhythms gen-
erated by these clocks have a period of approximately 24-hours, and it is necessary that 
they are synchronized to the environment to meet the exact 24-hour light/dark cycle. 
The synchronization of clocks between body time and solar time is called entrainment 
of the clock and is adjusted every day by light (2). The SCN regulates peripheral clocks 
trough both the autonomic nervous system and neuroendocrine systems. Circadian 
clocks in the SCN neurons as well as in the peripheral clocks make use of the same set 
of clock genes (4).
The circadian clock regulates about 10-15% of the transcriptome and influences diverse 
functions as the rest-activity period, physiological processes, and cellular proliferation. 
Hence, the circadian timing system plays an important role in the development of 
cancer. Disruption of circadian rhythmicity, either genetic or functional may contribute 
to genomic instability and accelerate cellular proliferation, two conditions that favor 
carcinogenesis (5). Recent studies indicate that clock genes influence susceptibility to 
chemotherapeutic agents (6-8). Treatment with chemotherapy usually damages both 
malignant and healthy cells, leading to toxicity and adverse side-effects which is a major 
limitation to their use. Not only susceptibility to the efficacy of chemotherapeutic drugs, 
but also the adverse side-effects may vary over a 24-hours period (7, 9). Chronotherapy 
takes advantage of the fact that there are asynchronies in circadian rhythm between 
normal and cancer tissue, by administering chemotherapy when minimal side effects 
and maximal antitumor effect is anticipated (10). Although the clinical relevance of chro-
notherapy has been demonstrated in randomized multicenter trials, chronomodulated 
therapy is not yet part of daily clinical practice (11-13).
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Dietary restriction induced stress resistance
Dietary restriction (DR) is a non-invasive intervention that prolongs lifespan in a variety 
of model organisms including worms, yeast, fruit flies, mice and rats (14-19). DR can 
be achieved by different regimens including caloric restriction (CR) and fasting. CR is 
defined as a reduction in food intake without causing malnutrition, while fasting is 
abstinence of food, with ad libitum access to water. The fact that DR increases lifespan 
indicates that it slows down the aging process. In 1956, Harman proposed the free radi-
cal theory of aging, which is based on the recognition that metabolic use of oxygen is 
a major source of free radicals (20). DR lowers steady state levels of oxidative stress, 
decreases mitochondrial electron and proton leak, increases bio-energetic efficiency, 
and attenuates damage resulting from intracellular oxidative stress (21-25). A full un-
derstanding of the underlying mechanistic basis of DR is far from complete. However, 
fasting turned out to be a powerful means to increase resistance against acute stressors 
such as oxidative stress. It has been previously shown that preoperative fasting and CR 
protect against acute oxidative damage including ischemia-reperfusion injury in both 
liver and kidney (26-29), surgical trauma (30), heat shock (31), and paraquat toxicity (32). 
Irinotecan is one of the chemotherapeutic agents which has been reported to cause 
high levels of oxidative stress, which will lead to disturbance of normal cellular functions 
in healthy cells and may contribute to severe dose-limiting toxicities (33, 34). Rats that 
were caloric restricted for 35% during 3 weeks were protected against a lethal dose of 
the hepatotoxic compound thioacetamide. CR rats showed 70% survival compared with 
10% in ad libitum fed rats (35, 36). Bleomycin, a cytotoxic drug that is associated with 
DNA damage and oxygen radical production was injected into rats kept on a four week 
40% CR diet and ad libitum control rats. The DNA mutant frequency was higher in ad 
libitum fed- compared to CR rats, indicating that CR reduced mutagenesis to bleomycin 
(37). Importantly, it has been shown that the beneficial effects of CR can be induced 
rapidly by a short-term fasting period. The benefit of fasting above CR is that fasting can 
be induced more rapidly, is non-invasive, and a cost-free method of protecting against 
multiple forms of stress. Three days of fasting and 2-4 weeks of 30% CR both led to a 
similar protection against oxidative damage induced by renal ischemic injury (26). A 
short-term fasting regimen provided complete protection to mice from a high dose of 
the chemotherapeutic agent etoposide. All ad libitum fed animals died within 5 days af-
ter administration of 110 mg/kg etoposide, whereas all fasted animals survived without 
showing visible signs of toxicity (38). Taken together, these findings demonstrate that 
CR and fasting increase stress resistance and protect against the adverse effects of toxic 
agents.
In this thesis we studied two new strategies to improve the chemotherapeutic treat-
ment of colorectal liver metastases. We investigated the behavior of the biological clock 
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Chapter 1 | Introduction
1in a colorectal cancer model in mice, and the potential benefits of a restrictive diet on irinotecan induced side effects. The colorectal model was chosen as this type of cancer 
is one of the main causes of cancer related mortality in western countries.
Aims and outline of the thesis
Chemotherapeutic agents are part of the multimodality approach for treatment in 
patients with CRLM. The associated toxicity is a major limitation to their use, and leads 
to early discontinuation of treatment. Therefore, the aim of the studies described in this 
thesis was to describe two experimental subjects to ameliorate chemotherapeutic treat-
ment in the multi-modality approach of colorectal liver metastases: the impact on the 
circadian clock and dietary restriction.
Chapter 2 gives a systematic review of the literature on the function of the clock gene 
machinery and circadian gene expression in relation to frequently seen abdominal 
cancer types. In chapter 3 we compared the 24-hour expression levels of important 
circadian clock genes in liver and kidney of healthy control mice with those of mice bear-
ing C26 colorectal tumor metastases in the liver. We also investigated clock periodicity in 
kidney and liver tissue in healthy and C26 tumor bearing mice. In chapter 4 we set out to 
translate this to a clinical setting and therefore we studied clock gene expression levels 
in colorectal liver metastases in patients. We compared clock gene expression levels of 
the liver to those of colorectal liver metastases and primary tumors, and related these 
expression levels to clinicopathological factors. In chapter 5 we explored the value of 
dietary restriction and the benefits on chemotherapy associated toxicity. We studied the 
effects of 3-days fasting prior to irinotecan treatment on toxicity and anti-tumor activ-
ity in a FabplCre;Apc15lox/+ mouse model, which spontaneously develops intestinal 
tumors. In chapter 6 we explored the effects of fasting on irinotecan induced toxic-
ity and pharmacokinetics in plasma, liver, and tumor. In chapter 7 we tried to unravel 
the mechanisms of protection induced by fasting and investigated the transcriptional 
responses to fasting and irinotecan treatment in both tumor and healthy liver tissue 
using array analyses. In chapter 8 the results of the studies performed in this theses are 
summarized and discussed.
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Abstract
Circadian clocks impose near (circa) 24-hour (dies) rhythmicity on important cellular 
and physiological functions. The mammalian circadian system is composed of a light-
entrainable central clock in the suprachiasmatic nucleus (SCN) in the hypothalamic 
region, which in turn synchronizes peripheral clocks, present in virtually all other cells 
and tissues. Circadian rhythms are generated by a cell-autonomous molecular oscilla-
tor composed of a set of clock genes that act in positive and negative transcription-
translation feedback loops. Numerous studies have investigated the role of the circadian 
machinery in relation to different types of malignancies. There is mounting evidence 
that circadian genes may play a pivotal role in oncogenesis and prognosis of the disease. 
In this review, we evaluate the expression levels of circadian genes in human abdominal 
cancerous tissue in relation to disease development, prognosis and treatment. Compre-
hensive searches were carried out in multiple databases until February 2016 to search 
for articles regarding expression levels of circadian genes in human tissues. Of the 3571 
studies retrieved, 27 articles fell within the scope of our review. Based on our findings, 
we conclude that the expression levels of the circadian genes are disturbed in malignant 
tissue in comparison to normal tissue. The genes PER1, PER2, and PER3 seem to be con-
sistently down regulated in different types of abdominal cancers. The other clock genes 
show discrepancies in expression levels in different studies. These aberrant expression 
levels between normal and cancerous tissue may serve as biomarkers for prognosis and 
may facilitate chronomodulated cancer therapy.
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Introduction
The circadian clock is an internal time keeping system that imposes temporal organi-
zation to an organisms biological functions and is present in nearly all organisms (1). 
Circadian rhythms have a periodicity of approximately 24-hours (circa diem: about one 
day) and allow an organism to anticipate daily recurring changes in the environment, 
notably the light-dark cycle. In mammals, the circadian system is composed of a master 
clock in the suprachiasmatic nuclei (SCN), located in the hypothalamus, and peripheral 
clocks in virtually all other cells and tissues. To keep pace with the day-night cycle, the 
SCN clock is daily synchronized by light. In turn, the SCN synchronizes the peripheral 
clocks through humoral and neuronal stimuli (2). Circadian rhythms are generated by 
a cell autonomous molecular oscillator, involving transcription-translation feedback 
loops composed of a set of interplaying clock genes and proteins. The maintenance and 
generation of rhythms is similar in the central and the peripheral clocks, although, the 
resulting output pathways can be different and more tissue specific.
The positive branch of the clock machinery consists of the CLOCK (Circadian Locomo-
tor Output Cycles Kaput) and BMAL1 (Brain-Muscle Arnt-Like protein 1) genes. CLOCK 
and BMAL1 are transcription factors that heterodimerise and induce the expression of 
core circadian genes by binding to E-box elements in their promotors. Core circadian 
genes are defined as genes whose protein products are necessary for the generation 
and regulation of circadian rhythms within individual cells throughout the organism 
(3). There are two families of core circadian genes, the period (PER1, PER2 and PER3) 
and cryptochrome (CRY1 and CRY2) families, that encode proteins which translocate 
back to the nucleus to repress their own transcription by acting on the CLOCK/BMAL1 
complex. The core mechanism is more complex than a single autoregulatory loop. 
Several interconnected feedback loops operate in concert (4, 5). BMAL1 is regulated 
by two orphan nuclear receptors: retinoic acid related orphan receptor-α (RORα) and 
REV-ERBα. These proteins are transcription factors that bind to the BMAL1 promotor at 
REV-ERBα and RORα response elements. RORα activates BMAL1 transcription (6), instead 
of REV-ERBα, which inhibits it (7). The interacting positive and negative feedback loops 
of the circadian timing system take approximately 24-hours to complete a cycle and 
are governed by post-translational modification like phosphorylation and ubiquitina-
tion. Casein kinase 1 e.g. plays an important role in phosphorylation by affecting the 
stability of clock proteins (Fig1) (8). The molecular core oscillator is coupled to circadian 
output processes through a series of clock-controlled genes. Some of these genes play 
an essential role in cell-cycle control. CLOCK-BMAL1 directly regulates cell-cycle genes 
such as WEE1 (G2-M transition), TIM and TIPIN (DNA replication), and SERPINE (protease 
inhibition).
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The circadian clock controls physiology, metabolism, and behavior through clock-
controlled genes, which may encompass up to 10-15% of a tissues transcriptome (9-13). 
There is building evidence that disturbances in the expression of these genes may lead 
to disturbances in physiology and behavior which in turn may lead to pathology (14). 
From epidemiological and experimental studies it is known that rotating shift-workers 
face a higher risk of developing cancer (15-18). Altered expression of circadian clock 
genes could have important effects on the transactivation of downstream targets that 
control the cell cycle and on the ability of cells to undergo apoptosis. This may lead to 
genomic instability and accelerated cellular proliferation which promotes carcinogen-
esis (19). Desynchronizing this rhythmicity seems to be implicated in several pathologic 
conditions, including tumorigenesis and progression of cancer (20-23). During the last 
years, human studies have described involvement of the circadian clock in the devel-
opment and progression of specific cancer types. In this systematic review we provide 
an overview of the role of the clock gene machinery and circadian gene expression in 
relation to human abdominal cancer.
Fig.1 Molecular mechanism of the circadian clock.
The core mammalian clock is comprised of the heterodimeric activators CLOCK and BMAL1 that activate 
transcription of E-box genes, including the repressors PERIOD (PER) and CRYPTOCHROME (CRY). An inter-
locked regulatory loop directs alternating activation and repression of BMAL1 expression by the nuclear re-
ceptors RORα and REV-ERBα, respectively, via binding at the ROR enhancer elements (ROREs) in the BMAL1 
promoter.
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Methods
All aspects of the Cochrane Handbook for Interventional Systematic Reviews were fol-
lowed and the manuscript was written according to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement (24).
Literature search strategy
Comprehensive searches were carried out in Embase, Medline OvidSP, CENTRAL (the Co-
chrane Library 2013, issue 10), Web-of-Science, PubMed Publisher and Google Scholar. 
The search was performed for articles published up to February 2016 using terms spe-
cific for each search-engine, provided in the supplemental data.
Inclusion and exclusion criteria
Studies which reported on the expression of circadian genes in specimens of human tis-
sue by real-time quantitative polymerase chain reaction, immunohistochemistry (IHC), 
microarray analysis, or by RNA sequencing were included. Only studies that reported 
expression of circadian genes in abdominal cancers were included. Other cancer types 
were not included. Animal studies, in vivo, in vitro and pharmacological experimental 
studies, letters, conference abstracts and editorials were excluded. Articles not written 
in English were also excluded.
Literature screening
All titles obtained by the search were screened for relevance and all those that were irrel-
evant were identified and discarded. Articles were considered relevant if the expression 
of one or multiple circadian genes were studied in human tissues, according to our in-
clusion criteria. Subsequently studies were evaluated for inclusion by two independent 
researchers (SAH, ARA) for relevance to the subject by screening the abstracts of the 
remaining studies. If necessary, the full texts were obtained and screened for relevance. 
In case of discrepancy, a third author was consulted (RWFdB) to reach consensus.
Results
The systematic search in multiple databases retrieved a total of 3571 articles. Of these, 
27 fell within the scope of the review. Two additional references were added that were 
not included in the search. The up and down regulation of the core circadian genes as 
described in the reviewed studies is shown in table 1. The PRISMA flow diagram for 
systematic reviews is presented in table 2.
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Gastrointestinal tumors
Colorectal cancer
Colorectal cancer (CRC) is the third most common cancer in men and the second most 
common in women. Mortality of CRC is 8.5% of the total mortality caused by all forms 
of cancer (25). Mounting evidence suggests that deregulation of circadian genes play a 
crucial role in tumorigenesis and prognosis of patients with CRC.
Table 2. PRISMA flow-chart of the systematic literature search.
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Mazzoccoli et al. studied the expression levels of core clock genes in tumor tissue and 
healthy mucosa of patients with CRC (26). Expression levels of BMAL1, PER1, PER2, PER3, 
and CRY2 were lower in tumor tissue compared to adjacent healthy mucosa. The expres-
sion levels of TIM were higher in tumor tissue. No significant differences were observed 
for the expression levels of TIPIN, CSNK1, CRY1 and CLOCK. A significant association was 
found between low CRY1 expression levels in the tumor, age, and female sex, whereas 
high CRY1 expression levels in tumor mucosa were associated with cancer location in 
the distal colon. Authors conclude that abnormal expression levels of core clock genes 
in CRC tissue may be related to the process of tumorigenesis and exert an influence on 
host/tumor interactions. In a recent study, the same authors studied expression levels 
of specifically CRY1 and CRY2 in CRC tissue and adjacent normal tissue of 50 patients by 
qRT-PCR. The mRNA levels were significantly lower in CRC tissue. Moreover, low CRY1 
mRNA levels correlated with patients of 62-74 years of age. Also, lower CRY1 mRNA levels 
were found in female patients. Survival was better in CRC patients expressing lower CRY1 
and CRY2 levels in tumor tissue (27). In a study where CRY2 expression was evaluated 
in relation to chemoresistance, authors found that CRY2 overexpression was correlated 
with poor patient survival. They also found in these patients with stage III primary rectal 
cancer, treated with neoadjuvant chemotherapy that CRY2 was overexpressed in che-
moresistant CRC patients (28).
Several studies have been conducted to assess the ability of deregulated circadian 
genes as potential biomarkers for clinical characteristics and prognosis. Mazzoccoli et 
al. found up-regulation of BMAL2 and SERPINE1 in 50 CRC specimens (29). A statistically 
significant association was found between high BMAL2 mRNA levels and vascular inva-
sion, and between high SERPINE1 mRNA levels and microsatellite instability. Sorting the 
subjects into quartile groups, a statistically significant association was found between 
high BMAL2 expression and lymph node involvement, between high SERPINE1 expres-
sion and grading, and between high SERPINE1 expression and micro satellite instability 
(MSI) status.
Yu et al. demonstrated that CRY1 over expression correlates with tumor progression 
and poor prognosis in patients with CRC (30). Clinical pathological analysis showed that 
high CRY1 expression was significantly correlated with lymph node metastasis and the 
tumor/node/metastasis (TNM) stage. Furthermore, high CRY1 expression corresponded 
with poor overall survival in CRC patients. These results suggest that CRY1 is important 
in the development and progression of CRC.
PER2 expression levels in CRC have been determined in 38 human specimens (31). Us-
ing IHC most colorectal cells in non-cancerous tissues were homogeneously stained. In 
contrast, in the cancerous tissue, a heterogeneous pattern was found with a significant 
portion of cancer cells displaying negative or weak PER2 staining. In over 60% of the 
cases, the staining for PER2 was stronger in healthy cells than in the cancerous cells. 
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Furthermore, decreased PER2 levels correlated with younger patients with age no more 
than 50, a higher histological grade, a more advanced TNM stage, and a higher Ki-67 
score. qRT-PCR for PER2 showed similar results. Similar deregulated expression of PER2 
was found in another study (32).
Wang et al. aimed to determine whether PER3 expression was associated with CRC 
incidence number and progression (33). As compared to normal tissue, a 2.8-fold de-
crease in PER3 mRNA levels was observed in cancerous tissue. In addition, altered PER3 
expression was related to multiple clinicopathological factors, including tumor location, 
differentiation, and stage. Furthermore, mortality rates were higher in patients in which 
PER3 was down-regulated in tumor tissue.
An analysis of CLOCK protein and gene expression was performed in 30 cases of CRC 
(34). Higher levels of CLOCK expression was observed in CRC mucosa tissue compared 
with non-cancerous healthy mucosa. CLOCK expression was significantly higher in 
poorly differentiated, or late-stage, Dukes’ grade tumors and in 64.3% of tumor cases 
with lymph node metastasis.
Karantanos et al. evaluated the expression levels of clock genes in 42 CRC patients 
and sought to correlate them with prognosis (35). In cancerous tissue, CLOCK, and 
BMAL1 expression levels were higher, while PER1, and PER3 expression levels were lower 
compared to matched healthy tissue. No difference was observed in the expression 
levels of PER2. Except for the differential clock gene expression levels between tissues, 
no correlations were found with clinicopathological factors or prognosis of the patients. 
Several other studies investigated the role of circadian genes and CRC and their relation-
ship to prognosis. They hypothesized that core clock genes are functionally involved in 
the process of carcinogenesis, and that the relevance of circadian gene expression to 
determine prognosis should be considered in relation to tumor staging (36-41).
In summary, in CRC PER1, PER2, PER3, and CRY2 are down-regulated, and this down 
regulation is associated with poor survival, high tumor staging and development of 
metastasis. CLOCK and CRY1 over expression is correlated with poor differentiation, high 
grading, and lymph node metastasis.
Hepatocellular carcinoma
Hepatocellular carcinoma (HCC) mainly occurs in Asia and Africa. It is the fifth most com-
mon cancer in men (554.000 cases, 7.5% of the total) and the ninth in women (228.000 
cases, 3.4%). Hepatic cancer is the second cause of cancer related deaths worldwide. 
With an overall ratio of mortality to incidence of 0.95, the prognosis is poor (42).
Several studies evaluated the role of circadian genes in HCC. Expression levels of 9 
circadian genes were measured in 46 HCC tissues and paired non-cancerous tissues of 
the liver (43). Decreased expression levels were shown for PER1, PER2, PER3, CRY2 and 
TIM. Lin et al. state that the decreased expression of circadian genes may result in dis-
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turbances of cell cycle, and is correlated with bigger tumor size. These disturbances may 
disrupt the control of the central pacemaker and benefit selective survival of cancerous 
cells and promote carcinogenesis.
The expression of WEE1 kinase, and its correlations to clinicopathological factors has 
been investigated in 26 HCC patients (44). WEE1 is a key regulator of mitosis, and its 
transcription is directly driven by the circadian clock. Reduction of WEE1 could result 
in less mitosis control and therefore faster cell cycling. Using IHC, non-cancerous tis-
sues and cirrhotic tissues did not show any expression of WEE1. WEE1 expression was 
detected in 30% of the HCC samples, and was correlated with higher levels of albumin, 
and prothrombin time. Furthermore, the prognosis was better, and the duration until 
recurrence longer in WEE1-postive HCC patients. It is thought that WEE1 kinase may 
suppress the hyper cell-cycle in HCC at the G2/M phase. WEE1 up-regulation was also 
found in 42 HCC specimens compared with 20 cirrhosis, and 23 normal liver tissues (45). 
In this study however, up-regulated WEE1 expression was correlated with worse tumor 
differentiation and pathological grade.
One of the main functions of casein kinase 1 epsilon (CK1ε) is to regulate circadian 
rhythm by phosphorylation and degradation of PER genes (46). A recent study used IHC 
to examine CK1ε expression in 230 HCC specimens by tissue microarray. It showed that 
low cytoplasmic CK1ε expression was significantly correlated with a decrease in 5-year 
survival. Furthermore, low CK1ε expression correlated with high tumor vascular invasion 
potential (47).
In summary, down-regulated expression of clock genes PER1, PER2, PER3, CRY2 and TIM 
has been found in HCC and is correlated with bigger tumor size and selective survival 
of cancerous cells which may promote carcinogenesis. Two studies found up-regulated 
expression of WEE1 in HCC specimens, but clinicopathological factors were shown to 
be differentially distributed and its significance remains uncertain. Low CK1ε expression 
was correlated with a decreased survival rate.
Pancreatic cancer
Pancreatic cancer has a relatively low incidence rate of 337.872 cases worldwide (2.4% 
of total cancer incidence). However, pancreatic cancer is an aggressive form with a high 
mortality rate of 4.0% of all cancer-related deaths worldwide (42).
Evidence that circadian genes might play a significant role in pancreatic ductal ad-
enocarcinoma (PDA) was published by Pogue-Geile et al. in 2006 (48). In tumor tissues 
of PDA patients, expression levels of circadian (controlled) genes were lower, including 
BMAL1, CLOCK, PER1, PER2, PER3, CRY1, CRY2, TIPIN, TIM, and CKIε. Comparing PDA tumors 
with adjacent normal pancreatic tissue, or benign pancreas specimens like intraductal 
papillary mucinous neoplasms (IPMNs), adenomas, cystadenomas, or epithelial cysts; 
circadian genes were also significantly lower expressed for PER1, PER2, PER3, CRY2, TIPIN, 
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and CKIε. A significant association between low expression levels in tumors and reduced 
survival was found for almost all genes. Higher gene expression levels in benign tis-
sues and matched adjacent tissues may be indicative of their role during the process 
of tumorigenesis. The potential of using circadian genes as predictive markers for the 
outcomes and survival and distinguishing PDA from benign pancreas must be studied 
in larger populations to validate and demonstrate their eventual clinical relevance (49).
In summary, core circadian genes and their downstream effectors were down-regulat-
ed in PDA which may indicate that the peripheral clock is disrupted and that circadian 
genes in healthy tissue act as tumor suppressors.
Renal cancer
Renal cancer has an incidence of 337.860 cases (2.4% of total cancer incidence) with 
a mortality of 143.369 cases (1.7% of total cancer related mortality) worldwide (42). 
Renal cancer is associated with an alteration in pathways regulated by the von Hippel-
Lindau protein and hypoxia inducible factor-α. Hypoxia-inducible transcription factors 
are transcriptional regulators of genes controlling mammalian oxygen homeostasis, 
energy metabolism, neovascularization, internal pH, cell survival, and migration and are 
considered powerful promoters of tumor growth. Tight interrelationships have been 
evidenced between hypoxia response pathways and circadian pathways (50). Severe 
deregulation of genes involved in the circadian clock circuitry and response to hypoxia 
has been found in patients affected by renal cancer, influencing the process of carcino-
genesis, as well as disease progression and outcome.
The clock gene machinery was evaluated in primary renal carcinoma and matched 
adjacent non-cancerous tissues in a cohort of 11 consecutive patients (51). A significant 
down-regulation was found for PER2, TIM and TIPIN. The only up-regulated gene was 
SERPINE1. A statistically significant correlation was found between mRNA levels of PER2 
and CSNKIE, TIPIN, and SERPINE1. Other significant correlations were found between 
TIMELESS, TIPIN, and CSNKIE. Authors concluded that the circadian clock circuitry is de-
regulated and the altered expression of clock genes might be involved in disease onset 
and progression.
In summary, kidney cancer is associated with alteration in the pathways regulated by 
von Hippel-Lindau protein and hypoxia inducible factor-α, which plays an important 
role in interaction with the circadian pathway. A single study shows the dysregulation of 
several key circadian genes in kidney cancer. More research is needed to confirm these 
first findings and determine their clinical significance.
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Discussion
Circadian disruptions may lead to pathology, such as cardiovascular diseases, meta-
bolic disease and behavioral changes. The link between circadian disturbance (e.g. by 
shiftwork and jetlag), and the association with cancer has been demonstrated both 
experimentally (52) and in humans (16, 53). A meta-analysis by Wang et al. estimated 
that the risk increase in breast cancer is 3% for every five year of rotating shift work and 
13% for every 500 night shifts (54). However whether this is caused by disruption of 
the circadian clock or by stress or other factors related to an altered lifestyle is difficult 
to determine and remains controversial (55). Nonetheless mounting evidence suggests 
the pivotal role of the circadian clock in the development and prognosis of cancer (20). 
We have reviewed the expression of circadian genes in abdominal cancers and their 
association with clinicopathological factors. Many studies showed altered expression of 
circadian genes in different abdominal cancer types, however it is difficult to distinguish 
whether the altered expression leads to oncogenesis or whether the process of onco-
genesis leads subsequently to altered clock function. Down-regulation of clock genes 
with tumor suppressor functions as PER1, PER2, and PER3 may enhance oncogenesis and 
up-regulation of TIM and CLOCK are correlated with higher tumor staging, malignant 
tumors and overall poorer survival. These alterations in clock gene expression have a 
direct effect on fundamental biological rhythms, the cell cycle, apoptosis and the DNA 
damage response (56). These disturbances in gene expression can be attributable to 
methylation or hypermethylation of the promotor sites or by structural changes. Aber-
rant expression of these genes or their downstream targets may prevent the cells from 
apoptosis and may even promote cell division by losing cell cycle regulators. The ex-
pression of these genes or the proteins they produce are being explored as biomarkers 
in clinical use for early detection of the disease, tumor staging, tumor aggressiveness 
and the potential of metastasis or as a predictor of survival. In general the majority of 
the studies show similar expression in cancer in terms of down- or up-regulation and 
the relationship with clinicopathological factors. However, whereas some studies show 
elevated expression of specific clock genes, others demonstrate decreased expression 
of the same specific clock genes with different clinicopathological factors. Thus there 
seems to be a discrepancy, which may be explained by a difference in pathways where 
these genes are up- or down-regulated.
To our knowledge this is the first review describing the aberrant expression of circa-
dian genes in human abdominal cancers. This study further strengthens that circadian 
genes play a significant role in carcinogenesis. A major drawback in human studies is 
that all studied samples are surgical resection specimens taken at only one time point, 
and not all resection specimens are collected at the same time.
34
As discussed above the aberrant expression of clock genes in cancer tissue may be used 
to develop novel therapies or be used as biomarkers to assess prognosis of patients. As 
a result of our increased understanding of the circadian system, the term chronotherapy 
was born (57-59). Chronotherapy consists in the administration of medication according 
to biological rhythms and has already proven to be effective. The cellular circadian clocks 
are coordinated by endogenous physiological rhythms, so that they tick in synchrony in 
the host tissues that can be damaged by anticancer agents (60). As a result, circadian 
timing can modify the tolerability of anticancer medications in experimental models 
and in cancer patients and may improve drug tolerability. Conversely, host clocks are 
disrupted whenever anticancer drugs can be administered at their most toxic time. On 
the other hand, circadian disruption accelerates experimental and clinical cancer pro-
cesses. The clinical relevance of the chronotherapy principal has been demonstrated in 
randomized, multicenter trials (60-62). Chronotherapeutic schedules have been used to 
document the safety and activity of oxaliplatin against metastatic CRC and have formed 
the basis for a new approach of management of the disease. Several trials investigating 
the role of chronotherapy have been deployed and used successfully against metastatic 
colon cancer for example (59, 61, 63-66). Kloth et al. investigated the chronopharmacol-
ogy of the orally administrated drug sunitinib, and found that there is variation in phar-
macokinetics of sunitinib dependent on the time of administration. They showed that 
administration in the afternoon or evening resulted in higher plasma concentrations 
(67). Chronotherapy can be a powerful tool to add to our consisting arsenal of cancer 
treatment options. Options to apply chronotherapy on different forms of human cancer 
have been investigated for years now (58, 68). Investigating the circadian machinery 
may also be useful to elucidate some general mechanisms in the development and 
progress of cancer. New technologies such as recent advances in DNA sequencing have 
the potential to shed light on mutations and epigenetic changes in molecular clocks 
and on how human cancer develops (69). Many circadian regulated genes seem to be 
down regulated in cancerous tissue of different types of abdominal cancer. This down 
regulation is most consistently seen in core clock genes like PER1, and PER2. Therefore, 
it is suggested that these genes could serve as biomarkers to determine the patients’ 
prognosis in several abdominal cancer types. However more research is needed in hu-
man cancer specimens to confirm previous findings and fully understand the role of the 
circadian clock in development, treatment, and prognosis of human cancer. Time will 
tell.
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Supplemental Data
Literature search
Embase.com
((‘circadian rhythm’/de AND genetics/exp) OR ‘transcription factor CLOCK’/de OR 
‘transcription factor ARNTL’/de OR ‘molecular clock’/de OR ‘PER1 protein’/de OR ‘PER2 
protein’/de OR ‘cryptochrome 1’/de OR ‘cryptochrome 2’/de OR ‘protein BMAL1’/de OR 
‘casein kinase I’/de OR chronotherapy/de OR ‘circadian rhythm signaling protein’/de OR 
(((circadian OR clock OR rhythm*) NEAR/6 (genetic* OR gene OR expression*)) OR per1 
OR per2 OR per3 OR cry1 OR cry2 OR ARNTLOR ((per OR cryptochrome OR cry) NEXT/1 
(1 OR 2 OR 3)) OR bmal1 OR ‘bmal 1’ OR wee1 OR ‘wee 1’ OR ‘Rev Erb’ OR ‘casein kinase I’ 
OR CKI OR chronotherap*):ab,ti) AND (‘human tissue, cells or cell components’/exp OR 
((human/de OR (human* OR patient*):ab,ti AND (‘cell, tissue or organ culture’/exp OR 
(tissue* OR culture* OR cell*):ab,ti)))) AND (neoplasm/exp OR ((tumo* OR cancer* OR 
carcinom* OR metasta* OR malign* OR carcinogen* OR neoplas*)):ab,ti)
Medline (OvidSP)
(“circadian rhythm”/ge OR “circadian clocks”/ge OR exp “Circadian Rhythm Signaling 
Peptides and Proteins”/ OR exp “casein kinase I”/ OR exp chronotherapy/ OR (((circadian 
OR clock OR rhythm*) ADJ6 (genetic* OR gene OR expression*)) OR per1 OR per2 OR 
per3 OR cry1 OR cry2OR ARNTL OR ((per OR cryptochrome OR cry) ADJ (1 OR 2 OR 3)) 
OR bmal1 OR “bmal 1” OR wee1 OR “wee 1” OR “Rev Erb” OR “casein kinase I” OR CKI OR 
chronotherap*).ab,ti.) AND (((human/ OR (human* OR patient*).ab,ti. AND (exp “Cells, 
Cultured”/ OR (tissue* OR culture* OR cell*).ab,ti.)))) AND (exp neoplasms/ OR ((tumo* 
OR cancer* OR carcinom* OR metasta* OR malign* OR carcinogen* OR neoplas*)).ab,ti.)
Cochrane
((((circadian OR clock OR rhythm*) NEAR/6 (genetic* OR gene OR expression*)) OR per1 
OR per2 OR per3 OR cry1 OR cry2 OR ARNTL OR ((per OR cryptochrome OR cry) NEXT/1 
(1 OR 2 OR 3)) OR bmal1 OR ‘bmal 1’ OR wee1 OR ‘wee 1’ OR ‘Rev Erb’ OR ‘casein kinase I’ 
OR CKI OR chronotherap*):ab,ti) AND ((((human* OR patient*):ab,ti AND ((tissue* OR cul-
ture* OR cell*):ab,ti)))) AND (((tumo* OR cancer* OR carcinom* OR metasta* OR malign* 
OR carcinogen* OR neoplas*)):ab,ti)
Web-of-science
TS=(((((circadian OR clock OR rhythm*) NEAR/6 (genetic* OR gene OR expression*)) OR 
per1 OR per2 OR per3 OR cry1 OR cry2 OR per-1 OR per-2 OR per-3 OR cry-1 OR cry-2 
OR cryptochrome-1 OR cryptochrome-2 OR ARNTL OR bmal1 OR “bmal 1” OR wee1 OR 
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“wee 1” OR “Rev Erb” OR “casein kinase I” OR CKI OR chronotherap*)) AND ((((human* OR 
patient*) AND ((tissue* OR culture* OR cell*))))) AND (((tumo* OR cancer* OR carcinom* 
OR metasta* OR malign* OR carcinogen* OR neoplas*))))
Scopus
TITLE-ABS-KEY(((((circadian OR clock OR rhythm*) W/6 (genetic* OR gene OR expres-
sion*)) OR per1 OR per2 OR per3 OR cry1 OR cry2 OR per-1 OR per-2 OR per-3 OR cry-1 
OR cry-2 OR cryptochrome-1 OR cryptochrome-2 OR ARNTL OR bmal1 OR “bmal 1” OR 
wee1 OR “wee 1” OR “Rev Erb” OR “casein kinase I” OR CKI OR chronotherap*)) AND ((((hu-
man* OR patient*) AND ((tissue* OR culture* OR cell*))))) AND (((tumo* OR cancer* OR 
carcinom* OR metasta* OR malign* OR carcinogen* OR neoplas*))))
PubMed publisher
((((circadian[tiab] OR clock[tiab] OR rhythm*[tiab]) AND (genetic*[tiab] OR gene[tiab] OR 
expression*[tiab])) OR per1[tiab] OR per2[tiab] OR per3[tiab] OR cry1[tiab] OR cry2[tiab] 
OR ARNTL [tiab] OR per-1[tiab] OR per-2[tiab] OR per-3[tiab] OR cry-1[tiab] OR cry-2[tiab] 
OR cryptochrome-1[tiab] OR cryptochrome-2[tiab] OR bmal1[tiab] OR bmal-1[tiab] OR 
wee1[tiab] OR wee-1[tiab] OR Rev-Erb[tiab] OR casein-kinase-I[tiab] OR CKI[tiab] OR 
chronotherap*[tiab])) AND ((((human*[tiab] OR patient*[tiab]) AND ((tissue*[tiab] OR 
culture*[tiab] OR cell*[tiab]))))) AND (((tumor*[tiab] OR tumors*[tiab] OR tumour*[tiab] 
OR cancer*[tiab] OR carcinom*[tiab] OR metasta*[tiab] OR malign*[tiab] OR 
carcinogen*[tiab] OR neoplas*[tiab]))) AND publisher[sb]
Google Scholar
per1|per2|per3|cry1|cry2|ARNTL|”per1|2|3”|”cry1|2”|”cryptochrome1|2”|bmal1|”bmal 
1”|wee1|”wee 1”|”Rev Erb”|”casein kinase I”|CKI ~human tissue|culture|celltumor|tumou
r|cancer|carcinoma|metastasis|malignancy|neoplasm|neoplasms
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Abstract
Circadian clock genes regulate 10-15% of the transcriptome, and might function as tu-
mor suppressor genes. Relatively little is known about the circadian clock in tumors and 
its effect on surrounding healthy tissues. We therefore compared the 24-hour expres-
sion levels of key circadian clock genes in liver and kidney of healthy control mice with 
those of mice bearing C26 colorectal tumor metastases in the liver. Metastases were 
induced by injection of C26 colorectal carcinoma cells into the spleen. Subsequently, 
tumor, liver and kidney tissue was collected around the clock to compare circadian 
rhythmicity. Expression levels of 5 clock genes (Rev-Erbα, Per1, Per2, Bmal1, Cry1) and 
3 clock controlled genes (Dbp, p21 and Wee1) were determined by qRT-PCR. Liver and 
kidney tissue of healthy control mice showed normal 24-hour oscillations of all clock 
and clock-controlled genes, consistent with normal circadian rhythmicity. In colorectal 
liver metastases, however, 24-hour oscillations were completely absent for all clock 
and clock-controlled genes except Cry1. Liver and kidney tissue of tumor-bearing mice 
showed a shift in clock periodicity relative to control mice. In the liver we observed a 
phase advance, whereas in the kidney the phase was delayed. These data show that he-
patic metastases of C26 colon carcinoma with a disrupted circadian rhythm phase shift 
liver and kidney tissue clocks, which strongly suggests a systemic effect on peripheral 
clocks. The possibility that tumors may modify peripheral clocks to escape from ordinary 
circadian rhythms and in this way contribute to fatigue and sleep disorders in cancer 
patients is discussed.
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Introduction
The circadian timing system plays an essential role in the development of cancer. Cancer 
cells carry a similar machinery of increased proliferation rate, reduced apoptotic sensi-
tivity and escaping cell cycle control. These parameters are controlled by the circadian 
clock (1-4).
Circadian rhythms are generated by a molecular oscillator composed of a set of clock 
genes that act in a cell-autonomous way and are present in all cell types. These clocks 
are coordinated by a master clock in the neurons of the suprachiasmatic nuclei (SCN), 
which is located in the anterior hypothalamus (5). Peripheral clocks are regulated by the 
SCN through both the autonomic nervous system and neuroendocrine systems. Clocks 
in the SCN neurons and peripheral cells make use of the same set of clock genes (6). 
The positive branch of the mammalian clock machinery consists of CLOCK (Circadian 
Locomotor Output Cycles Kaput) and BMAL1 (Brain-Muscle Arnt-Like protein 1). CLOCK 
and BMAL1 are transcription factors that heterodimerize and activate transcription of 
the Cryptochrome (Cry1 and Cry2) and Period (Per1 and Per2) genes by binding to E-box 
elements in their promoters. After being synthesized in the cytoplasm, CRY and PER pro-
teins heterodimerize and enter the nucleus where they inhibit CLOCK-BMAL1-mediated 
transcription and accordingly close the negative feedback loop (7). The core mechanism 
is more complex than a single auto regulatory loop. Several interconnected feedback 
loops operate in concert. Bmal1 is regulated by two orphan nuclear receptors: RORα and 
REV-ERBα. These proteins are transcription factors that bind to the Bmal1 promoter at 
REV-ERBα and RORα response elements. RORα activates Bmal1 transcription (8) whereas 
REV-ERBα, inhibits it (9).
This molecular core oscillator is coupled to circadian output processes through a 
series of clock-controlled genes (CCGs). Some of these CCGs play an essential role in 
cell-cycle control. CLOCK-BMAL1 directly regulates cell-cycle genes such as Wee1 (G2-M 
transition), c-Myc (G0-G1 transition), and Cyclin D1 (G1-S transition) (10).
The circadian timing system plays an important role in the development of cancer. 
Genetic or functional disruption of the molecular circadian clock may contribute to 
genomic instability and accelerate cellular proliferation, two conditions that favor car-
cinogenesis (11). The role of circadian dysfunction in tumor development has been well 
documented during the last decades. One of the first discoveries of circadian disruption 
in rodents was seen in mammary tumors (12-14). Subsequently, Fu et al. showed that 
mice deficient in the mPer2 gene are cancer prone after γ-radiation (10, 15). Other animal 
studies were performed comparing disabled circadian clocks with healthy controls which 
showed a higher incidence of spontaneously developing tumors (2, 16). Furthermore, 
mice with SCN ablation or exposure to experimental chronic jetlag showed significantly 
accelerated tumor growth (17). In SCN-lesioned mice, transplanted tumors grow twice 
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as fast as in sham-lesioned animals (18). In chemically induced colorectal tumors using 
azoxymethane (AOM) and dextran sodium sulfate (DSS), daily expression levels of clock 
genes remained mostly coordinated but damped in amplitude. Especially, the rhythm 
of Bmal1 was completely abrogated in colorectal tumors. In the same study a temporal 
shift of clock gene rhythms in the liver of tumor-bearing mice was observed (19).
Down-regulation of Per2 expression increases the proliferation of cancer cells in vitro, 
and stimulates tumor growth in vivo, whereas Per2 over-expression inhibits cell growth 
both in vitro and in vivo (20, 21). The same effects have been observed for Per1 (22). In ad-
dition, Bmal1 and Cry mutant mice show accelerated spontaneous or radiation induced 
tumor development (15). Epidemiological findings of relevance includes several stud-
ies showing that shift workers, flight attendants and pilots are more likely to develop 
malignancies because of their disrupted circadian cycles (23-26). These findings suggest 
that there is a close connection between the circadian organization and development 
of different types of cancer.
The prognosis of almost 60 percent of patients with colorectal cancer (CRC) is wors-
ened by the development of liver metastases (27, 28). Disruption of circadian genes in 
CRC has been reported. The functioning of the circadian clock in Colorectal Liver Me-
tastases (CRLM) remains unclear, and the effect of CRLM on peripheral clocks is not well 
established. In this study we therefore investigated the 24-hour expression levels of key 
circadian clock genes in C26 derived colorectal liver metastases, adjacent liver tissue and 
kidney tissue, and compared them with clock gene expression in healthy control mice.
Materials and methods
Cell culture
The murine colon carcinoma cell line C26 (kindly provided by Dr. R. Schiffelers, Utre-
cht University, the Netherlands) was cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) (Sigma Aldrich, St. Louis, MO, USA), supplemented with 10% fetal calf serum 
(Lonza, Verviers, Belgium), penicillin (100 units/ml) and streptomycin (100 units/ml) 
(Invitrogen, Auckland, NZ) at 37 degrees Celsius in a 5% carbon dioxide environment. 
Cells were harvested by brief trypsinization (0.05% trypsin in 0.02% ethylenediamine 
tetra-acetic acid (EDTA)). Cell suspensions were prepared to a final concentration of 5.0 
× 103 cells/ml.
Animals
Male BALB/c mice of 6-8 weeks weighing approximately 25 grams were obtained from 
Charles River, Maastricht, the Netherlands. Upon arrival, animals were housed at random 
in individually ventilated cages (n= 3-4 animals/cage) in a licensed biomedical facility 
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at Erasmus University Medical Center, Rotterdam, the Netherlands. Standard laboratory 
conditions were maintained, i.e. temperature ~22ºC, humidity ~50%, and a 12 hr light/12 
hr dark cycle. All mice had free access to water and food (Special Diet Services, Witham, 
United Kingdom). Animals were allowed to acclimatize for one week before the start of 
the experiments. The experimental protocol was approved by the Animal Experiments 
Committee under the Dutch National Experiments on Animals Act, and complied with 
the 1986 directive 86/609/EC of the Council of Europe.
Intrahepatic tumor growth
Mice were anaesthetized with isoflurane inhalation (2%) and placed on a heating pad to 
maintain their body temperature. A left lateral incision was made to expose the spleen. 
Next, 5.0 × 104 C26 colorectal carcinoma cells (resuspended in PBS in a volume of 100 
μl) were injected into the spleen, allowing transport to the liver through the portal vein 
where they develop into intrahepatic micro-metastases. After 10 minutes, the spleen 
was removed to prevent intrasplenic tumor growth. In control animals, the spleen was 
not removed. An additional experiment comparing splenectomized mice with control 
animals revealed no differences in clock gene expression (Fig1). There were no differ-
ences in handling and tissue sampling between the groups.
Experimental setup
To compare the performance of the circadian clock in different tissues, mRNA expression 
levels of clock genes were determined at six time points (08.00h, 12.00h, 16.00h, 20.00h, 
0.00h, 04.00h, corresponding to Zeitgeber Time ZT0, ZT4, ZT8, ZT12, ZT16 and ZT20, in 
which ZT0 represents “lights on”). Three weeks after tumor inoculation, macroscopically 
visible tumor noduli were present, and the 24-hour time point experiment was started. 
At each time point, four mice were sacrificed by exsanguination under anesthesia with 
isoflurane inhalation. Liver and kidneys were removed, and the hepatic tumor load was 
scored on a semi-quantitative macroscopic tumor load scale ranging from 0-3 (0: no 
macroscopic tumor, 1: 1-30% of liver surface covered by tumor nodules, 2: 31-70% of 
liver surface covered by tumor nodules, 3: 71-100% of liver surface covered by tumor 
nodules). Once tumor-free liver tissue and tumor tissue were identified, small pieces 
of both were immediately snap frozen in liquid nitrogen until analysis. We used tumor 
tissue from the viable tumor border where no necrotic cells were present. At the ZT12, 
ZT16 and ZT20 time points, animals were sacrificed in dark using red light to prevent in-
fluence on the circadian clock. To study the circadian rhythm of healthy liver and kidney, 
age matched mice without tumor inoculation were used.
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Real-time quantitative RT-PCR (qRT-PCR)
RNA was isolated from all obtained tissues using Trizol reagent (Invitrogen, Carlsbad, 
CA, USA) according to the manufacturer’s instructions. To avoid genomic DNA con-
tamination, RNA was purified by a DNAse treatment (RQ1 RNase-Free DNase; Promega, 
Madison, WI, USA). RNA was then reverse transcribed into cDNA using random primers 
(Invitrogen) and Superscript II RT (Invitrogen). Gene expression was analyzed by real-
time quantitative PCR using an Applied Biosystems 7700 PCR machine (Foster City, CA, 
USA). RT-PCR was performed for 5 core clock transcripts: Bmal1, Rev-Erbα, Per2, Per1, Cry1 
and 3 clock-controlled genes: Dbp, p21 and Wee1 (for primer sequences see table 1). 
Each sample was tested in triplicate.
Normalization of RT-PCR data using multiple internal control genes
Because different tissue types were used, a stringent method was applied to identify the 
most stable internal control genes. We selected four RNA samples from different liver 
tissues, and four tumor samples from different animals taken at different time points. 
Primers were designed for 12 commonly used housekeeping genes: Ywhaz, Actb, Tbp, 
Table 1: Primer sequences of clock genes and housekeeping genes.
Clock gene Forward primer Reverse primer
Per1 CTGGGGACCAGGTCATTAAGT CACACACGCCATCACATCAA
Per2 CCATCCACAAGAAGATCCTAC GCTCCACGGGTTGATGAAGC
Rev-erbα AGCTCAACTCCCTGGCACTTAC CTTCTCGGAATGCATGTTGTTC
Dbp ACCGTGGAGGTGCTAATGAC CCTCTTGGCTGCTTCATTGTT
Bmal1 GCAGTGCCACTGACTACCAAGA TCCTGGACATTGCATTGCAT
p21 GAGCAAAGTGTGCCGTTGTC GGTTGGAGACTGGGAGAGG
Cry1 CAGACTCTCGTCAGCAAGATG CAAACGTGTAAGTGCCTCAGT
Wee1 GCTGGAGAAAATTGGTTCTGGA CTCAAAGCATTCTGCTCATCAAC
Housekeeping gene Forward primer Reverse primer
Ywhaz ACGGAGCTGCGTGACATCTG GCAACCTCGGCCAAGTAACG
Actb GACCCAGATCATGTTTGAGACC GATGGGCACAGTGTGGGTGAC
Tbp CCTGCCACACCAGCTTCTGA AAGTGCAATGGTCTTTAGGT
Rpl13a GGTGGTGGTCGTACGCTGTG TCATCCGCTTCCGGAGAAAG
18s GATCCCTGAGAAGTTCCAGCACA TGTCTGCTTTCCTCAACACCACA
CypA CATGGCAAATGCTGGACCAA CCAAAACGCTCCATGGCTTC
Gapdh CATCCTGCACCACCAACTGC ACGCCACAGCTTTCCAGAGG
Hprt AAGCAGTACAGCCCCAAAATGG CCAACAAAGTCTGGCCTGTATCC
Ubc AAGGTCAAACAGGAAGACAGACGTA CATCACACCCAAGAACAAGCACA
SdhA TACGCACCTGTTGCCAAGGA GGCCACAGCCTCTTCCTTCA
B2m TCACTGACCGGCCTGTATGC GAGGCGGGTGGAACTGTGTT
Hmbs GTGCCATTGTCCTGGCTGTG TGCATTCCTCTGGGTGCAAA
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Rpl13a, 18S rRNA, CypA, Gapdh, Hprt, Ubc, SdhA, B2M and Hmbs (for primer sequences 
see table 1). The 8 RNA samples were tested using a gene-stability measure developed 
by Vandensompele et al (29). This measure relies on the principle that the expression 
ratio of two ideal internal control genes is identical in all samples. All samples were 
tested in triplicate. The most stable housekeeping genes were identified with the use 
of a Microsoft Excel-based Visual Basic Application, geNorm (v3.5) (provided by Dr. J. 
Vandesompele, Ghent University Hospital, Belgium) that automatically calculates the 
gene-stability measure “M” for all control genes. The most stable housekeeping genes 
proved to be TATA-binding proteins (TBP), YWHAZ and beta-actin (ACTB). For accurate 
averaging of the control genes, the geometric mean was used.
Statistical analyses
For each set of parameters means and standard errors of the mean were computed. 
To detect circadian oscillation, CircWave v1.4 was used. CircWave software is using the 
cosinor analyses in addition with a linear harmonic regression fit (30). A rhythm was 
present when the null hypothesis was rejected by p < 0.05. Multiple-way analyses of 
variance (ANOVA) was used to test three variables 1) an overall difference between tis-
sues, 2) a possible overall difference among time points and 3) the interaction between 
the two. We report a significance level for the interaction to show a possible significant 
difference between measured expression through time. All standard statistical tests 
were performed using SPSS 21 for Windows software (Statistical Package for Social Sci-
ences, Chicago, IL), and p < 0.05 was considered to be significant.
Results
Hepatic tumor load
Three weeks after intrasplenic injection of 5.0 x 104 tumor cells (n=24 mice), animals 
were taken from the experiment at 4 hour intervals (n=4 per time point) and hepatic 
tumor load was assessed using a macroscopic tumor load score as described. The mu-
rine colon carcinoma cell line C26 forms multiple tumors in the liver after intrasplenic 
injection (31). Four mice had a tumor load 1, 6 mice a tumor load 2 and 14 mice a tumor 
load 3 (Fig2). We did not observe major differences in hepatic tumor load between dif-
ferent time points (p>0.05). In all animals multiple tumors were observed which allowed 
adequate sampling of tumor tissue. No tumors were found in kidney tissue.
Gene expression of core clock genes
To compare circadian gene expression in liver tissue and colorectal liver metastases, we 
analyzed mRNA expression levels over a time course of 24 hours in samples of liver and 
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tumor tissue by qRT-PCR. In tumor-free liver tissue from tumor bearing mice the cosinor 
analysis showed circadian rhythms on the mRNA level of all core clock genes, except for 
Per1 (Table 2A). As expected, the expression profile of Bmal1 shows an opposite phase 
as compared to the other (E-box promoter containing) core clock genes, particularly 
Rev-Erbα and Per2. Since BMAL1 is highly expressed during the dark phase of the day, 
it will together with CLOCK induce the transcription of the other core clock genes. REV-
ERBα represses the transcription of Bmal1, after ZT4, when Rev-Erbα is highly expressed.
In colorectal liver metastases, the cosinor analysis showed the absence of circadian 
rhythms of all core clock genes, except Cry1 (p<0.01; Table 2A). The ANOVA analysis 
revealed significant differences in expression between liver metastases and tumor-free 
liver for Bmal1 (p<0.001), Rev-Erbα (p<0.001) and Cry1 (p<0.05). No circadian rhythm 
was observed for Per2 using the cosinor analysis and, ANOVA showed no significant dif-
ference between tumor-free liver and liver metastases (p=0.2). Moreover, there was no 
statistical difference in Per1 expression (Fig3).
In conclusion, circadian rhythms were detected in tumor-free liver tissue from tumor 
bearing mice for Bmal1, Rev-Erbα, Cry1 and Per2. Colorectal liver metastases showed no 
circadian rhythms for Bmal1, Rev-Erbα, Per2 and Per1.
Gene expression of clock-controlled genes
Next, we measured the expression of the clock-controlled genes Dbp, Wee1 and p21 to 
determine whether the clock machinery provides output in colorectal liver metastases 
and tumor-free liver (Fig4). Using cosinor analysis, Dbp, Wee1 and p21 were shown to be 
rhythmically expressed in tumor-free liver (Table 2B).


	



	



	












Figure 2. Tumor load. Three weeks after the induction of hepatic metastases, there were 4 mice with tumor 
load 1, 6 mice with tumor load 2 and 14 mice with tumor load 3 (n=24). On average mice had the same 
tumor load per time point (2.42 ± 0.16 per time point; p>0.05).
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Figure 3. Circadian mRNA expression of core clock genes in colorectal liver metastases (○) and tu-
mor-free liver (●). The relative mRNA expression of each gene of interest was normalized to Tbp, Ywhaz 
and Beta-actin. Each point represents the mean of 4 mice (±SEM). The sampling circadian times (ZTs) are 
relative to the time of light onset, ZT0. White rectangles indicate daily light span (ZT0 – ZT12) and black 
rectangles indicate nightly dark span (ZT12 – ZT20). P value indicates significance between liver metastases 
and tumor-free liver using multiway ANOVA analysis.
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Figure 4. Circadian mRNA expression of clock-controlled genes in colorectal liver metastases (○) and 
tumor-free liver (●). The relative mRNA expression of each gene of interest was normalized to Tbp, Ywhaz 
and Beta-actin. Each point represent the mean of 4 mice (±SEM). The sampling circadian times (ZTs) are 
relative to the time of light onset, ZT0. White rectangles indicate daily light span (ZT0 – ZT12) and black 
rectangles indicate nightly dark span (ZT12 – ZT20). P value indicates significance between liver metastases 
and tumor-free liver using multiway ANOVA analysis.
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In liver metastases, Dbp mRNA levels are strongly reduced (almost zero) and not 
oscillating (Table 2B). ANOVA analysis revealed significant differences between liver 
metastases and tumor-free liver for Dbp (p<0.001) but not for Wee1 and p21. In contrast 
to Dbp, Wee1 and p21 showed small amplitude oscillations. However, using cosinor 
analyses tumor tissue showed only a circadian rhythm for Wee1 (p<0.05; Table 2B). The 
mRNA expression levels of clock-controlled genes are explicitly lower in liver metastases 
compared to tumor-free liver. In summary, in line with the rhythmic clock gene expres-
sion in tumor-free liver, circadian rhythms have been observed for Dbp, Wee1 and p21 
gene expression while, surprisingly, in the absence of an active core oscillator Wee1 
remains rhythmically expressed in liver metastases.
Clock gene expression in liver tissue of tumor bearing mice and healthy 
controls
To determine the effect of liver tumors on the circadian rhythm of the liver, we compared 
tumor-free liver of tumor bearing mice with the liver of healthy control mice for clock 
gene expression patterns. In the liver of healthy controls, circadian rhythms were ob-
served for all core clock genes and clock-controlled genes that were tested (Table 2C). 
Interestingly, in tumor bearing liver a phase advance was found for Rev-Erbα and Dbp 
(approximately 2.75 h), Bmal1 (1.5 h), Cry1 (1.2 h), and Per2 (0.5 h) while clock-controlled 
Wee1 and p21 showed similar phase as in healthy control livers (Fig5, Table 2C). Since 
there is no circadian rhythm observed in tumor bearing liver tissue for Per1, it is not 
possible to compare this with the rhythm found in healthy control mice. Cosinor analysis 
showed circadian rhythms for all genes in healthy control livers (Table 2C).
Clock gene expression in the kidney
To determine whether the presence of tumor in the liver affects clocks in peripheral tis-
sues (systemic) other than the liver (local), we measured circadian rhythmicity in kidneys 
of mice with liver metastases as well as in healthy controls. Again, circadian rhythmicity 
was detected for all clock- and clock-controlled genes (Fig6, Table 2D). Cosinor analysis 
showed a circadian rhythm in the kidneys of liver-tumor-bearing-mice as well in the 
kidneys of healthy controls (Table 2D). Phase delays of circadian oscillation were ob-
served for all measured genes ranging from -0.1 h for p21 expression to -4.8 h for Per2 
expression (Table 2D). Interestingly, Per1, Wee1 and p21 showed less robust differences 
between tumor bearing mice and healthy controls (Fig6; Table 2D). Thus, in the kidney 
we observed a phase delay whereas in the liver we found a phase advance in tumor 
bearing mice.
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Figure 5. Clock gene expression in healthy and tumor bearing liver. Graphs represent percentages 
of relative mRNA expression where the highest value is set to 100% to compare results between healthy 
control liver (□) and tumor-free liver (●). Each point represent the mean of 4 mice (±SEM). The sampling 
circadian times (ZTs) are relative to the time of light onset, ZT0. White rectangles indicate daily light span 
(ZT0 – ZT12) and black rectangles indicate nightly dark span (ZT12 – ZT20).
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Figure 6. Clock gene expression in healthy kidney and in kidney from mice bearing liver metastases. 
Graphs represent percentages of relative mRNA expression where the highest value is set to 100% to com-
pare results between healthy control kidney (□) and kidneys from mice bearing colorectal liver metastases 
(●). Each point represent the mean of 4 mice (±SEM). The sampling circadian times (ZTs) are relative to the 
time of light onset, ZT0. White rectangles indicate daily light span (ZT0 – ZT12) and black rectangles indi-
cate nightly dark span (ZT12 – ZT20).
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Discussion
The experiments presented here show that the circadian clock in C26 colorectal liver 
metastases is disrupted. We also observed a phase shift of the clock in healthy areas of 
the liver and in kidney tissue of tumor bearing animals. The circadian alterations are most 
pronounced in the tumor tissue obtained from our C26 liver metastatic tumor model. 
Core clock genes like Bmal1, Rev-Erbα and Cry1 show a significant reduction in expres-
sion, absence of circadian rhythm, and reduction in circadian output, as demonstrated 
by a significant depression of Dbp gene expression in colorectal liver metastases. Other 
clock-controlled genes that regulate the cell cycle were deregulated as well. The expres-
sion of Wee1, a key regulator of mitosis, was severely repressed in the tumor compared 
to tumor-free liver. Wee1 transcription is directly driven by the circadian timing system, 
as shown by low Wee1 expression in Clock-mutant mice(4). Reduction of Wee1 could 
result in less mitosis control and therefore faster cell cycling. For the CDK inhibitor p21, 
there were no statistical differences in mRNA expression levels.
To our knowledge, this is the first study that reveals changes in daily circadian rhyth-
micity in colorectal liver metastases, and shows that the presence of these metastases 
induces a circadian phase shift. In the liver a phase advance was observed whereas in 
the kidney a phase delay was found, suggesting that this is a systemic effect. In healthy 
control animals, the transcription of clock genes Bmal1, Rev-Erbα, Per1, Per2 and Cry1 
varied largely as a function of circadian time in the liver. Peak times and amplitudes are 
consistent with those presented in previous reports (9, 10, 32). The expression of BMAL1, 
the transcription factor that heterodimerizes with CLOCK to drive the expression of 
genes, was completely disrupted in liver metastases, but showed normal 24- hour gene 
expression in tumor-free liver tissue. The perturbation in the tumor is in accordance with 
previous findings where Bmal1 was also disrupted in a C26 colon carcinoma (33). The 
low expression of Bmal1 in the tumor indicates that the core mechanism of the clock 
is less active. This is supported by the fact that other core clock genes as well as clock 
controlled genes show a lower expression in the tumor. In osteosarcoma bearing mice, 
circadian amplitudes were also dampened in the tumor compared to liver tissue (32).
While Per2 did not oscillate in the tumor according to the cosinor analyses, there was a 
significant difference in expression level in time. This could be explained by the fact that 
Per2 expression is not only controlled by the circadian clock, but also food driven in the 
liver. In the liver of Cry1-/-/Cry2-/- mice under restricted (i.e. daytime) feeding conditions, 
Per2 mRNA expression levels increase immediately after food intake (34). Postprandial 
rise in body temperature may activate Per2 transcription via Heat Shock Factor (HSF) 
binding to cis-acting elements in the Per2 promoter (35). The time of Per2 induction be-
tween ZT 8 and 12 coincides with feeding activity, which underscores the food induced, 
rather than circadian induced Per2 activity.
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We found a phase advance in tumor-free liver tissue compared to healthy control livers 
for Bmal1, Rev-Erbα, Cry1 and Dbp mRNA rhythms. Remarkably, in the kidneys from these 
tumor-bearing mice we found a phase delay for Bmal1, Rev-Erbα, Per2, Cry1 and Dbp. 
This phase shift can be caused by different processes regulated systemically via the SCN 
or locally by the tumor itself. Tumor cells secrete a plethora of mediators such as TGF-β 
that is able to modulate the circadian clockwork by activating the ALK-SMAD3-DEC1 
pathway. Activation of this pathway induces Dec1 expression and resets the peripheral 
clock in vivo. Injection of TGF-β was shown to induce a phase shift in kidney and adrenal 
gland tissue. In the same study, it was shown that the phase-shifting effect of TGF-β was 
absent in Dec1-/- mice. Variation in TGF-β levels in peripheral tissues can provide phase 
shifts in different directions, both advanced and delayed (36). TGF-β could activate dif-
ferent pathways to entrain peripheral clocks. This might be a manner of the tumor to 
manipulate surrounding cells and escape from the natural tumor suppressive effect of 
the circadian clock. Alternatively, the phase shifts could be caused by other cytokines 
produced by host cells secondary to tumor invasion, that signal to the central nervous 
system via the SCN. For example, elevated levels of transforming growth factor-alpha 
(TGF-α) and IL-6 were correlated with altered behavior and dampened 24-hour rest-
activity patterns in patients with metastatic colorectal cancer (37). In an animal model, 
micromolar infusion of TGF-α into the hypothalamic subparaventricular zone blocks 
signaling from the SCN. In this way hypothalamic signaling for the circadian regulation 
of i.e. sleep, motor activity and body temperature was impaired (38).
Cancer-related fatigue is one of the most prevalent symptoms experienced by cancer 
patients and is reported by as many as 40% of patients at time of diagnosis. It is not only 
highly prevalent, but also affects the patient’s quality of life and daily activities in a nega-
tive way (39). There is a great lack in understanding cancer-related fatigue. Disruption of 
circadian rhythms in cancer patients has been documented mainly via salivary cortisol 
and locomotor activity (40). In a recent trial, patients received first-line chemotherapy 
for metastatic colorectal cancer, to identify toxic symptoms associated with circadian 
disruption. Patients with an impaired circadian function, showed a higher incidence 
of clinically relevant fatigue and weight loss (41). It may well be that the phase shifts 
observed in our study also occur in cancer patients, and provide a mechanistic basis to 
understand cancer-related fatigue.
In this experimental study we show a disrupted circadian clock in colorectal liver 
metastases, while liver and kidney still show circadian output. These results could sup-
port the hypothesis that the host circadian timing system is a target for tumor-related 
substances, also used in the field of chronotherapy. One of the first experimental studies 
in this field of research was performed by treating mice with 5-FU at different times of 
the day, showing that circadian timing of chemotherapy administration influences both 
toxicity and anti-tumor activity in mice (42). In more recent studies it has been shown 
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that chronotherapy in combination with highly toxic hepatic arterial infusion is feasible, 
well tolerated and resulted in a doubling of secondary surgical resection rate in patients 
with colorectal liver metastases (43, 44).
In a recent study by Sotak and coworkers, azoxymethane (AOM)/dextran sodium 
sulfate (DSS) induced colorectal tumors showed significantly reduced circadian mRNA 
expression levels compared with healthy colon tissue. Subsequent analysis of the liver, 
where AOM is primarily metabolized, revealed a temporal phase delay for Bmal1, Rev-
Erbα, Dbp and Wee1 mRNA rhythms in AOM treated mice (19). Whether this phase shift 
is the result of the AOM treatment or induced by the colon tumor itself could not be 
determined. We show that the presence of C26 colon carcinoma metastases in the liver 
induces a phase advance in the adjacent liver tissue. These discrepancies in phase shifts 
could be explained by major differences in experimental models. Sotak and coworkers 
used a different mouse strain, older mice and induced cancer chemically by AOM treat-
ment.
In summary, the present study shows for the first time that the core clock machinery is 
severely disrupted in a murine colorectal liver metastases model, and results in reduced 
expression levels of output genes such as Dbp. We also show that the presence of a 
tumor in the liver induces a phase shift in liver and kidney tissue clocks, strongly sug-
gesting that this is a systemic effect. How these perturbations are involved in tumor 
progression and cancer related fatigue remain intriguing questions to be answered.
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Abstract
The circadian timing system controls about 10-15% of the transcriptome, and is impor-
tant in the regulation of a wide variety of biological processes including metabolic and 
proliferative functions. Disruption of the circadian clock could have significant effect 
on human health, and has an important role in the development of cancer. Here, we 
compared the expression levels of core clock genes in primary colorectal cancer (CRC), 
colorectal liver metastases (CRLM), and liver tissue within the same patient. Surgical 
specimens of 15 untreated patients with primary CRC and metachronous CRLM were 
studied. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to 
measure the expression of 10 clock genes: CLOCK, BMAL1, PER1, PER2, PER3, CRY1, CRY2, 
CSNK1E, Timeless (TIM), and timeless interacting-protein (TIPIN). Expression levels of 7 
core clock genes were down-regulated in CRLM: CLOCK (p=0.006), BMAL1 (p=0.003), PER1 
(p=0.003), PER2 (p=0.002), PER3 (p<0.001), CRY1 (p=0.002), and CRY2 (p<0.001). In CRC, 
5 genes were down-regulated: BMAL1 (p=0.02), PER1 (p=0.004), PER2 (p=0.008), PER3 
(p<0.001), and CRY2 (p<0.001). CSNK1E was up-regulated in CRC (p=0.02 ). Related to 
clinicopathological factors, a significant correlation was found between low expression 
of CRY1 and female gender, and low PER3 expression and the number of CRLM. Our data 
demonstrate that the core clock is disrupted in CRLM- and CRC tissue from the same 
patient. This disruption may be linked to altered cell-cycle dynamics and carcinogenesis.
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Introduction
The circadian timing system controls important biological processes, including meta-
bolic and proliferative functions (1-3). The rhythmic behavior of these processes takes 
approximately 24 hours and is called circadian rhythm (rhythms of approximately one 
day). The circadian clock consists of a master oscillator which is located in the neurons 
of the suprachiasmatic nuclei (SCN) in the anterior hypothalamus of the brain (4-6). The 
master circadian oscillator coordinates peripheral circadian clocks through both the 
autonomic nervous system and neuroendocrine systems in most cells of the body (7). 
Peripheral circadian oscillators all consist of the same set of clock genes, but regulate 
their expression in a tissue specific way (8).
The human molecular clock system involves a set of core clock genes that act in 
transcription-translation feedback loops. The primary feedback loop consists of CLOCK 
(Circadian Locomotor Output Cycles Kaput) and BMAL1 (Brain-Muscle Arnt-Like protein 
1) which heterodimerize and subsequently activate transcription of the Cryptochrome 
(CRY1 and CRY2) and Period (PER1, PER2, and PER3) genes by binding to E-box elements 
in their promoters. The PER and CRY proteins translocate to the cytoplasm where PER 
proteins are phosphorylated by CKIε. Phosphorylated PER proteins are unstable and are 
degraded by ubiquitination. CRY proteins promote the formation of PER/CRY complexes 
and re-enter the nucleus, where they inhibit the transcription of their own genes by 
blocking CLOCK/BMAL1. This molecular core oscillator is coupled to circadian output 
processes through a series of clock-controlled genes (CCGs), which together regulate 
about 10-15% of the transcriptome (9, 10).
Perturbations in the function of circadian clock genes may have significant effects 
on human health, and may cause sleep disorders, depression, and gastrointestinal and 
cardiovascular diseases. Furthermore, the circadian timing system plays an important 
role in the development of cancer. Epidemiological studies have demonstrated that 
circadian disruption in shift-workers increases the risk of various epithelial cancers (11-
14). An important part of the cell cycle is regulated by the circadian clock. CLOCK/BMAL1 
directly regulates cell-cycle genes that control cell proliferation, DNA damage, and 
apoptosis. These CCGs include Wee-1, c-Myc, and Cyclin D1. Disruption of the circadian 
timing system may lead to a deregulated cell cycle which favors carcinogenesis (15).
It has been demonstrated that inhibition of Per1 caused reduced apoptosis in HCT116 
colon cancer cells, while overexpression of Per1 leads to DNA damage-induced apoptosis 
(16). Inactivation of Per2 caused deregulation of Bmal1 expression which contributed to 
a high incidence of tumor formation. In addition, mice deficient in Per2 showed an in-
crease in tumor formation after γ-radiation (17). Recently we showed that the core clock 
machinery is severely disrupted in murine colorectal liver metastases (CRLM) and that the 
presence of tumor in the liver induces a phase-shift in liver and kidney tissue clocks (18).
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In humans, CRLM worsen the prognosis of almost 60% of patients with colorectal 
cancer (19). In animal models the core clock machinery is disrupted in several types 
of cancer. The functioning of the circadian clock in patients with CRLM has remained 
unclear. A better understanding of how tumors affect the circadian clock may help elu-
cidate the role of the clock in cancer patients. We therefore investigated the expression 
levels of core clock genes in human CRLM tissue, adjacent liver tissue, and the primary 
colorectal tumor. Furthermore, we related the expression levels to clinicopathological 
factors in these patients.
Material and Methods
Patients
Surgical resection specimens of the primary colorectal tumor, liver metastases, and ad-
jacent normal liver tissue were obtained from 15 CRLM (male: 8, female: 7) patients who 
did not receive neo-adjuvant chemotherapy treatment. The patients underwent surgery 
at the Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The 
Netherlands between January 2005 and January 2012. Clinical data including tumor 
characteristics of these patients are shown in Table 1. All operations started between 
8:00 AM and 11:00 AM and mean time patients were in the operation room was 3.30h. 
All tissues were collected between 09:00 AM and 13:30 PM and immediately frozen into 
liquid nitrogen and stored at -80ºC until further analysis. Informed consent was obtained 
from all patients and the study was approved by the Ethics Committee at our institution.
Sampling procedure
All surgical resection specimens from primary colorectal tumor, liver metastases, and 
adjacent normal liver tissue were first macroscopically, than microscopically identified 
by an experienced pathologist. Frozen resection specimens were retrieved from the ar-
chives of the pathology department and at least 1 cm in diameter of viable tumor tissue 
was included using a frozen tissue slicer (Leica CM1850 UV, Leica Biosystems). There was 
no admixture of stromal tissue and no necrosis was identified in the included samples. 
Tumor characteristics are shown in Table 1.
Fresh frozen tissue, RNA extraction, and cDNA synthesis
RNA was isolated from all tissues by phenol extraction using Trizol reagent (Invitro-
gen, Carlsbad, CA, USA) according to the manufacturer’s instructions. The amount of 
extracted RNA was measured by Nanodrop Spectrophotometry (Nanodrop Technol-
ogy, Wilmington, DE, USA). To avoid genomic DNA contamination, RNA was purified by 
DNAse treatment (RQ1 RNase-Free DNase; Promega, Madison, WI, USA). RNA was then 
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Table 1. Characteristics of clinicopathological factors from 15 patients evaluated for circadian rhythm and 
outcome
N (%) Male/Female
Age (years), mean (±SD) 67.5 ± 9.8 M 66.9 ± 10.2
F 68.3 ± 10.0
Sex
Male (M)/ Female (F) 8/7
Number of metastases
1 7 (46.7) M4/F3
2 3 (20.0) M2/F1
3 2 (13.3) M1/F1
4 1 (6.7) M0/F1
5 1 (6.7) M0/F1
6 1 (6.7) M1/F0
Diameter of largest metastasis (cm)
1.20-2.20 5 (33.3) M2/F3
2.40-4.40 7 (46.7) M4/F3
5.00-9.00 3 (20.0) M2/F1
CRLM in number of segments
1 4 (26.7) M3/F1
2 6 (40.0) M3/F3
3 1 (6.7) M0/F1
4 4 (26.7) M2/F2
Primary tumor location
Ascending colon 2 (13.3) M1/F1
Transverse colon - - -
Descending colon 5 (33.3) M4/F1
Ascending + descending colon 1 (6.7) M0/F1
Rectum 7 (46.7) M3/F4
Histological type CRC
Moderately differentiated adenocarcinoma 13 (86.7) M7/F6
Poorly differentiated adenocarcinoma 2 (13.3) M1/F1
Depth of tumor invasion CRC
T1 - - -
T2 4 (26.7) M2/F2
T3 9 (60.0) M5/F4
T4 1 (6.7) M1/F0
Missing 1 (6.7) M0/F1
Lymph node metastasis CRC
N0 8 (53.3) M5/F3
N1-N2 7 (46.7) M3/F4
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reverse transcribed into cDNA using random primers (Invitrogen) and Superscript II RT 
(Invitrogen). cDNA samples were stored at -20ºC until further analysis.
Quantitative Real-Time Reverse Transcriptase Polymerase Chain Reaction 
(qRT-PCR)
Gene expression was analyzed by real-time quantitative PCR to assess differential 
expression of clock genes in CRC tissue, CRLM, and adjacent liver tissue using an Ap-
plied Biosystems 7700 PCR machine (Foster City, CA, USA). RT-PCR was performed 
using SYBR Green-based Quantitect Primer Assay (Qiagen, Venlo, The Netherlands) for 
10 clock transcripts; CLOCK (QT00054481), BMAL1 (QT00011844), PER1 (QT00069265), 
PER2 (QT00011207), PER3 (QT00097713), CRY1 (QT00025067), CRY2 (QT00094920), TIM 
(QT00019789), TIPIN (QT00054334), and CSNK1E (QT02323916). PCR reactions were car-
ried out in a total volume of 25 µL using the Quantifast SYBR Green PCR kit (Qiagen, 
Venlo, The Netherlands). Each sample was tested in triplicate according to the follow-
ing PCR protocol: 10 min at 50ºC, 5 min at 95ºC, followed by 40 cycles at 95ºC for 10 
seconds, and at 60ºC for 30 seconds. ΔCt values of the genes of interest were calculated 
as described by the method of Pfaffl et al. using the glutaraldehyde-3-phosphate dehy-
drogenase (GAPDH; QT00079247) as a housekeeping gene (20). GAPDH is a commonly 
accepted marker for normalization of qPCR data obtained from human tissues. Triplicate 
values of GAPDH showed low standard deviations, and a one-way ANOVA analysis 
between GAPDH values of all tissues showed no significant differences (p>0.05). ΔCt 
values were normalized to the average ΔCt of the normal liver tissue. The fold change 
was calculated using the Pfaffl equation, 2−ΔΔCt. Results are expressed as median with 
the interquartile range (IQR). The IQR is the difference between the upper and lower 
quartiles (IQR= Q3 − Q1).
Statistical analysis
Gene expression levels of CRLM, and CRC were compared with those of adjacent liver tis-
sue and calculated using the Pfaffl equation, 2−ΔΔCt. To assess the statistical significance 
of the up- or down-regulation of genes the Wilcoxon signed-rank rest was used. Correla-
tion analyses between gene expression levels and all nine clinical pathological factors 
was performed using Spearman correlation. All analyses were corrected for multiple 
testing by the Bonferroni method. All statistical tests were two-sided and performed 
using SPSS 21 for Windows software (Statistical Package for Social Sciences, Chicago, IL). 
p < 0.05 was considered to be significant, unless otherwise mentioned.
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Results
Clock gene mRNA expression in CRLM compared to adjacent liver
To compare clock gene expression in CRLM with adjacent normal liver tissue, we analyzed 
mRNA expression levels of 10 clock genes (CLOCK, BMAL1, PER1, PER2, PER3, CRY1, CRY2, 
CSNK1E, TIM, TIPIN). Liver metastasis and liver tissue were used from 15 patients. Relative 
mRNA expression levels of clock genes in the liver and CRLM are presented in Figure 
1. Tumor samples were normalized to the average ΔCt of the liver tissue, and 7 genes 
were subsequently observed to be down-regulated in CRLM: CLOCK (median=0.46, Q1-
Q3=0.22-0.75, p=0.006), BMAL1 (median=0.21, Q1-Q3=0.14-0.36, p=0.003), PER1 (me-
dian=0.14, Q1-Q3=0.05-0.52, p=0.003), PER2 (median=0.63, Q1-Q3=0.25-0.86, p=0.002), 
PER3 (median=0.14, Q1-Q3=0.04-0.37, p<0.001), CRY1 (median=0.50, Q1-Q3=0.32-0.98, 
p=0.002), and CRY2 (median=0.31, Q1-Q3=0.09-0.61, p<0.001). The expression levels of 
TIM and TIPIN showed no significant difference (median=0.81, Q1-Q3=0.73-1.04, p=0.54, 
and median=1.05, Q1-Q3=0.62-1.48, p=0.74, respectively).
Clock gene mRNA expression in the primary colon tumor compared to liver tissue
To determine whether clock gene expression was also impaired in the primary tumor, we 
measured mRNA expression levels of colorectal tumors of the same patients. Five of 10 
genes were down-regulated namely BMAL1 (median=0.37, Q1-Q3=0.16-0.53, p=0.02), 
PER1 (median=0.13, Q1-Q3=0.06-0.6, p=0.004), PER2 (median=0.33, Q1-Q3=0.17-0.80, 
p=0.008), PER3 (median=0.09, Q1-Q3=0.04-0.22, p<0.001), CRY2 (median=0.11, Q1-
Q3=0.07-0.20, p<0.001). Again, CSNK1E was up-regulated (median=1.35, Q1-Q3=1.11-
2.22, p= 0.02). The expression of four genes did not show significant differences: CLOCK 
(median=0.73, Q1-Q3=0.29-1.16, p=0.43), CRY1 (median=0.51, Q1-Q3=0.47-1.30, 
p=0.23), TIM (median=1.04, Q1-Q3=0.78-1.23, p=0.52), TIPIN (median=1.11, Q1-Q3=0.53-
1.43, p=0.70) (Fig1).
Relation between clock gene mRNA expression levels and clinicopathological 
factors
Patients clinical and pathological features were retrieved using the electronical patient 
database (Table 1), and associations between mRNA expression levels and clinico-
pathological factors were determined. A statistically significant correlation was found 
between CRLM mRNA levels of PER3 and the number of metastases. Lower PER3 mRNA 
levels were found with an increasing number of metastases (r= 0.645, p=0.009) (Fig2A). 
Another significant correlation was found between CRLM CRY1 mRNA levels and patient 
gender. Lower CRY1 mRNA levels were found in female patients compared to male 
patients (r=0.700, p=0.005) (Fig2B). There were no other significant correlations found 
between mRNA expression levels and clinicopathological factors.
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Figure 1. mRNA expression levels of clock- and clock-controlled genes in liver, colorectal liver metas-
tases (CRLM), and colon tumor. The relative mRNA expression of each gene of interest was normalized to 
glutaraldehyde-3-phosphate dehydrogenase (GAPDH). ΔCt values were normalized to the average ΔCt of 
the normal liver tissue. For each gene, boxes show the median with the interquartile range (IQR= Q3-Q1). 
Asterisks indicate significance of the difference in expression of each gene in liver as compared to CRLM 
and CRC as assessed by the Wilcoxon signed-rank test (*p<0.05, **p<0.01, ***p<0.001).
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Figure 2. Correlation between clock gene mRNA expression levels, CRLM, and gender. (A) The correla-
tion between PER3 mRNA expression levels in CRLM and the number of metastases, evaluated by Spear-
man test (r= 0.645, p=0.009). (B) The correlation between CRY1 mRNA expression levels in CRLM and pa-
tient gender evaluated by Spearman test (r=0.700, p=0.005).
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Discussion
In the current study, we examined the expression levels of clock genes in colorectal liver 
metastases (CRLM), the primary colorectal tumor, and liver tissue in surgical resection 
specimens of CRC patients. We also studied possible relations between gene expression 
levels and clinical and pathological factors of these patients. We used quantitative real-
time polymerase chain reaction (qRT-PCR) to identify the expression levels of CLOCK, 
BMAL1, PER1, PER2, PER3, CRY1, CRY2, CSKN1E, TIM, and TIPIN. We observed a down-
regulation of core clock mRNA levels in both liver metastases and colorectal cancer. The 
genes encoding CLOCK and BMAL1, the two core clock proteins that heterodimerize and 
drive transcription of clock (controlled) genes, were both significantly down-regulated 
in CRLM. BMAL1 expression was also lowered in colorectal tumors. In line with the lower 
expression levels of CLOCK and BMAL1, genes activated by the CLOCK/BMAL1 complex, 
such as PER1, PER2, PER3, CRY1, and CRY2 all show a significant reduction in expression 
compared to normal liver tissue. The only gene that was significantly up-regulated in 
the primary tumor was CSKN1E. We observed no differences in the expression levels of 
TIM, and TIPIN.
To our knowledge this is the first study describing severe down-regulation of clock 
genes in human CRLM. Our findings are in line with previous studies describing circa-
dian disruption in other malignancies. In more than 95% of breast cancer tissue from 55 
women, expression levels of PER1, PER2, and PER3 were severely disrupted in comparison 
with adjacent non-cancerous tissue (21). Pancreatic cancer has a low incidence rate, but 
is very aggressive with high mortality rates. Especially PER1 and downstream effectors of 
the circadian clock are lower expressed in pancreatic cancer which further suggests they 
may act as tumor suppressor genes in healthy tissue (22). Our data are supported by a 
study in human primary colorectal cancer. A down regulation in expression of BMAL1, 
PER1, PER2, PER3, and CRY2 was found. Furthermore, differential expression of clock 
genes was associated with differences in survival (23). In a study of 202 untreated CRC 
patients, PER1 and PER3 expression levels were significantly lower compared to normal 
tissue. In contrast, the expression of CLOCK and CKIε was significantly higher in cancer 
tissue. PER2 was shown to be differentially expressed related to survival, with a better 
survival corresponding with a high PER2 expression (24).
In this study, the only gene that was significantly up-regulated in CRC and showed 
a trend towards increased expression in CRLM was CSNK1E. The CSNK1E gene encodes 
the CKIε protein, whose main function is to regulate circadian rhythm by phosphoryla-
tion and degradation of Period genes (25). We showed that PER1, PER2, and PER3 gene 
expression levels were all lower in cancer tissue than in liver tissue, while CSNK1E gene 
expression was higher in cancer tissue. The decreased expression levels of both tran-
scription activator-, (BMAL1) and transcription inhibitor genes (CRYs and PERs) suggest 
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that the clock in the primary tumor and CRLM may be dampened and/or less robust. Up-
regulation of CSNK1E may lead to enhanced phosphorylation of the PER2 protein which 
is known to destabilize the PER protein and target it for ubiquitination and subsequent 
proteosomal degradation. Furthermore, CKIε plays an essential role in the early develop-
ment of CRC. CKIε is involved in cell proliferation by stabilizing β-catenin and mimicking 
the effect of WNT-signaling. Subsequently, this will lead to increased levels of β-catenin 
in the nucleus to control transcription and maintain tumorigenesis (26, 27). Knocking 
down CSNK1E in a human sarcoma cell-line led to growth inhibition of cells, and CSNK1E 
was found to be up-regulated in ten different human cancer tissues compared to normal 
tissue (28).
In contrast to others, we found no significant difference in TIMELESS (TIM) and 
timeless-interacting protein (TIPIN) mRNA expression levels. These genes interact with 
components of the DNA replication system to regulate DNA replication processes under 
normal and stress conditions and are essential in regulating different phases of the cell-
cycle (29). Down-regulation of TIM increased doxorubicin toxicity in HCT116 cancer cells, 
and it is suggested that TIM inhibition could be used to enhance cytotoxic effectiveness 
of chemotherapeutic drugs (30). Down-regulation of TIM and TIPIN was found in kidney 
cancer patients compared to normal kidney tissue (31).
We related the expression levels of clock genes to clinical and pathological factors. Low 
expression of PER3 was correlated with a higher number of metastases. In another study, 
low PER1 expression was correlated with the development of CRLM in CRC patients (24). 
We also found a significant correlation between gender and the expression of CRY1 in 
CRLM. The lowest levels of CRY1 mRNA expression were found in female patients. This 
correlation was also found in a study where differential expression levels of core clock 
genes were determined in tumor specimens of CRC patients (23). The fact that female 
patients show lower CRY1 expression levels could be related to a difference in metabolic 
pathways and xenobiotic detoxification between genders. In the Chronotherapy Group 
Trial, including a schedule of chronomodulated delivery of chemotherapy, female 
patients were shown to have shorter survival and greater toxicity when treated with 
5-fluorouracil and leucovorin (32).
The mRNA expression levels of CRLM of all core clock genes in this study show dif-
ferential expression compared to liver tissue. These results support the hypothesis of the 
apparent coupling between the circadian rest-activity cycle and the time-dependent 
toxicity of drugs, which may be exploited in the field of chronotherapy. The basis of 
chronotherapy relies on the principle of administering chemotherapy at times when 
toxicity is expected to be lowest (33, 34). A phase III study in CRC patients has shown 
better tolerability and anti-tumor activity compared with conventional therapy when 
chemotherapy was administered according to least toxic dosing times (32). In a phase 
II study, patients with unresectable CRLM were treated with chronotherapy and highly 
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toxic hepatic arterial infusion which resulted in a doubling of secondary surgical resec-
tion rates (35).
Albeit our study shows evidence of a disrupted timing system in CRLM and CRC in 
patients, we studied a relatively small cohort of patients. By expanding the number of 
patients, more correlations might be found between mRNA expression levels and clini-
copathological factors. The mRNA expression levels of CRC are normalized to the levels 
of adjacent liver, but not colon tissue. Based on experiments with rats, it is expected that 
the circadian timing system in the colon is in phase with that in the liver (36). Further-
more, we were only able to study gene expression at the timepoint at which the resec-
tion specimen was obtained. Since patients are operated on at different times of the day, 
and surgical resections are not procedures with a fixed time frame, this is a limitation 
inherent to a clinical study. To further elucidate this issue, we are currently investigating 
the impact of clock gene expression levels in cancer cells in vitro by knocking down and 
overexpressing clock genes in various tumor cell lines, followed by systematic pheno-
typing of cancer properties of the cell (i.e. proliferation rate, cell migration and invasion 
properties, and drug sensitivity).
In summary, the present study shows that there are differences in clock gene expres-
sion in CRLM- and CRC tissue compared to liver in patients without neo-adjuvant chemo-
therapy treatment. The differential expression might be related to carcinogenesis, tumor 
burden and survival, and supports the application of chronomodulated chemotherapy.
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Abstract
Irinotecan is a widely used topoisomerase-I-inhibitor with a very narrow therapeutic 
window because of its severe toxicity. In the current study we have examined the 
effects of fasting prior to irinotecan treatment on toxicity and anti-tumor activity. 
FabplCre;Apc15lox/+ mice, which spontaneously develop intestinal tumors, of 27 weeks 
of age were randomized into 3-day fasted and ad libitum fed groups, followed by treat-
ment with a flat-fixed high dose of irinotecan or vehicle. Side-effects were recorded until 
11 days after the start of the experiment. Tumor size, and markers for cell-cycle activity, 
proliferation, angiogenesis, and senescence were measured. Fasted mice were protected 
against the side-effects of irinotecan treatment. Ad libitum fed mice developed visible 
signs of discomfort including weight loss, lower activity, ruffled coat, hunched-back pos-
ture, diarrhea, and leukopenia. Irinotecan reduced tumor size in fasted and ad libitum 
fed groups similarly compared to untreated controls (2.4 ± 0.67 mm and 2.4 ± 0.82 mm 
versus 3.0 ± 1.05 mm and 2.8 ± 1.08 mm respectively, p<0.001). Immunohistochemi-
cal analysis showed reduced proliferation, a reduced number of vascular endothelial 
cells, and increased levels of senescence in tumors of both irinotecan treated groups. 
In conclusion, 3 days of fasting protects against the toxic side-effects of irinotecan in a 
clinically relevant mouse model of spontaneously developing colorectal cancer without 
affecting its anti-tumor activity. These results support fasting as a powerful way to im-
prove treatment of colorectal carcinoma patients.
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Introduction
Irinotecan is extensively used in first and second line treatment for unresectable and 
metastatic disease of colorectal cancer (1). In 1996, approval was obtained in the United 
States for the second-line treatment of patients with metastatic colorectal carcinoma. 
Today, irinotecan is approved as a single agent as well as in combination with other 
drugs (i.e. oxaliplatin, and fluorouracil) for treatment of colorectal cancer (2, 3). It is a 
pro-drug of the topoisomerase I inhibitor SN-38, and is metabolized by CYP3A into inac-
tive metabolites (4). Irinotecan is typically known for its narrow therapeutic window, 
which explains its unpredictable toxicities, including severe myelosuppression, massive 
diarrhea, and in some cases even death as a complication of other side-effects (5, 6). 
These side-effects may lead to dose reductions and early discontinuation of treatment, 
and limit the anti-tumor activity of this chemotherapeutic agent (7).
A potentially protective intervention against these severe side-effects is dietary 
restriction (DR), i.e. a reduction of caloric intake before drug delivery. We previously 
showed that 3-days of fasting up-regulates cytoprotective and antioxidant enzymes, 
and induces protection against oxidative stress (8, 9).
While much information is obtained from studies that revealed beneficial effects of 
fasting and DR using transplantable tumor models, there is a need to perform these 
studies in more clinically relevant animal models (10-12). FabplCre;Apc15lox/+ mice express 
an adenomatous polyposis coli (APC) mutant allele, Apc15lox, based on loxP sites flanking 
exon 15, and a Cre-mediated knockout by deletion of this exon (13). These mice are 
genetically predisposed to develop macroscopic adenomas in the distal small and large 
intestine emerging at approximately 3 months of age. Humans with germ-line inactivat-
ing mutations of this gene are also predisposed to develop many adenomatous polyps 
in the colon and rectum, a hereditary cancer syndrome called familial adenomatous 
polyposis (FAP). In addition, 80% of the sporadic colorectal tumors are initiated by a 
germ-line mutation in APC (14, 15).
To study the role of APC in prevention and treatment of colorectal cancer, many 
inactivating mutant alleles of the mouse Apc gene were investigated. Morbidity and 
mortality rates of most of these models were high at a rather young age (16, 17). An 
advantage of the conditional Apc-mutant mouse model discussed here is the slow onset 
of tumor development, mimicking the growth of a spontaneously developing tumor 
in a more mature mouse model. Furthermore, this model accounts for neoplasia in the 
small intestine as well as in the large intestine, which makes it a relevant model to study 
colorectal cancer.
In this study we examined the effects of fasting before administration of a high dose 
irinotecan on the occurrence of side-effects, and number and size of tumors in this con-
ditional Apc-mutant mouse model for colorectal carcinoma. In addition, we performed 
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immunohistochemistry on tumor tissue to compare the anti-tumor activity of irinotecan 
in fasted and ad libitum fed animals.
Materials and methods
Animals
FabplCre;Apc15lox/+ mice (n=36) with a C57Bl/6 background were generated, bred, and 
maintained under pathogen-free conditions at a licensed biomedical animal facility, 
Erasmus University Medical Center, Rotterdam, the Netherlands, as previously reported 
(13). During 27 weeks they were housed in individually ventilated cages (n=3-4 animals 
per cage) where standard laboratory conditions were maintained, i.e. temperature 
~22ºC, humidity ~50%, and a 12 h light/12 h dark cycle. During this period, there were 
no visible signs of disease in the studied animals. All mice had free access to water and 
food (Special Diet Services, Witham, UK) unless mentioned otherwise. Previously we 
have shown that after 27 weeks of age, intestinal tumors were macroscopically present. 
Mice were divided into four groups; 1. Ad libitum group (n=9; males (m) n=4, females (f ) 
n=5), 2. Fasted group (n=9; m, n=4, f, n=5), 3. Ad libitum group with irinotecan treatment 
(n=10; m, n=5, f, n=5), and 4. Fasted group with irinotecan treatment (n=8; m, n=4, f, 
n=4). The experimental protocol was approved by the Animal Experiments Committee 
under the Dutch National Experiments on Animals Act, and complied with the 1986 
directive 86/609/EC of the Council of Europe.
Fasting
The two ad libitum fed groups were allowed unrestricted access to food. Before the start 
of the experiment, all mice were transferred to a clean cage and the 2 fasted groups 
were withheld food for 3 days starting at 4:00 PM and were fed ad libitum again 3 days 
later at 10:00 AM. All animals were given continuous access to water. No mortality oc-
curred during fasting.
Chemotherapy
Irinotecan, HCl-trihydrate 20 mg/mL (Hospira, Benelux) was diluted in sodium chloride 
0.9% (Braun, Melsungen, Germany) to a final volume of 200 µL per injection, and was 
given intraperitoneally. The optimal cumulative drug dose (400 mg/kg) was determined in 
a pilot experiment and defined as the concentration that induces severe toxicity without 
causing mortality (data not shown). All animals received the same amount of irinotecan, 
called a flat-fixed dose, based on the average weight of ad libitum fed male mice, which 
was 25 gram. All animals in the ad libitum fed group as well as in the fasted group received 
167 µL irinotecan supplemented with 33 µL sodium chloride 0.9% per injection.
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Experimental setup
All mice in the irinotecan treated groups received a cumulative flat-fixed dose of 400 
mg/kg irinotecan. On days 1,3 and 5 after fasting, mice received 133 mg/kg irinotecan . 
The control groups received vehicle (sodium chloride 0.9%). Following the first irinote-
can injection mice were weighed and scored daily for adverse side effects by a mouse 
wellbeing-score protocol adapted from ‘the guidelines for welfare of animals in experi-
mental neoplasia research’ (1988: United Kingdom Co-ordinating Committee on Cancer 
Research, UKCCCR). Assessing wellbeing by one researcher took 20 minutes per cage 
with 4 mice. Side-effects were scored independently by two experienced researchers. 
Mouse cages were removed from racks and placed on a bench to facilitate improved vi-
sualization of mice, but cages were not opened at any point during the scoring process, 
except for the determination of the stool consistency at the end of the process. Mouse 
activity level was scored according to the amount each mouse moved in its cage. A score 
of 2 indicates an animal that moved around the cage normally. A score of 1 indicates an 
animal that was moving slowly with an altered gait. A score of 0 indicated an animal that 
was not moving and was taking no more than 5 steps. The appearance of the coat was 
scored according to the smoothness. A score of 2 indicated a healthy, smooth uninter-
rupted coat. A score of 1 indicated a slightly fluffy coat. A score of 0 indicated a severe 
fluffy coat with evident parts of visible skin. Posture was scored according to a hunched 
appearance. A score of 2 indicated a normal body posture. A score of 1 indicated a mod-
erately hunched posture. A score of 0 indicated a severely hunched posture. Severity of 
diarrhea was assessed according to the stool consistency score (0: normal, 1: loose stool, 
2: loose/some diarrhea, 3: diarrhea, 4: severe watery diarrhea) (34). Before every stool 
consistency measurement clean white tissues were placed at the bottom of the cage to 
allow determination of the consistency of the stool. Results are expressed as mean ± SD. 
Leukocyte numbers were determined on day 8 after the first irinotecan injection with a Z 
series Coulter Counter (Beckman Coulter, Woerden, The Netherlands). Ten days after the 
first irinotecan injection mice were sacrificed by exsanguination.
Determination of tumor burden
Directly after sacrificing the animals, the entire gastrointestinal tract was removed for 
dissection but the stomach, duodenum and cecum were omitted from the analysis 
because of their low tumor incidence. The intestinal tract was opened along the cepha-
locaudal axis, flushed with phosphate-buffered saline (PBS), cut into five segments of 
approximately equal lengths, and spread out flat on filter paper. These preparations 
were fixed overnight at 4°C in 10% phosphate-buffered formalin and thereafter stored 
in 70% EtOH until further analysis. Tumor enumeration was performed using a dissect-
ing microscope. Diameter of each tumor was determined using an ocular micrometer 
that allows precise measurements with a resolution of 0.1 mm. The smallest detected 
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tumor was 0.8 mm. All tumors were scored by two experienced researchers blinded to 
the treatment.
Immunohistochemistry
After determination of tumor size, 4 tumors per intestinal tract were embedded in 
paraffin, sectioned at 5µm, and stained with the following antibodies: 1. polyclonal an-
tibody against pHiston H3 (Ser10; 9701S, dilution 1:200, Cell Signaling, Danvers, MA). 2. 
monoclonal antibody against Cyclin D1 (VP-RM03, dilution 1:500, Bio-Connect, Huissen, 
The Netherlands). 3. Monoclonal antibody against Ki-67 (D3B5; 12202S, dilution 1:500, 
Cell Signaling, Danvers, MA). 4. Monoclonal antibody against CD146 (EPR3208; ab75769, 
dilution 1:200, Abcam, Cambridge, UK) 5. Monoclonal antibody against p21 (Waf1/Cip1; 
12D1; 2947S, dilution 1:500, Cell Signaling, Danvers, MA). All primary antibodies were 
visualized with a polyclonal horseradish peroxidase-Y-conjugated secondary antibody 
(goat-anti-rabbit IgG/HRP, P0448, dilution 1:500, DAKO, Denmark). Slides were scored 
using the number of positive cells for pHiston H3, CD146, and p21. For Cyclin D1, and 
ki-67 the percentage of positive cells was used. Two independent observers blinded to 
the treatment scored the slides at a magnification of 200-400x. Five microscopic fields 
per tumor were measured. Results are expressed as mean ± SD.
Statistical analyses
Categorical data are presented as number (percentage) and continuous variables as 
mean ± SD. Means between two groups were compared using the t-test for parametric 
data. One-way analysis of variance (ANOVA) in combination with the Bonferroni multiple 
comparison test was used to assess whether fasting significantly altered irinotecan 
induced toxicity in treated mice compared to the other groups. Two-way ANOVA was 
used to assess if fasting or irinotecan treatment significantly influenced expression of 
immunohistochemical markers. All standard statistical tests were performed using SPSS 
version 21 for Windows software (Statistical Package for Social Sciences, Chicago, IL), 
and p < 0.05 was considered to be significant.
Results
Adverse side-effects in irinotecan treated Apc-mutant mice
During the first 3 days of the experiment, animals in the fasting group were withheld 
from food, and had ad libitum access to water. Bodyweight was presented as a relative 
percentage of the starting weight. Weight loss was 22.5 ± 3.0% during fasting relative to 
the animals starting weight in both fasting groups. The ad libitum fed groups gained 2.3 
± 1.9% body weight during this period. Directly after the first irinotecan injection, fasted 
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Figure 1. Protection of fasting against side-effects of irinotecan in Apc-mutant mice. Side-effects were 
monitored from the start of the fasting regimen until 11 days after the first irinotecan injection (*). Graphs 
represent a total of 36 mice: 1. Ad libitum group (n=9; males (m) n=4, females (f ) n=5), 2. Fasted group 
(n=9; m, n=4, f, n=5), 3. Ad libitum group with irinotecan treatment (n=10; m, n=5, f, n=5), and 4. Fasted 
group with irinotecan treatment (n=8; m, n=4, f, n=4). (A) Effects of fasting and irinotecan treatment on 
body weight. Fasted (F) mice lost weight during the fasting regimen, but gained weight during irinotecan 
treatment. In contrast, ad libitum (AL) fed animals lost weight during irinotecan administration. (B-E) Effects 
of fasting and irinotecan treatment on activity, coat, posture, and stool. ***: indicates significant difference 
(p<0.001) between ad libitum fed animals treated with irinotecan compared to each of the other groups. 
(F) Effect of fasting and irinotecan treatment on bone marrow toxicity. Number of leukocytes on day 8 after 
the first irinotecan injection was significantly lower in ad libitum fed animals compared to fasted animals in 
the irinotecan treated groups. ***: p<0.001.
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mice were fed ad libitum again. In the ad libitum fed group, mice showed weight loss 
following the first irinotecan injection, and at the end of the experiment they had lost 
22.1 ± 3.7% of their starting weight. In contrast, the fasted mice gained weight following 
the first injection and at the end of the experiment their weight had returned to baseline 
levels (94.8 ± 3.5% of their starting weight) (Fig1A). From day 3 after the first irinotecan 
injection, mice in the ad libitum fed group were less active (p<0.001) and showed a 
ruffled coat compared with fasted mice treated with irinotecan and untreated controls 
(p<0.001). Furthermore, ad libitum fed mice treated with irinotecan showed a hunched-
back posture (p<0.001) and suffered from diarrhea from day 3 after the first injection, 
whereas this was not observed in fasted mice treated with irinotecan and untreated 
controls (p<0.001) (Fig1B-E). Thus, mice in the fasted group treated with irinotecan did 
not show signs of toxicity and showed no significant differences in side-effects com-
pared with both untreated control groups. Eight days after the first irinotecan injection 
the number of leukocytes was determined to measure bone marrow toxicity. Among 
the mice receiving irinotecan, the ad libitum fed group showed a significant reduction 
in leukocyte numbers compared to fasted animals (3.4 ± 0.6*106/mL vs. 6.6 ± 0.7*106/
mL, p<0.001) (Fig1F). There was no significant difference between the control groups.
Number and size of intestinal tumors
At the end of the experiment the entire gastrointestinal tract from each mouse was re-
moved, and the small and large intestine were opened for tumor enumeration. The average 
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Figure 2. Number and size of intestinal tumors. Tumors from the gastrointestinal tract were counted 
and measured under a dissection microscope. (A) Number of intestinal tumors per mouse. In the irinotecan 
treated groups, ad libitum (AL) fed and fasted (F) mice had respectively 14.0 ± 3.6 and 14.6 ± 2.5 tumors per 
intestine. In control groups, ad libitum (AL) fed and fasted (F) mice had respectively 16.4 ± 3.1 and 17.3 ± 3.3 
tumors per intestine. (B) Size of all intestinal tumors. Tumor size in irinotecan treated mice was 2.4 ± 0.82 
mm in fasted, and 2.4 ± 0.67 mm in ad libitum fed and fasted mice respectively. In control groups this was 
2.8 ± 1.08 mm and 3.0 ± 1.05 mm (p<0.001).
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Figure 3. Anti-tumor effect of irinotecan. (A-C) Irinotecan treatment significantly inhibited tumor cell 
proliferation as shown by differential expression of Cyclin D1, pHiston H3, and Ki-67. (D) This corresponded 
with an up-regulation of the CDKI p21. (E) CD146, a marker for endothelial cells, was significantly down-
regulated in irinotecan treated animals. Representative photomicrographs of irinotecan treated (middle 
panels) and control (right panels) tumor specimens (magnification 200x). *:p<0.05, **:p<0.01, ***:p<0.001.
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number of tumors was 17% lower in the irinotecan-treated groups compared to controls. 
There were 16.4 ± 3.1 and 17.3 ± 3.3 tumors per mouse in the ad libitum and fasted group 
without irinotecan treatment, whereas in the ad libitum and fasted group with irinotecan 
treatment mice had 14.0 ± 3.6 and 14.6 ± 2.5 intestinal tumors, respectively (Fig2A). Inter-
estingly, the size of the tumors showed a significant difference between irinotecan treated 
and control groups. Tumor size of ad libitum fed and fasted control groups was 2.8 ± 1.08 
mm (range: 0.8 mm – 6.5 mm) and 3.0 ± 1.05 mm (range: 1.0 mm – 6.0 mm) respectively, 
while tumor size in irinotecan treated groups was 2.4 ± 0.82 mm (range: 1.0 mm – 4.8 mm) 
and 2.4 ± 0.67 mm (range: 1.0 mm – 4.3 mm) (p<0.001) (Fig2B).
Antitumor effect of irinotecan
We examined whether fasting changed the effects of irinotecan on the cell cycle, cellular 
proliferation, induction of senescence, and angiogenesis by immunohistochemistry on 
four randomly chosen tumors per intestinal tract. Cyclin D1, a marker that indicates the 
G1/S-phase of the cell cycle and that is often seen overexpressed in tumors, showed 
a significantly lower expression in irinotecan treated animals compared to controls 
(p<0.01) (Fig3A). This corresponded with a significantly lower expression of the mitosis 
marker pHiston H3 in irinotecan treated animals (p<0.001) (Fig3B). Ki-67, the prolifera-
tion marker that is present in all active phases of the cell cycle was also significantly lower 
expressed in both irinotecan treated groups (p<0.01) (Fig3C). Expression of the cyclin 
dependent kinase inhibitor (CDKI) p21, indicating senescence and S/G2-phase, was sig-
nificantly up-regulated in both irinotecan treated groups (p<0.05) (Fig3D). CD146, pres-
ent on vascular endothelial cells and a marker for angiogenesis, showed significantly 
lower expression in both treated groups (p<0.01) (Fig3E). There were no significant 
differences between irinotecan treated ad libitum and fasted animals. Collectively these 
data show that irinotecan treatment significantly inhibited tumor cell proliferation, and 
has a comparable anti-tumor effect in both ad libitum fed-, and fasted mice.
Discussion
The experiments presented here show that 3-days of fasting prior to treatment with a 
high dose of the chemotherapeutic agent irinotecan protects against its side-effects 
in an Apc-mutant mouse model that spontaneously develops intestinal tumors. We 
observed a similar reduction in tumor size in fasted and ad libitum fed irinotecan treated 
groups compared to controls. Furthermore, we found a significant decrease in cell cycle 
activity, proliferation, and angiogenesis, while senescence was increased in both fasted 
and ad libitum fed irinotecan treated groups, indicating that fasting does not affect the 
anti-tumor activity of irinotecan.
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To our knowledge, this is the first study that shows beneficial effects of fasting on che-
motherapy toxicity in a mouse model that spontaneously develops colorectal cancer. 
In support of these observations, others have shown that long term dietary-restricted 
rodents are more resistant against a variety of toxic agents (18-21). We showed that ben-
eficial effects seen after long-term dietary restriction, can also be induced rapidly using 
a 3-day fasting regimen (8). Others have observed the beneficial effects of short-term 
fasting on chemotherapy treatment as well. Mice injected with neuroblastoma cells and 
subsequently fasted for 48 hours were protected against side-effects of etoposide, while 
anti-tumor activity was preserved (11). In previous studies, tumor-cells or tissues were 
placed subcutaneously, whereas in the current study we used an Apc-mutant mouse 
model that mimics spontaneous intestinal tumor formation (13). Spontaneously devel-
oping tumor models are needed to better develop strategies to control malignant cell 
growth, including chemotherapy treatment. In this regard, the ApcMin/+ mouse model is 
one of the most studied models of intestinal tumorigenesis in which tumor growth is 
suppressed by different anticancer agents (22, 23).
In the present study we used fasting as a pre-conditioning method to protect against 
the side-effects of irinotecan. Previously, we reported that 3-days of fasting increases 
stress-resistance, including upregulation of the Nrf2 pathway, which is involved in the 
protection against oxidative stress (8, 24). In contrast to the up-regulation of protective 
pathways by normal cells, it is thought that cancer cells are unable to obtain a protected 
state by dietary restriction. This phenomenon is called differential stress sensitization 
(DSS) and is based on the fact that cancer cells have acquired a number of mutations 
that progressively decrease their ability to adapt to diet restriction (25).
A key finding in this study is that 3-day fasted Apc-mutant mice do not show any signs 
of toxicity in response to a very high dose irinotecan while the anti-tumor response is 
still present. Using immunohistochemistry, we found no significant differences between 
ad libitum fed- and fasted animals in both the irinotecan treated groups as well as the 
control groups, indicating that the effects of irinotecan are unimpaired in fasted animals. 
Phosphorylation of Histone H3 at serine 10 takes place during mitosis of the cell (26). The 
reduced expression of pHiston H3 in tumors of irinotecan treated mice indicates that 
mitosis is suppressed. Cyclin D1 regulates the progression of cells into the proliferative 
stage (27). Both fasted and ad libitum fed irinotecan treated animals showed a similarly 
reduced expression of cyclin D1. Ki-67, a widely used proliferation marker, confirmed the 
anti-proliferative effect of irinotecan in all treated animals.
Due to irinotecan induced DNA damage, the p53/p21 pathway is activated and sub-
sequently arrests cells from division and causes cellular senescence (28, 29). We evalu-
ated the expression of p21 as a senescence marker, and showed that irinotecan treated 
tumors express significantly higher levels of p21 compared to controls. The expression 
of CD146, a marker present on vascular endothelial cells, was significantly reduced in 
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tumors from irinotecan treated mice. The effects of irinotecan on vascular endothelial 
cells remain largely unknown. Irinotecan decreases hypoxia inducible factor 1α accumu-
lation in tumors, which may inhibit tumor angiogenesis (30). These findings support our 
observation that irinotecan reduces CD146 expression and thus angiogenesis.
We investigated both male and female FabplCre;Apc15lox/+ mice. The number of male 
and female mice was evenly distributed between the different groups, and we observed 
no differences in side-effects, number and size of tumors, and anti-tumor effect of iri-
notecan between genders. The only difference was seen in bodyweight; at the start of 
the experiment, at 27 weeks of age, male mice were on average 30% heavier. Therefore, 
bodyweight is presented as a relative percentage of the starting weight. Several studies 
have compared gender differences in the ApcMin/+ model. The small molecule compound 
SHetA2 significantly reduced incidence and size of intestinal polyps, both in males 
and females (22). In contrast, in a dietary study using the retinoid-x-receptor agonist 
bexarotene, a greater reduction of intestinal tumors was found in male mice compared 
to female mice (31). The observation that we did not find differences between genders 
could be attributed to the fact that we administered a flat-fixed dose to all mice, based 
on the bodyweight of male mice. Thus, female mice received a higher concentration 
irinotecan relative to their bodyweight, but are known to be less susceptible to the 
toxicity induced by irinotecan (32).
Based on existing evidence from in vitro and in vivo experiments, fasting has a great 
potential to be implemented in clinical cancer patients. Although the introduction of 
fasting remains challenging, a study with self-reported patients showed a decrease in 
side-effects and an increase in subjective well-being after chemotherapy treatment (33). 
Therefore, randomized controlled clinical trials are needed to validate the beneficial ef-
fects of fasting in a clinical setting.
In conclusion, fasting significantly prevented the occurrence of side-effects of iri-
notecan in a genetic mouse model that spontaneously develops intestinal neoplasms 
through an inactivating mutation of the Apc gene. Irinotecan significantly reduced 
tumor size and proliferation in fasted and ad libitum fed animals, indicating that fast-
ing does not abrogate the anti-tumor response. These results support fasting before 
irinotecan treatment as a powerful way to improve treatment for colorectal carcinoma 
patients.
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Abstract
The main limitation to the use of irinotecan in the treatment of colorectal cancer is 
the severity of side-effects, including neutropenia and diarrhea. Here, we explored the 
effects of 3 days of fasting on irinotecan induced toxicities, plasma, liver and tumor 
pharmacokinetics, and anti-tumor activity in mice. Male Balb/c mice received C26 colon 
carcinoma cells subcutaneously. They were randomized 1:1 into ad libitum fed and fasted 
groups after which they were treated with irinotecan. Weight and adverse side-effects 
were recorded daily. At the end of the experiment, tumors were resected, weighed, 
and concentrations of irinotecan and its active metabolite SN-38 were determined. 
Fasting prevented side-effects induced by irinotecan as shown by absence of diarrhea 
and visible signs of discomfort. Ad libitum fed animals developed leukopenia compared 
to untreated controls whereas fasted mice did not (3.2±0.1*106 leukocytes/mL versus 
6.5±0.2*106/mL, p<0.001). Irinotecan significantly suppressed tumor growth in both the 
fasted and ad libitum fed groups compared to untreated controls (1,263±54 mg and 
1,278±36 mg in fasted and ad libitum fed animals versus 2,195±113 mg in untreated 
controls, p<0.001). SN-38 AUC values were significantly lower in fasted mice in both 
plasma and liver, but not in tumor tissue (p=0.02, p=0.003, and p=0.27, respectively). 
Our data demonstrate that fasting protects against irinotecan induced side-effects with-
out interfering with its anti-tumor efficacy. Fasting induces a lower systemic exposure to 
SN-38 which may explain the absence of adverse side-effects, while tumor AUC values 
remain unchanged. These data offer important new opportunities to improve irinotecan 
treatment in patients.
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Introduction
Colorectal cancer is the second most prevalent cancer, with more than 1,2 million new 
cancer cases and over 600,000 deaths per year (1). About 15% to 20% of patients at 
initial presentation have liver metastases, and an additional 45% is diagnosed with me-
tastases in follow-up after resection of the primary tumor (2). A potent anticancer agent 
in first and second line treatment for unresectable and metastatic disease is irinotecan 
(CPT-11), today’s most widely used topoisomerase-I-inhibitor. Irinotecan can produce 
severe and unpredictable hematologic, intestinal and systemic toxicities, including deep 
myelosuppression, massive diarrhea, vomiting, fatigue and in some cases even death as 
a complication of the other side-effects (3-6). It is generally accepted that this toxicity 
is mediated by the active metabolite of irinotecan, SN-38 (7). Importantly, irinotecan is 
one of the chemotherapeutic drugs which has been reported to generate high levels 
of oxidative stress (8), which will lead to failure of normal cellular functions and may 
contribute to the discussed toxicities (9).
Fasting is a powerful means to increase resistance against acute stressors such as 
oxidative stress. We have previously shown that preoperative fasting and dietary restric-
tion protect against acute oxidative damage induced by ischemia-reperfusion injury 
in both kidney and liver (10-13). In addition, preoperative dietary restriction reduces 
hepatic tumor load and the hepatic expression of the endothelial cell specific adhesion 
molecule, E-selectin (14). It has been suggested that fasting protects normal cells by 
rearrangement of energy into maintenance pathways instead of reproduction and 
growth (15, 16). In this way, dietary restriction could protect against toxic side-effects of 
anti-cancer drugs, but how this affects pharmacokinetics and anti-tumor activity is still 
largely unknown.
Therefore, in this study we examined the effects of fasting prior to administration of a 
high dose of the chemotherapeutic agent irinotecan on the occurrence of side-effects 
and anti-tumor activity in C26 colon carcinoma bearing mice. In addition, to elucidate 
the mechanism involved, we have examined the pharmacokinetics of irinotecan in 3-day 
fasted mice in plasma, liver, and tumor.
Materials and methods
Animals
Male BALB/c mice of 6-8 weeks old --weighing approximately 25 grams-- were obtained 
from Charles River, Maastricht, the Netherlands. Upon arrival, animals were housed at 
random in individually ventilated cages (n= 3-4 animals per cage) in a licensed biomedi-
cal facility at Erasmus University Medical Center, Rotterdam, the Netherlands. Standard 
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laboratory conditions were maintained, i.e. temperature ~22ºC, humidity ~50%, and a 12 
h light/12 h dark cycle. All mice had free access to water and food (Special Diet Services, 
Witham, UK) unless mentioned otherwise. Animals were allowed to acclimatize for one 
week before the start of the experiments. The experimental protocol was approved by 
the Animal Experiments Committee under the Dutch National Experiments on Animals 
Act, and complied with the 1986 directive 86/609/EC of the Council of Europe. For in vivo 
experiments the ARRIVE guidelines were used (17).
Fasting protocol
Mice in the ad libitum fed groups were allowed unrestricted access to food. Before the 
start of the experiment, all mice were transferred to a clean cage and mice in the fast-
ing groups were withheld food for 3 days starting at 4:00 PM. All animals were given 
continuous access to water.
C26 colon carcinoma cells
The murine colon carcinoma cell line C26 was kindly provided by dr. R. Schiffelers 
(Utrecht Medical Centre, The Netherlands). The C26 cell line originally derived from the 
BALB/c mouse and was cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma 
Aldrich, St. Louis, MO), supplemented with 10% fetal calf serum (Lonza, Verviers, Bel-
gium), penicillin (100 units/ml) and streptomycin (100 units/ml) (Invitrogen, Auckland, 
NZ) at 37 degrees Celsius in a 5% carbon dioxide environment (18). Cells were harvested 
by brief trypsinization (0.05% trypsin in 0.02% ethylenediamine tetra-acetic acid (EDTA)). 
For subcutaneous injection, cells were harvested and after centrifugation, single-cell 
suspensions were prepared in phosphate buffered saline (PBS) to a final concentration 
of 5.0 x 105 cells/100 µL. Cell viability was determined by trypan blue staining, and was 
always ≥90%.
Chemotherapy
Irinotecan, HCl-trihydrate 20 mg/mL (Hospira, Benelux) was used for in vivo experiments. 
Irinotecan was diluted in sodium chloride 0.9% (Braun, Melsungen, Germany) to a final 
volume of 200 µL per injection, and was given intraperitoneally. Optimal drug doses 
were determined in a pilot experiment (Fig.1). All drug and molecular target nomencla-
ture follows the standard of ‘Concise guide to pharmacology’ (19).
Effect of fasting on irinotecan induced side-effects
A total of 24 mice were anaesthetized with isoflurane inhalation (2%). Body temperature 
was maintained by placing the mice on heating pads. A lateral incision on the right flank 
was made to implant a tumor cube, derived from mice carrying C26 tumors subcutane-
ously. All mice received 0.05 mg/kg buprenorphine (Temgesic, Schering Plough, Houten, 
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The Netherlands) via subcutaneous injection before the implantation of tumors. Tumor 
cubes measured approximately 15 mm3, and were implanted at least 4 mm away from 
the incision site. Mice were randomly divided into four groups (n=6/group); group 
1: ad libitum fed group receiving vehicle treatment, group 2: fasting group receiving 
vehicle treatment, group 3: ad libitum fed group receiving irinotecan, group 4: fasting 
group receiving irinotecan treatment. After 3 days of fasting as well as in the ad libitum 
fed group, mice received a cumulative weight-adjusted dose of 400 mg/kg irinotecan 
administered on days 1,3 and 5 relative to fasting. The control groups received vehicle 
treatment (sodium chloride 0.9%). From the first irinotecan injection mice were weighed 
and inspected daily for adverse side effects by a mouse wellbeing-score protocol 
adapted from ‘the guidelines for welfare of animals in experimental neoplasia research’ 
(1988: United Kingdom Co-ordinating Committee on Cancer Research, UKCCCR). As-
sessing wellbeing by one researcher took approximately 10 minutes per cage with 4 
mice. Side-effects were scored independently by two experienced researchers. Mouse 
cages were removed from racks and placed on a bench to facilitate visualization of the 
mice, but cages were not opened at any point during the scoring process, except for 
the determination of the stool consistency at the end of the process. Mouse activity 
level was scored according to the amount each mouse moved in its cage. A score of 2 
indicates that an animal moved around the cage normally. A score of 1 indicates that 
an animal was moving slowly or less frequently and with an altered gait. A score of 0 
indicated that an animal was not moving and was taking no more than 5 steps. The 
appearance of the coat was scored according to the smoothness. A score of 2 indicated 
a healthy, smooth uninterrupted coat. A score of 1 indicated a slightly fluffy coat. A score 
of 0 indicated a severe fluffy coat with evident parts of visible skin. Severity of diarrhea 
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Figure 1. Survival of ad libitum fed mice treated with different doses of irinotecan. Ad libitum fed mice 
(n=6 per group) were treated on 3 intermittent days with a cumulative dose of 400 mg/kg, 500 mg/kg, 
600 mg/kg, or 800 mg/kg irinotecan (*). Using 500-, 600-, and 800 mg/kg irinotecan, all animals had to be 
sacrificed because of severe discomfort induced by irinotecan within 4, 8, and 10 days respectively. With a 
concentration of 400 mg/kg all mice survived and recovered from the side-effects of irinotecan.
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was assessed according to the stool consistency score (0: normal, 1: loose stool, 2: loose/
some diarrhea, 3: diarrhea, 4: severe watery diarrhea) (20). Before every stool consis-
tency measurement clean white tissues were placed at the bottom of the cage to allow 
determination of the consistency of the stool. Posture was scored as follows; A score of 2 
indicated a normal body posture. A score of 1 indicated a moderately hunched posture. 
A score of 0 indicated a severely hunched posture. Results are expressed as mean ± SEM. 
Leukocyte numbers were determined on day 8 after the first irinotecan injection with a Z 
series Coulter Counter (Beckman Coulter, Woerden, The Netherlands). Ten days after the 
first irinotecan injection, mice were sacrificed by exsanguination. Tumors were resected, 
and weighed.
Effects of fasting on irinotecan pharmacokinetics
A total of 54 mice were anaesthetized with isoflurane inhalation (2%). The right lateral 
flank was shaved for precise injection. 5.0 x 105 C26 cells were injected in a volume of 
100 µL suspension, using a 21G needle. Growth kinetics following C26 tumor cube im-
plantation are similar to growth after injection of C26 cells (Fig2). Tumors were allowed 
to grow for 14 days before start of the experiment. The mice were randomly divided into 
three groups (n=18/group). Two groups were fasted for 3 days and one group was fed ad 
libitum. After the fasting period, mice were fed ad libitum again. The ad libitum fed group, 
and one group of fasted animals, were treated with a single weight-adjusted dose of 100 
mg/kg (±2.5 mg, and ±2.0 mg respectively) of irinotecan intraperitoneally. The other 
fasted group received a flat-fixed dose. This dose contained the same concentration as 
in ad libitum fed mice (2.5 mg), which were approximately 20% heavier compared to the 
fasted mice. The flat-fixed dosed group was included to provide an alternative dosing 
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Figure 2. Tumor surface of ad libitum fed mice implanted with tumor cubes and injected with cells. 
Ad libitum fed mice (n=6 per group) were implanted with C26 tumor cubes from approximately 15mm3 or 
injected with 5.0 x 105 C26 tumor cells. At T=0 tumor cubes were implanted and tumor cells were injected. 
On day 5 after injection, tumors were macroscopically visible in this group and showed similar growth ki-
netics as the tumor cubes at times of implantation. At the day of harvesting the tumors (day 21 and day 25 
respectively), both groups had a similar tumor surface (p>0.05).
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to correct for bodyweight loss in fasted animals, especially during the first irinotecan 
injection. Mice were sacrificed by exsanguination and 100 µL plasma, 100 µg liver and 
100 µg tumor were collected at 1,4,8,12, 24 and 48h after irinotecan injection. Each time 
point included three mice per group.
Tissue pretreatment
Tumor and liver samples were obtained and kept frozen at -70ºC until used. Tissues 
were diluted in human plasma (1:4 w/v) into a 2-mL Eppendorf tube. Hereafter a 5-mm 
stainless steel bead (Qiagen, Venlo, The Netherlands) was added and the samples were 
homogenized with a Tissuelyser (Qiagen, Venlo, The Netherlands) and processed for 4 
minutes at 40 Hz. Beads were removed and homogenized samples were stored at -70ºC 
until analyses. Homogenized tissue samples were further processed as plasma samples.
Determination of irinotecan, SN-38, and SN-38G concentrations
Total irinotecan and total SN-38 were quantified using a validated method involving 
reversed-phase high-performance liquid chromatography with fluorescence detection 
as described before (21-23). All frozen samples were thawed at 4°C and were homog-
enized by vortex-mixing. A 250-aliquot of plasma was mixed for 10 min with 500 µL 5% 
perchloric acid- methanol (1:1, v/v) in 1.5-mL polypropylene tubes (Eppendorf, Hamburg, 
Germany). After centrifugation for 5 min at 18,000*g, 250 µL of the clear supernatant 
was mixed with 250 µL phosphate buffer. Hereafter, 100 µL was injected into the HPLC 
system. Chromatographic analysis was performed using an Agilent® HPLC system 1100 
series (Agilent Technologies, Santa Clara, CA). Chemstation software was used for data 
monitoring and analysis. Separation of the compounds was achieved using a Inertsil 
ODS 80A (4.6 mm x 150 mm, 5 µm particle size) analytical column. The analytical column 
was maintained at a temperature of 50°C. A gradient at a flow-rate of 1.00 mL/min was 
achieved with mobile phase A, composed of 0.1 M ammonium acetate containing 0.01 
M tetra-butyl-ammonium sulphate and mobile phase B composed of methanol. A linear 
gradient was used, with 67-50% mobile phase A, from 0 to 25 min, followed by 50-10% 
mobile phase A for 5 min. This was succeed by a linear gradient back to 67% mobile 
phase A from 30 to 31 min which was held for 2 min to re-equilibrate. The column eluent 
was monitored fluorimetrically at an excitation wavelength of 375 nm and an emission 
wavelength of 460 nm for detection of irinotecan and an excitation wavelength of 380 
nm and an emission wavelength of 532 nm for the detection of SN-38. Calibration curves 
were computed using the ratio of the peak height of irinotecan or SN-38 versus the 
nominal concentration, with a lower limit of detection of 5.00 ng/mL for irinotecan and 
0.500 ng/mL for SN-38. Uridine diphosphate glucuronosyltransferase 1A (UGT1A) is ca-
pable of inactivating SN-38 to its glucuronide form, SN-38G. SN-38G in plasma samples 
was quantified by the amount of SN-38 released following treatment for 3 h at 37°C with 
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100U of E. coli ß-glucuronidase. Concentrations from 48 hour samples were below the 
detection limit and therefore we decided to include 0-24h time points.
Real-time quantitative RT-PCR (qRT-PCR)
RNA was isolated from liver and tumor tissues collected at 1, 8 and 12h after irinotecan 
injection from the ad libitum fed and the fasted group (flat-fixed dosed) using Trizol 
reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. 
To avoid genomic DNA contamination, RNA was purified by a DNAse treatment (RQ1 
RNase-Free DNase; Promega, Madison, WI, USA). RNA was then reverse transcribed 
into cDNA using random primers (Invitrogen) and Superscript II RT (Invitrogen). Gene 
expression was analyzed by real-time quantitative PCR using an Applied Biosystems 
7700 PCR machine (Foster City, CA, USA). RT-PCR was performed for carboxylesterase 
2 (CES2) forward, 5-ggccatgtgtctgcaaaatc-3 and reverse, 5-caccatcacaggcaggttag-3. 
Glutaraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a housekeeping 
gene. Each sample was tested in triplicate. ΔCt values were normalized to the average 
ΔCt of the ad libitum fed group. The fold change was calculated using the Pfaffl equation, 
2-ΔΔCt. Results are expressed as mean with the standard error of the mean (SEM).
Statistical analyses
For analyzing the pharmacokinetic (PK) data Phoenix WinNonlin version 6.1 (Certara USA 
Inc, St. Louis, MO) software was used. All standard statistical tests were performed using 
SPSS version 21 for Windows software (Statistical Package for Social Sciences, Chicago, 
IL), and p < 0.05 was considered to be significant. For each set of parameters means and 
standard errors of the mean were computed. One-way analyses of variance (ANOVA) was 
used to assess whether fasting significantly altered side-effects. Bonferroni correction 
was applied to correct for multiple testing. To show statistics between pharmacokinetic 
differences, the highest, intermediate, and lowest area under the plasma concentration 
time curve (AUC) value for each group was calculated. The students t-test was used to 
determine statistical differences.
Results
To study the effect of fasting on irinotecan toxicity, we first treated ad libitum fed mice 
with different doses of irinotecan. Using cumulative doses of 500,600 and 800 mg/kg all 
mice died within 11 days from the first injection (Fig1). Using a cumulative dose of 400 
mg/kg mice experienced serious adverse effects like diarrhea, hair loss, and a ruffled coat 
but survived and recovered in the 15-day observation period. Therefore, we decided to 
use the cumulative dose of 400 mg/kg in our first experiment.
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Fasting protects against the adverse side-effects of irinotecan and does not 
abrogate anti-tumor activity
To examine the effects of fasting before irinotecan administration on the occurrence of 
irinotecan-induced side-effects and anti-tumor effect in C26 colon carcinoma bearing 
mice, we compared 3 day-fasted with ad libitum fed mice. In the ad libitum fed group, 
mice showed weight loss from the first irinotecan injection, while the fasted mice gained 
weight during the treatment and observation period (Fig3A). From day 4 after the first 
irinotecan injection, other side-effects were observed in the ad libitum fed group. They 
were less active (p=0.003), had a ruffled coat (p<0.001), suffered more from diarrhea 
(p<0.001) and showed a hunched-back posture (p<0.001) (Fig3B-E). The fasted mice 
showed no visible side-effects. On day 8 after the first irinotecan injection the fasted 
group had a significantly higher blood leukocyte count than the ad libitum group (6.5 
± 0.2*106/mL vs. 3.2 ± 0.1*106/mL, p<0.001) (Fig3F). Survival during the observation 
period was 100% in the chemotherapy treated groups. At the end of the experiment all 
tumors were resected and weighed. Irinotecan treated tumors were significantly smaller 
both in fasted and ad libitum fed groups compared to untreated controls (1,263 ± 54 mg 
and 1,278 ± 36 mg vs. 2,195 ± 113 mg, p < 0.001). Fasting alone had no significant effect 
on tumor growth (Fig4).
Taken together, these results show that 3 days of fasting prior to treatment with a high 
dose of irinotecan prevents against side-effects but does not abrogate its anti-tumor 
effects.
Fasting reduces the systemic exposure to SN-38
To elucidate the mechanism of fasting induced resistance against its side-effects, we 
have examined the pharmacokinetics of total irinotecan and its active metabolite SN-38 
in plasma, liver, and tumor tissue of 3 day fasted and ad libitum fed mice. Furthermore, 
SN-38G concentrations were measured in plasma to indicate activity of uridine diphos-
phate glucuronosyltransferase 1A (UGT1A). Area under the plasma concentration time 
curve (AUC) data were computed, normalized, and set to 100% for ad libitum fed groups 
(Fig5). To express differences between AUC curves more clearly, and to perform statis-
tics on these curves, figures were computed where the highest, intermediate and lowest 
AUC values were plotted (Fig6A-G).
AUC values of the active metabolite SN-38 were significantly lower in plasma and liver in 
fasted animals compared to ad libitum fed animals while in the tumor SN-38 AUC values 
did not differ between fasted and ad libitum fed animals.
Plasma AUC values of irinotecan were increased with 35% and 47% in the weight-
adjusted dosed fasting group and flat-dosed fasting group respectively compared with 
ad libitum fed controls (AUC0-inf 56.1 vs. 41.7 and AUC0-inf 61.4 vs. 41.7 µg*h/mL, Fig6A). 
108
"%#$-
	

	

   
         
	






	
	
%("!0,

"%
#$
-#
+
(
 -%/%-0
 

%
+%)*

%+%)
*
		
	

	


	


 
-%/
%-0
, 
*+
"	

*-
 

%
+%)*

%+%)
*
		
	

	


	


*
-
, 
*+
"	

%++$"
 

%
+%)*

%+%)
*
	





-
**
' 
*)
,%,
-")
 0
, 
*+
"
*,-.+"
 

%
+%)*

%+%)
*
		
	

	


	


*
,-.
+"
, 
*+
"	

".&* 0-",


%
+%)* 

%+%)
*
	





	


"
.&
* 
0-"
,

	

(

 
 
 
Figure 3. Protective effects of fasting against irinotecan toxicity. A total of 24 mice, 6 mice per group, 
were observed for adverse side-effects until ten days after the first irinotecan injection (*). (A) Effect of fast-
ing on body weight. Fasted (F) mice lost about 20% of their body weight during 3-days fasting. During iri-
notecan treatment ad libitum (AL) fed mice showed 20% weight loss, while fasted mice gained weight and 
reached their starting weight at day 5. (B to E) Effects of fasting on activity (p=0.003) (B), coat (p<0.001) (C), 
diarrhea(p<0.001) (D), and the posture of the mice (p<0.001) (E). (F) Effect of fasting on leukocyte numbers. 
On day 8 after the first irinotecan injection, treated ad libitum (AL) fed mice showed leukopenia compared 
to fasted (F) mice (6.5 ± 0.2*106/mL vs. 3.2 ± 0.1*106/mL, p<0.001).
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Figure 4. Effect of irinotecan treatment on tumor growth in fasted and ad libitum fed groups. At the 
end of the experiment irinotecan treated tumors were significantly smaller in both the fasted (F) and ad 
libitum (AL) fed groups compared to untreated controls (1,263 ± 54 mg and 1,278 ± 36 mg vs. 2,195 ± 113 
mg, p < 0.001). Fasting alone had no significant effect on tumor weight.
Figure 5. Pharmacokinetics of irinotecan and SN-38 in plasma, tumor and liver. Area under the plasma 
concentration time curve (AUC) data was normalized, and set to 100% for ad libitum fed groups (black rect-
angles). Fasted weight-adjusted dosed (white rectangles) and fasted flat-fixed dosed (striped rectangles) 
animals show a trend towards higher plasma irinotecan AUC values, while irinotecan AUC values in the liver 
and tumor are lower in fasted animals. SN-38 AUC values are lower in both fasted groups in plasma and 
liver, and SN-38G AUC values are lower in plasma. SN-38 AUC values in tumor tissue show large variation.
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SN-38 AUC values were reduced by 51% and 26% in the weight-adjusted dosed fast-
ing group, and the flat-dosed fasting group respectively compared with ad libitum fed 
controls (AUC0-24 0.56 vs.1.15 µg*h/mL, p=0.02 and AUC0-24 0.85 vs. 1.15 µg*h/mL, Fig6B). 
SN-38G AUC values were reduced by 51% and 35% in the weight-adjusted dosed fast-
ing group, and the flat-dosed fasting group respectively compared with ad libitum fed 
controls (AUC0-24 8.3 vs.16.9 µg*h/mL, p=0.01 and AUC0-24 11.0 vs. 16.9 µg*h/mL, p=0.04, 
Fig6C).
In the liver, a reduction of 39% and 14% in irinotecan AUC values was observed in 
the weight-adjusted dosed fasting group, and the flat-dosed fasting group respectively 
compared with ad libitum fed controls (AUC0-inf 354 vs. 575 ng*h/mg and AUC0-inf 495 
vs. 575 ng*h/mg, Fig6D). SN-38 AUC values showed a 47% and 41% reduction in the 
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Figure 6. Statistical validation of pharmacokinetic differences. Graphs represent the highest, interme-
diate, and lowest area under the plasma concentration time curve (AUC) value for each group. No sig-
nificant differences were found for irinotecan AUC values between ad libitum (AL) fed, weight-adjusted 
dosed fasted (F), and flat-fixed dosed fasted (F flat) groups in plasma (A+B), liver (D+E), and tumor (F+G). 
SN-38 AUC values in plasma were significantly lower in weight-adjusted dosed fasted animals (p=0.02), and 
SN-38G AUC values were significantly lower in weight-adjusted dosed fasted animals and fasted flat-fixed 
dosed animals (p=0.01, and p=0.04 respectively, C). SN-38 AUC values in the liver were significantly lower 
in both fasted groups (p=0.003 and p=0.003). No significant differences were seen in SN-38 AUC values for 
tumor tissues (p=0.27).
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weight-adjusted dosed fasting group, and the flat-dosed fasting group respectively 
compared with ad libitum fed controls (AUC0-24 15.5 vs. 29.2 ng*h/mg, p=0.003 and 
AUC0-24 17.1 vs. 29.2 ng*h/mg, p=0.003, Fig6E).
In the tumor, a reduction of 21% in irinotecan AUC values was observed in the weight-
adjusted dosed fasting group. In the flat-dosed fasting group no difference was found 
compared with ad libitum fed controls (AUC0-inf 77.9 vs. 98.4 ng*h/mg, Fig6F). Interest-
ingly, SN-38 AUC values showed an increase of 166% in both fasted groups, compared 
with ad libitum fed controls (AUC0-24 1.11 and 1.11 vs. 0.669 ng*h/mg, Fig6G). Although 
this increase is not significantly different, it implies that the intratumoral SN-38 concen-
trations do not decrease after fasting.
These data demonstrate that irinotecan AUC values are not changed in fasted animals, 
while SN-38(G) AUC values are significantly lower in plasma and liver tissue from fasted 
animals, indicating that 3 days of fasting prior to irinotecan administration induces an 
important change in its metabolism, and lowers the systemic exposure to toxic SN-38.
CES2 activity in liver and tumor
Conversion of irinotecan to SN-38 primarily occurs in the liver by CES enzymes. Fasting 
is known to affect liver function and size. Therefore, irinotecan metabolism by CES may 
be changed during fasting. We measured CES2 activity by mRNA expression at 1,8, and 
12 hour(s) after irinotecan injection in liver and tumor tissue from ad libitum fed and 
fasted animals. There are no significant differences in CES2 expression levels between 
ad libitum fed and fasted groups in liver and tumor tissue (Fig7).
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Figure 7. CES2 mRNA expression in liver and tumor tissue from ad libitum fed and fasted mice. CES2 
expression at 1, 8, and 12 hour(s) after irinotecan injection in liver and tumor tissue from ad libitum (AL) fed 
and fasted (F) animals did not reveal any significant differences.
Discussion
The experiments presented in the current study show that 3 days of fasting prior to 
treatment with a high dose of irinotecan prevents the occurrence of drug related side-
effects while anti-tumor efficacy is not affected. To elucidate the mechanisms behind 
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the fasting-induced protection to irinotecan induced side-effects we studied its phar-
macokinetics in fasted and fed mice. We found no differences in irinotecan AUC values 
between fasted and ad libitum fed animals and demonstrated that the AUC of the active 
and toxic metabolite of irinotecan, SN-38, is lower in plasma and liver tissue in fasted 
animals. Furthermore, SN-38G AUC values are significantly lower in plasma from fasted 
animals. The intratumoral SN-38 AUC values in fasted mice remained unchanged. These 
data indicate that fasting induces important changes in irinotecan metabolism, and 
lowers the systemic exposure to irinotecan and SN-38.
A remarkable finding in this study is that 3-day fasted BALB/c mice do not show any 
signs of toxicity in response to a high dose of irinotecan. In contrast, animals regained 
the weight that was lost during the fasting period, approximately 20%, during high dose 
irinotecan treatment, while control animals lost approximately 20% of their bodyweight 
during both irinotecan exposure and the subsequent observation period. It is currently 
thought that fasting induces a hormetic response. This is a common biological phenom-
enon in which exposure to a low intensity stressor induces a general adaptive response 
that has beneficial effects, including protection against different types of stress (24, 25). 
We observed relevant differences in irinotecan pharmacokinetics between ad libitum fed 
and fasted mice. In plasma from fasted mice, there is a trend towards higher AUC values 
of irinotecan compared with ad libitum fed mice, while SN-38 AUC values in plasma from 
fasted mice are lower compared with ad libitum fed groups. In the liver, there is a trend 
towards lower AUC values of irinotecan in fasted mice, and AUC values of SN-38 are sig-
nificantly lower in fasted groups compared to ad libitum groups. SN-38 is approximately 
100-1,000-fold more cytotoxic than the pro-drug (7). The conversion of irinotecan to 
SN-38 occurs primarily in the liver by carboxylesterase (CES) enzymes, but in patients 
this conversion is rather inefficient (only 2-5%) when irinotecan is injected intravenously 
(26, 27). Therefore it is thought that intratumoral CES expression is responsible for the 
anti-tumor effect in patients (28). We found reduced levels of SN-38 in liver and plasma 
of fasted mice, but CES expression is not altered in these mice. Tumor cells have the same 
if not higher levels of SN-38, but CES expression is not higher in tumor cells of fasted 
mice. This may indicate that tumor cells of fasted mice are taking up more SN-38 rather 
than metabolism by CES is higher in fasted mice. UGT1A is capable to inactivate SN-38 to 
its glucuronide form SN-38G, leading to excretion from the circulation (29). We showed 
significantly lower SN-38G AUC values in plasma from fasted mice, indicating that the 
lower amount of SN-38 in plasma is not due to induced UGT1A activity.
In an attempt to explain the differential effects of fasting on the systemic level versus 
tumor tissue, the term ‘differential stress resistance’ was coined (16, 30). Drug metabolism 
can be largely divided into 3 phases: phase-I (redox and hydrolysis), phase-II (conjuga-
tion), and phase-III (transport). Diet and nutrient signaling pathways have important 
effects on phase-I enzymes (31). These enzymes consist primarily of cytochrome P450 
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(CYP) superfamily proteins (32) and phase II proteins including enzymes regulated by 
Keap1-Nrf2 (33). During fasting, significant modulation of these pathways occurs in 
healthy tissue, but not in tumor tissue. We have previously shown that 3 days of fasting 
up-regulates canonical stress resistance pathways such as Nrf2, ‘xenobiotic metabolism’ 
and effector genes such as heme-oxygenase I, superoxide dismutase, and glutathione-
S-transferase (10, 34). These data may partly explain the concept of differential stress 
resistance, which predicts that these pathways are differentially regulated by fasting in 
healthy-, versus tumor tissue. How this affects pharmacokinetics and anti-tumor efficacy 
has remained unknown. We hypothesize that during fasting cells in the liver (among 
others) up regulate stress resistance pathways, which decreases conversion of irinotecan 
whereas in the tumor these pathways are unaffected. This supposition is strengthened 
by the fact that SN-38 AUC values remained unchanged in tumors of fasted mice.
Fasting down regulates Insulin-Like Growth Factor-1 (IGF-1) levels (10), which has a 
plethora of downstream effects that are likely linked to the protective effect induced 
by fasting. Many intrinsic factors may influence the PK of irinotecan (7). IGF-1 has been 
related to cetuximab + irinotecan treatment outcome in human (35). However, to the 
best of our knowledge, IGF-1 has never been related to the PK of irinotecan in vivo. 
Potential interactions between IGF-1 and irinotecan PK can, based on this study, not be 
determined.
Previously, protective effects against toxic agents have also been observed when ani-
mals were subjected to long term dietary restriction. Mice subjected to 5-8 months 40% 
dietary restriction were significantly more resistant against paraquat toxicity than ad 
libitum fed mice (36). Rats allowed to eat 65% of their normal intake for 3 weeks showed 
increased resistance to thioacetamide due to increased liver tissue repair mechanisms 
(37). Rats that were 40% calorically restricted for 4 weeks showed increased resistance 
against bleomycin induced DNA damage (38).
We showed that the beneficial effect of dietary restriction on acute stress resistance 
can be induced rapidly; 3 days of fasting led to protection against oxidative damage 
induced by renal ischemic injury similar in magnitude to 2-4 weeks of 30% dietary re-
striction (DR) (10). On a global level we found an overlapping transcriptional response, 
indicating that short-term fasting and long-term DR induce potentially overlapping 
mechanisms. Furthermore, it has been shown that an ad libitum diet deficient in protein 
or amino acids protects mice in a surgical ischemia-reperfusion injury model (39). More 
recently, a study in dogs with lymphoma that were treated with doxorubicin showed 
that 24 hours of fasting the night before administration resulted in significantly lower 
incidence of vomiting (40).
Implementation of dietary restriction and fasting in the clinic is still laborious. We 
have shown that preoperative dietary restriction and fasting are feasible and safe in 
surgical patients (11, 41). Furthermore, women at risk for breast cancer showed reduced 
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inflammation and oxidative stress during a 2 days/week fasting diet (42). Asthma 
patients maintained for 8 weeks on an alternate day fasting diet exhibited less clinical 
symptoms, pulmonary functions were improved, and oxidative stress and inflammation 
declined during the diet (43). Based on the existing evidence from animal and human 
studies, there is a great potential translating these results to clinical cancer patients. 
In a self-reported study of patients with a variety of malignancies, a voluntarily fasting 
regimen prior to (48-140 hours) and/or following (5-56 hours) chemotherapy resulted 
in a decrease of common side-effects and increased subjective well-being (44). These 
data suggest that fasting is safe, feasible, and might offer important new opportunities 
to improve chemotherapy treatment in cancer patients. However, development and 
completion of randomized controlled clinical trials is essential in unleashing its clinical 
potential.
It is known that ectopic and orthotopic tumor environments could respond differently 
on a variety of treatments. However, in a recent study using FabplCre;Apc15lox/+ mice, 
which spontaneously develop intestinal tumors, fasting also reduced tumor growth 
similarly as in ad libitum fed mice and protected against the side effects of irinotecan 
(45). However, the results from this orthotopic tumor model not directly prove that dif-
ferential alteration of PK is the primary mechanism, and needs further investigation. We 
show that fasting protects against side-effects of one cycle of irinotecan treatment. It re-
mains unclear if cancer cells are sensitized or not by multiple cycles of fasting/ irinotecan 
treatment in this experimental model. However, a recent study suggested that multiple 
cycles of fasting induces differential stress sensitization in a range of tumors (15).
In summary, the present study shows that short-term fasting protects against adverse 
side-effects of irinotecan in C26 colorectal carcinoma bearing mice without interfering 
with anti-tumor activity. The reduction of side effects may be the result of the lower 
systemic exposure to SN-38 in fasted compared to ad libitum fed mice. When confirmed 
in clinical trials, fasting before irinotecan treatment may offer important new opportuni-
ties to improve this treatment for colorectal carcinoma patients.
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Abstract
Irinotecan is an effective and frequently used chemotherapeutical agent, however its 
use is accompanied by severe toxicity. Previously, we reported that 3 days of fasting 
protects against side effects of irinotecan while preserving its antitumor activity. The 
mechanisms behind the protective effects of fasting have yet to be elucidated. Here, we 
investigated the transcriptional responses to fasting and irinotecan treatment in both 
tumor and healthy liver tissue.
Male BALB/c mice (n=36) were subcutaneously injected with murine colon carcinoma 
cell line C26. After 12 days, two groups were fasted for 3 days and two groups were 
allowed food ad libitum (AL). One group of each received irinotecan intraperitoneally, 
the other groups vehicle. Twelve hours after injection mice were sacrificed, and blood, 
tumor and liver samples were harvested. Blood samples were analyzed for organ func-
tion and leukocyte numbers, collected tissues were used for microarray analyses.
The AL fed irinotecan group had significantly altered liver and kidney function and 
decreased leukocyte numbers. These effects were abated in the fasted animals. At gene 
expression level, fasting led to a differential and ameliorated stress response, with 
fewer toxicity pathways, in liver upon irinotecan treatment compared to AL fed mice. In 
contrast, such diet-induced adaptation after irinotecan exposure was absent in tumor 
tissue, which showed a signature of increased sensitivity in the fasted group.
In conclusion, fasting reduces toxicity of irinotecan by inducing a protective stress 
response in healthy liver tissue, while it preserves or even increases the anti-tumor activ-
ity of irinotecan on a transcriptional level. These data give insight in the mechanisms 
involved in the protective effects of fasting on the side effects of irinotecan, and may 
pave the way to develop dietary restriction mimetics which may induce similar effects 
without the disadvantages of fasting.
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Introduction
The occurrence of cancer is rising continuously. Colorectal cancer (CRC) is the second 
most diagnosed cancer in women and the third most diagnosed in men. Estimated new 
colorectal cancer cases account for 1.4 million cases and 693.900 deaths worldwide 
occurring in 2012 (1). At initial presentation, 15-20% of patients already have liver me-
tastases and another 45% is diagnosed with liver metastases in the follow-up after resec-
tion of the primary tumor (2). Irinotecan is a pro-drug of the topoisomerase-I inhibitor 
SN-38, and is applied in first and second line chemotherapy treatment for colorectal 
carcinoma (3, 4). Irinotecan can induce severe and unpredictable side effects including 
deep myelosuppression, diarrhea, and in some cases even death as a complication of 
side-effects (5).
Dietary restriction (DR) is a method to trigger highly conserved survival mechanisms 
that enhance protection of organisms against stressors and diseases (6). In previous 
research we showed that 3 days of fasting induces a protection against oxidative 
stress (7, 8). Recently, we showed that 3-day fasting prior to a toxic dose of irinotecan 
significantly prevented the occurrence of side effects in an Apc-mutant mouse model. 
Furthermore, tumor size and proliferation were reduced equally in ad libitum fed and 
fasted animals, indicating that the anti-tumor effect of the drug was unimpaired by the 
dietary preconditioning (9). One of the theories on how this effect is initiated is called 
differential stress resistance. It has been suggested that fasting protects normal cells by 
shifting from growth to maintenance. The tumor cells are unable to make this shift and 
remain driven towards growth because of mutations and alterations (10, 11). It remains 
largely unknown what the mechanism behind this beneficial effect is.
Mechanistic insight and clarification of the underlying genes and pathways should 
facilitate translational research into the clinic since it may reveal alternative approaches, 
e.g. specialized forms of diet restriction, or dietary restriction mimetics which may in-
duce similar effects without the disadvantages of fasting.
Therefore, in this study we investigated the transcriptional responses to fasting and 
irinotecan exposure in tumor and in healthy liver tissue.
Materials and methods
Animals
Male BALB/c mice of 6-8 weeks old, weighing approximately 25 grams, were obtained 
from Charles River, Maastricht, the Netherlands. Upon arrival, animals were housed at 
random in individually ventilated cages (n=4 animals per cage) in a licensed biomedi-
cal facility at Erasmus University Medical Center, Rotterdam, the Netherlands. Standard 
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laboratory conditions were maintained, i.e. temperature ~22ºC, humidity ~50%, and a 12 
h light/12 h dark cycle. All mice had free access to water and food (Special Diet Services, 
Witham, UK) unless mentioned otherwise. Animals were allowed to acclimatize for one 
week before the start of the experiments. The experimental protocol was approved by 
the Animal Experiments Committee under the Dutch National Experiments on Animals 
Act, and complied with the 1986 directive 86/609/EC of the Council of Europe.
C26 colon carcinoma cells
The murine colon carcinoma cell line C26 originally derived from the BALB/c mouse and 
was cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma Aldrich, St. Louis, 
MO), supplemented with 10% fetal calf serum (Lonza, Verviers, Belgium), penicillin (100 
units/ml) and streptomycin (100 units/ml) (Invitrogen, Auckland, NZ) at 37 degrees 
Celsius in a 5% carbon dioxide environment. Cells were harvested by brief trypsinization 
(0.05% trypsin in 0.02% ethylenediamine tetra-acetic acid (EDTA)). For subcutaneous 
injection, cells were harvested and after centrifugation, single-cell suspensions were 
prepared in phosphate buffered saline (PBS) to a final concentration of 2.5 x 105 cells/100 
µL. Cell viability was determined by trypan blue staining, and was always ≥90%.
Experimental setup
Mice (n=36) were anaesthetized (isoflurane inhalation, 5% isoflurane inhalation initially 
and then 2% isoflurane with a 1:1 air:oxygen mixture for maintenance of anesthesia) 
(Fig1). Both flanks were shaved for precise injection. 2.5 x 105 C26 cells were injected 
on both sides in a volume of 100 µL, using a 21G needle. Tumors were allowed to grow 
for 12 days before start of the experiment. Mice were weighed and tumors were mea-
sured daily with digital calipers. The mice were randomly divided into four groups (n=6/
group). Two groups were fasted for 3 days and two groups were fed ad libitum (AL). 
After the fasting period, mice were fed AL again. One AL fed group, and one group of 
fasted animals, were treated with a single weight-adjusted dose of 133 mg/kg (±3.3 mg, 
and ±2.7 mg respectively) of irinotecan intraperitoneally. The control groups received 
RNA 
isolation 
 
 
Arrival Balb/c 
mice 
acclimatization
Subcutaneous 
C26 injection
Start fasting/ ad 
libitum
Irinotecan or 
vehicle injection 
ip
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Sacrifice groups 
3 to 6
8 pm
Figure 1. Schematic overview of the experimental set-up, including a timeline from arrival of the mice until 
sacrifice and subsequent RNA isolation for further analyses. IP = intraperitoneal
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vehicle treatment (sodium chloride 0.9%). Two hours after injection, the fasted groups 
received a weighed amount of AL food. Mice were sacrificed 12 hours after administra-
tion of irinotecan by exsanguination.
Fasting protocol
Mice in the AL fed groups were allowed unrestricted access to food, and amount of food 
eaten per cage was measured daily. Before the start of the fasting period, all mice were 
transferred to a clean cage and mice in the fasting groups were withheld food for 3 
days starting at 4:00 PM on a Friday until 10:00 AM on a Monday. All animals were given 
continuous access to water.
Chemotherapy
Irinotecan, HCl-trihydrate 20 mg/mL (Hospira, Benelux) was used for in vivo experiments. 
Irinotecan was diluted in sodium chloride 0.9% (Braun, Melsungen, Germany) to a final 
volume of 200 µL per injection, and was given intraperitoneally.
Serum measurements
Mice were killed by exanguination with cardiac puncture under anesthesia (isoflurane 
inhalation, 5% isoflurane inhalation initially and then 2% isoflurane with a 1:1 air:oxygen 
mixture for maintenance of anesthesia). After cardiac puncture, ± 900 µL of blood per 
mouse was transferred directly into 1 mL tubes (MiniCollect, Greiner Bio-one), contain-
ing EDTA. Samples were directly centrifuged (3,500 rpm; 10 min) after which the serum 
was transferred to a separate tube. Serum aspartate transaminase (AST), alanine trans-
aminase (ALT), lactate dehydrogenase (LDH), urea, and creatinine levels were analyzed 
at the Central Clinical Chemical Laboratory of the Erasmus University Medical Center. 
Fifty µL of blood was used to measure the number of leukocytes with a Z series Coulter 
Counter (Beckman Coulter, Woerden, The Netherlands).
Tissue sampling
Liver and tumors were collected and weighed. The median liver lobe was isolated for 
array analysis and directly stored in RNAlater® Solution (Life Technologies Europe BV, 
Bleijswijk, the Netherlands) and stored at 4ºC until further analysis. Parts of viable tumor 
border were identified and also directly stored in RNAlater® until further analysis.
RNA isolation
Tumor and liver samples obtained were kept at 4ºC in the RNAlater® Solution until 
further analyses. RNA isolation took place between 24 hours and 96 hours after sample 
collection. Total RNA was extracted via the QIAzol lysis Reagent and miRNAeasy Mini 
Kits (QIAGEN, Hilden, Germany), according to Qiagen protocol. Concentrated buffers 
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RPE and RWT (QIAGEN) for washing of membrane-bound RNA and purification were 
added mechanically by using the QIAcube (QIAGEN, Hilden, Germany) via the miRNeasy 
program. Subsequently, isolated RNA was stored at -80°C. RNA concentrations were 
measured using the Nanodrop (Thermo Fisher Scientific™, Breda, the Netherlands) 
and RNA quality was assessed using the 2100 Bio-Analyzer (Agilent Technologies, Am-
stelveen, the Netherlands), according to manufacturer’s instructions. The RNA quality 
was quantitatively expressed as the RNA Integrity Number (RIN, range 0-10). Out of 6 
tumor and 6 liver samples per group, the 4 samples with the highest RIN were used for 
microarray analyses. RIN-values of the tumor samples ranged between 7.8 and 10, the 
RIN-values of the liver samples ranged between 7.6 and 8.6.
Array analysis
Microarray hybridization was done at the Microarray Department of the University of 
Amsterdam (the Netherlands) to Affymetrix HT MG-430 PM Array Plates, according to 
the Affymetrix protocols. For each group, 4 biological replicates were used. The output 
of the hybridization contained raw mean expression data put into .CEL files. Subsequent 
quality control and normalization were done using the pipeline at the www.array-
analysis.org website (Maastricht University, the Netherlands) (12). Normalization was 
performed via the Robust Multichip Average (RMA) algorithm, and the output of the 
normalization consisted of 45141 probes (13). Both raw and normalized microarray data 
and their MIAME compliant metadata were deposited at the Gene Expression Omnibus 
(GEO) database, with number GSE72484 (www.ncbi.nlm.nih.gov/geo).
Statistical analyses
For each set of parameters means and standard errors of the mean were computed. All 
standard statistical tests were performed using SPSS version 21 for Windows software 
(Statistical Package for Social Sciences, Chicago, IL) and GraphPad Prism (GraphPad Soft-
ware Inc., version 5.01) . A p<0.05 was considered to be significant. Microarray analyses 
were performed using the free software package R (R foundation). Gene expression 
profiles were compared using the Linear Models for Microarray Data (limma) method 
with correction for multiple testing using the false discovery rate (FDR) according to 
Benjamini and Hochberg (14). Fold changes were expressed as the geometric mean 
per diet group against the corresponding AL fed control group, and cutoff values for 
a significant difference were put at FDR <5%. Functional annotation and analyses were 
performed using the Ingenuity software (http://www.ingenuity.com/products/ipa). 
Inhibition or activation prediction of the upstream transcription regulators (upstream 
analysis) was predicted with Ingenuity software by calculating statistical z-scores based 
on the observed gene expression changes in our dataset. Via z-scores, the chance of 
significant prediction based on random data is reduced (http://ingenuity.force.com/ipa/
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articles/Feature_Description/Upstream-Regulator-Analysis). Cutoff values for a signifi-
cant activation or inhibition were put at a z-score of ≥2 or ≤-2, respectively.
Results
Fasting induced chemoprotective phenotype
The direct systemic effects of chemotherapy and the effects of fasting were analyzed via 
markers of liver function, kidney function and leukocyte numbers at 12 hours after injec-
tion of irinotecan. Compared to AL fed mice injected with vehicle, a significant increase 
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Figure 2. (A) Liver function of the different experimental groups, measured via serum AST, ALT and LDH 
levels. (B) Kidney function of the experimental groups via serum urea and creatinine levels. (C) Leukocyte 
numbers of all the experimental groups. All values were determined 12 hours after administration of either 
vehicle or irinotecan. AST = aspartate transaminase, ALT = alanine transaminase, LDH = lactate dehydroge-
nase. *= P<0.05, **=P<0.01.
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in serum levels of ALT (P<0.05), AST (P<0.01) and LDH (P<0.05) was observed in AL fed 
irinotecan treated mice (Fig2A). The fasted vehicle group had significantly higher serum 
ALT levels than the AL vehicle group. The fasted irinotecan group had significantly lower 
levels of serum LDH than the AL irinotecan group (P<0.05).
Serum urea levels were significantly lower in the AL vehicle group than in fasted ve-
hicle (P<0.05), the AL irinotecan (P<0.01) and fasted irinotecan (P<0.01) group (Fig2B). 
The fasted irinotecan group had significantly lower serum urea levels than did the AL 
irinotecan group (P<0.05). Serum creatinine did not significantly change in any of the 4 
groups (Fig2B).
Both the AL irinotecan (P<0.01) and fasting irinotecan (P<0.05) group had a signifi-
cantly lower number of leukocytes than the AL vehicle group (Fig2C). The AL irinotecan 
group also had significantly lower leukocyte numbers than the fasted vehicle group 
(P<0.05). In contrast the fasted vehicle and fasted irinotecan group had comparable 
leukocyte numbers.
Liver array analyses
Principal component analysis
To investigate variability between and among our experimental groups, we performed 
an unbiased principal component analysis (PCA) of liver and tumor samples including 
all probe sets in the microarray. In the PCA plot of the liver samples, 50.77% of the vari-
ance was explained by principal components (PC) 1 and 16.81% by PC2 (Fig3). A pattern 
of distinct clustering of the 4 individual groups was seen, with the smallest intragroup 
variability in the fasting vehicle group. The fasting vehicle group was most different from 
the AL vehicle group, mainly on the PC1, while the difference with the AL irinotecan 
group was for the most part on PC2, indicating distinct gene expression patterns among 
these groups. The fasting vehicle group was closely related to the fasting irinotecan 
group, and showed the smallest difference observed between groups.
Gene expression profiles
To compare gene expression profiles between the different experimental groups, the 
numbers of differentially expressed probe sets (DEPS) were calculated. In the liver, 2667 
DEPS were found between the AL vehicle and AL irinotecan group, with 1144 DEPS down-
regulated and 1523 up-regulated (Fig4A). The number of DEPS between fasting vehicle 
and fasting irinotecan was 754, a 3.5 fold lower number than found in the AL vehicle and 
AL irinotecan comparison. Of these 754 genes, 459 DEPS were down-regulated and 295 
were up-regulated. To analyze common expression patterns between the AL and fasting 
groups, the overlapping DEPS were visualized using a Venn diagram and a scatterplot. 
The Venn diagram showed that 329 DEPS overlapped between the AL irinotecan and 
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fasting irinotecan groups, corresponding to 44% of the DEPS found after fasting, and 
only 14% of the DEPS after AL vehicle vs. AL irinotecan (Fig4B). Directionality and expres-
sion intensity of the unique and overlapping genes was visualized in a scatterplot. This 
scatterplot showed that 83% of all DEPS had a similar directionality in both comparisons, 
but fold change expressions of the AL irinotecan groups (red symbols) were on average 
higher than the fasting irinotecan groups (green symbols). Of the overlapping DEPS 
(black symbols) the vast majority had similar directionality patterns (Fig4C). Collectively, 
these results point towards a dampened response in de fasted group pertaining the 
signifi cantly regulated genes in the AL group and more pronounced expression changes 
for a diff erent subset of genes (green symbols).
Pathway analyses
To explore the pathways regulated by irinotecan, the liver of AL fed mice (2667 DEPS) 
was analyzed. A total of 19 pathways were regulated, defi ned as pathways with a sig-
nifi cant p-value of <0.05 and a z-score of ≥1 or ≤-1 (Table 1A). The activated pathways 
were mainly involved in induction of cytokine signaling, cellular immune response 
and tyrosine/kinase system signaling. The inhibited pathways were mainly part of the 
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Figure 3. Unbiased principal component analyses (PCA) of liver samples, based on all probe sets in the 
microarray. Principal component (PC) 1 is depicted on the x-axis and PC2 is depicted on the y-axis, includ-
ing the percentage of variance explained by each PC. Each symbol represents one sample of one mouse. 
Samples of the same group are shown in the same color. AL = ad libitum.
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cAMP system, cardiovascular signaling and inhibition of cellular growth, proliferation, 
development, and cellular stress and injury. To examine the changes on pathway level 
due to fasting, the diff erentially expressed pathways found in the AL fed groups were 
examined in the fasting groups. Of the 19 pathways regulated in the AL groups, 5 were 
regulated in the opposite direction in the fasting groups (Table 1A). These pathways 
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Figure 4. (A) Number of signifi cantly diff erentially expressed probe sets (DEPS) in the liver in the ad libitum 
(AL) and fasted groups. (B) Venn diagram of overlapping DEPS between the DEPS after the AL groups and 
the fasting groups, including the unique DEPS of both comparisons. (C) Scatterplot of the DEPS found in 
the liver with false discovery rate of 5%. On the x-axis are the fold changes found in the comparison of AL 
vehicle vs. AL irinotecan, on the y-axis the fold changes of fasting vehicle vs. fasting irinotecan. Red symbols 
= AL groups; green symbols = fasting groups; black symbols = overlapping DEPS. Symbols in the upper-
right quadrant are up-regulated in both groups; symbols in the lower-left quadrant are down-regulated 
in both groups; symbols in the upper-left quadrant resemble DEPS down-regulated in the AL groups and 
up-regulated in the fasting groups; the lower-right quadrant resemble DEPS that are up-regulated in the AL 
groups and down-regulated in the fasting groups.
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Table 1 Overview of the top overrepresented canonical pathways in liver following each comparison 
ranked by their –log P-value
(A) AL vehicle – AL irinotecan
Canonical Pathway Pathway classification P-value Genes Ratio Z-score Z-score
FV - FI
AMPK Signaling Intracellular and second 
messenger signaling; cellular 
growth and proliferation and 
development
2.90E-02 19/134 (14.2%) -1.000 N/A
Calcium-induced T 
Lymphocyte Apoptosis
Apoptosis; cellular immune 
response
3.79E-03 13/64 (20.3%) -1.732 -0.816
CXCR4 Signaling Cytokine signaling; cellular 
immune response
6.91E-05 29/152 (19.1%) +1.000 -0.832
Dopamine-DARPP32 
Feedback in cAMP 
Signaling
Intracellular and second 
messenger signaling; 
neurotransmitter and other 
nervous system signaling
1.02E-03 27/161 (16.8%) -1.279 -2.121
EIF2 Signaling Intracellular and second 
messenger signaling; cellular 
stress and injury; cellular 
growth and proliferation and 
development
7.43E-03 27/185 (14.6%) +2.138 N/A
fMLP Signaling in 
Neutrophils
Cytokine signaling; cellular 
immune response
1.89E-04 22/108 (20.4%) +1.342 -0.707
Growth Hormone Signaling Growth factor signaling; cellular 
growth and proliferation and 
development
4.10E-02 11/69 (15.9%) -1.265 0.000
IL-1 Signaling Cytokine signaling 6.33E-03 16/91 (17.6%) +1.604 +0.378
IL-8 Signaling Cytokines signaling; cellular 
immune response
3.04E-05 34/183 (18.6%) +1.219 -1.000
Integrin Signaling Cell cycle regulation; intracellular 
and second messenger signaling; 
cellular growth and proliferation 
and development
2.21E-02 27/202 (13.4%) +1.225 -0.905
LPS/IL-1 Mediated 
Inhibition of RXR Function
Nuclear Receptor Signaling 6.39E-03 31/218 (14.2%) +3.051 N/A
LPS-stimulated MAPK 
Signaling
Apoptosis 2.73E-02 12/73 (16.4%) +1.155 +0.707
Nitric Oxide Signaling in the 
Cardiovascular System
Cardiovascular Signaling 6.36E-03 17/99 (17.2%) -1.000 -0.333
P70S6 Signaling Cellular stress and injury; cellular 
growth and proliferation and 
development
4.17E-05 25/119 (21.0%) -1.043 -0.707
Remodeling of Epithelial 
Adherens Junctions
Cellular growth and proliferation 
and development
3.74E-02 11/68 (16.2%) +1.414 N/A
RhoA Signaling Intracellular and second 
messenger signaling
1.17E-02 19/122 (15.6%) +2.668 N/A
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Table 1 (continued)
Canonical Pathway Pathway classification P-value Genes Ratio Z-score Z-score
FV - FI
Role of BRCA1 in DNA 
Damage Response
Cellular stress and injury 2.50E-02 11/64 (17.2%) +1.134 N/A
Signaling by Rho Family 
GTPases
Intracellular and second 
messenger signaling
5.69E-03 33/234 (14.1%) +2.985 -1.265
Sphingosine-1- phosphate 
Signaling
Organismal growth and 
development
1.62E-02 17/109 (15.6%) +1.000 0.000
(B) Fasting vehicle – Fasting irinotecan
Canonical Pathway Pathway classification P-value Genes Ratio Z-score Z-score
ALV-ALI
Androgen Signaling Nuclear receptor signaling 2.82E-03 9/111 (8.1%) -1.134 +0.302
Aryl Hydrocarbon Receptor 
Signaling
Cell cycle regulation; apoptosis; 
xenobiotic metabolism; nuclear 
receptor signaling
3.34E-02 8/140 (5.7%) -2.121 N/A
Cardiac Hypertrophy 
Signaling
Cardiovascular signaling 2.64E-03 14/223 (6.3%) -1.387 +0.186
Chemokine Signaling Cytokine Signaling; Organismal 
Growth and Development
1.14E-02 6/71 (8.5%) -1.633 -0.302
Cholecystokinin/Gastrin-
mediated Signaling
Neurotransmitters and other 
nervous system signalling
4.50E-07 14/101 (13.9%) -1.069 0.447
Dopamine-DARPP32 
Feedback in cAMP 
Signaling
Intracellular and second 
messenger signaling; 
neurotransmitter and other 
nervous system signaling
2.82E-02 9/161 (5.6%) -2.121 -1.279
Glioblastoma Multiforme 
Signaling
Cancer 1.61E-02 9/146 (6.2%) -1.000 +0.209
GNRH Signaling Neurotransmitters and other 
nervous system signalling
1.70E-04 12/129 (9.3%) -1.732 +0.853
IL-8 Signaling Cytokines signaling; cellular 
immune response
3.17E-05 16/183 (8.7%) -1.000 +1.219
Leukocyte Extravasation 
Signaling
Cellular Immune response 3.91E-02 10/198 (5.1%) -1.000 N/A
NRF-mediated Oxidative 
Stress Response
Cellular stress and injury 1.07E-03 13/180 (7.2%) +1.414 N/A
P2Y Purigenic Receptor 
Signaling Pathway
Cardiovascular signaling 4.49E-03 9/119 (7.6%) -1.000 -0.894
PTEN signaling Apoptosis; cancer 4.24E-03 9/118 (7.6%) +1.000 N/A
Renin-Angiotensin 
Signaling
Cardiovascular signaling; growth 
factor signaling
2.49E-03 9/109 (8.3%) -1.000 +0.471
RhoGDI Signaling Intracellular and second 
messenger signaling
6.62E-03 11/173 (6.4%) +2.333 -0.471
Signaling by Rho Family 
GTPases
Intracellular and second 
messenger signaling
1.54E-03 15/234 (6.4%) -1.265 +2.985
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involved inhibition of cytokine signaling and cellular immune responses, and inhibition 
of the intracellular and second messenger signaling as well as cell cycle regulation and 
cellular growth and proliferation. Six pathways showed the same directionality, yet with 
lower activity scores than in the AL groups. These pathways were also mainly involved in 
cytokine signaling and cellular stress and injury. Eight pathways were not regulated in 
the fasting groups, mainly cellular growth and proliferation signaling pathways as well 
as the growth hormone inhibition.
Secondly, the isolated effect of fasting on irinotecan treatment was examined by ana-
lyzing the pathways regulated by the 754 DEPS found after fasting. This analysis revealed 
20 pathways, of which 16 were down-regulated and 4 were up-regulated (Table 1B). 
Most of the down-regulated pathways were connected to cellular immune response, 
cellular stress and injury, apoptosis and cardiovascular signaling pathways. Of these 16 
pathways, 12 were either not activated or were inhibited in the AL liver comparison. The 
4 up-regulated pathways were involved in pathogen-influenced signaling and cellular 
stress and injury. These up-regulated pathways were not differentially regulated in the 
comparison between AL vehicle and AL irinotecan (Table 1B).
Irinotecan-related gene expression
We have previously shown that SN-38 levels are lower in the livers of fasted mice. To 
identify the direct effect of irinotecan on liver tissue, target proteins of the metabolite 
SN-38 were highlighted and explored. The main target of SN-38 is topoisomerase-I 
(TOP1), and irinotecan directly interacts via inhibition of this gene (15). In AL fed irinote-
can treated animals, TOP1 showed a fold change of 1.373, while in the fasted group no 
differences were seen. Other molecules involved in the metabolism of irinotecan and 
colorectal carcinoma (CRC) are nuclear factor-kappa beta (NF-κβ) (16), mammalian tar-
get of rapamycine (mTOR) (17) and mouse double minute 2 homolog (MDM2) (18). NF-κβ 
was up-regulated (1.069) in the AL fed irinotecan group and inhibited in fasted animals 
Table 1 (continued)
Canonical Pathway Pathway classification P-value Genes Ratio Z-score Z-score
ALV-ALI
Sperm Motiliy Organismal growth and 
development
1.48E-02 8/120 (6.7%) -1.134 -0.243
Tec Kinase Signaling Intracellular and second 
messenger signaling
3.37E-03 11/158 (7.0%) -1.000 N/A
Thrombin Signaling Cardiovascular signalling 6.05E-04 14/191 (7.3%) -1.069 +0.192
Toll-like Receptor Signaling Apoptosis; humoral/cellular 
immune response
4.68E-02 5/74 (6.8%) +1.342 N/A
All canonical pathways with a z-score of ≤-1.000 or ≥+1.000 are listed. Pathways with a significant z-score of 
≤-2.000 or ≥+2.000 are depicted in bold. Genes ratio= the number and percentage of genes differentially 
expressed in ratio to the total number of genes involved in the pathway.
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(-1.293). Expression of mTOR was lower in the AL fed irinotecan treated group (-1.749), 
while it was slightly higher in fasted mice treated with irinotecan (1.116). Dihydropyrimi-
dine dehydrogenase (DPYD) and methylenetetrahydrafolate (MTHFD1) defi ciencies are 
both involved in drug clearance and toxicity (19, 20). Both genes were down-regulated 
in the AL irinotecan group compared to the AL vehicle group (DPYD: -2.455, MTHFD1: 
1.742). Both were not diff erentially expressed in the fasted liver groups.
Tumor transcriptome analysis
Principal component analysis
With a total of 59.49% of the variance explained by PC1 and 10.88% by PC2, the PCA plot 
of the tumor samples of the 4 experimental groups showed high heterogeneity among 
the groups with large intragroup variability (Fig5), also compared to the liver PCA plot 
(Fig3). The individual groups were not clearly separated as clusters, and showed only 
minor diff erences between groups. The tumor samples of the fasting vehicle group 
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Figure 5. Unbiased principal component analyses (PCA) of tumor samples, based on all probe sets in the 
microarray. Principal component (PC) 1 is depicted on the x-axis and PC2 is depicted on the y-axis, includ-
ing the percentage of variance explained by each PC. Each symbol represent one sample of one mouse. 
Samples of the same group are shown in the same color. AL = ad libitum.
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showed the smallest intragroup variability. A shift on the PC1 axis could be detected 
between the AL vehicle and fasting vehicle groups, while no shift on the PC2 axis was 
obvious. The irinotecan-treated groups showed high overlap within groups and no clear 
clustering of groups.
Gene expression profiles
Based on the heterogeneous PCA plot, a small number of differentially regulated genes 
between the AL groups was suspected. Indeed, comparison of AL vehicle and AL iri-
notecan showed 610 DEPS, of which 321 were down-regulated and 289 up-regulated 
(Fig6A). The number of regulated DEPS between fasting vehicle and fasting irinotecan 
was 3093. Comparing overlapping genes, we found 138 genes in common between the 
AL vehicle vs. AL irinotecan and the fasting vehicle vs. fasting irinotecan comparison, 
corresponding to 22,6% of the DEPS in the AL groups and only 4,5% of the fasting groups 
(Fig6B). All DEPS considered, only 17% had the same directionality in both comparisons, 
while the other DEPS had opposite directionalities (Fig6C).
Pathway analyses
To identify pathways in common between liver and tumor tissue treated with irinotecan, 
the pathways found regulated in the liver were examined in the tumor (Table 2). Firstly, 
of the pathways regulated in the AL vehicle vs. AL irinotecan groups, only one pathway 
was regulated in the tumor vehicle vs. tumor irinotecan groups. This downregulated 
pathway was the Nitric Oxide Signaling in the Cardiovascular System, a pathway involved 
in cardiovascular signaling, which was more downregulated in tumor tissue based on 
the z-score. Of the 19 pathways regulated in the liver in the AL groups, 10 were also 
found in the fasting vehicle vs. fasting irinotecan DEPS. Eight out of 10 showed the same 
directionality, yet showed on average less activation. These were involved in cytokine 
signaling and cellular immune responses as well as cellular growth and proliferation. 
The apoptosis pathway was unaffected and was still strongly activated. Also, 2 pathways 
were oppositely regulated, involved in cellular growth inhibition and activation of a cel-
lular stress and injury pathway.
Effect of irinotecan on gene expression in tumor tissue
The main target of metabolized irinotecan, TOP1 had a fold change of 1.689, in the 
tumor AL vehicle vs. AL irinotecan groups. In the fasting groups, the fold change was 
1.772. Analysis of tumor-related effects was performed with tumor-specific genes. The 
gene tumor protein 53 (Tp53) was higher regulated in the AL irinotecan than in the AL 
vehicle group (1.310), while it was lower in the fasting irinotecan than in the fasting ve-
hicle group (-1.815). Tumor suppressor phosphatase and tensin homolog (Pten) was not 
differentially expressed due to irinotecan treatment in the AL group, while it was higher 
134
in the fasting irinotecan group than in the fasting vehicle group. Irinotecan is known to 
induce apoptosis via activation of the cysteine-aspartic acid protease (caspase) group, 
amongst which caspase 3 (Casp3), caspase 9 (Casp9) and cyclin-dependent kinase in-
hibitor 1A (CDKN1A, also known as p21). Using the upstream analysis, the caspase group 
showed no diff erences between the AL vehicle and AL irinotecan groups. Following the 
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Figure 6. (A) Number of signifi cantly diff erentially expressed probe sets (DEPS) in the tumor in ad libi-
tum (AL) and fasted groups. (B) Venn diagram of overlapping DEPS between the DEPS after the AL tumor 
groups and the fasting tumor groups, including the unique DEPS of both comparisons. (C) Scatterplot of 
the DEPS found in the tumor with false discovery rate of 5%. On the x-axis are the fold changes found in 
the comparison of AL vehicle vs. AL irinotecan, on the y-axis the fold changes of fasting vehicle vs. fasting 
irinotecan. Red symbols = AL groups; green symbols = fasting groups; black symbols = overlapping DEPS. 
Symbols in the upper-right quadrant are up-regulated in both groups; symbols in the lower-left quadrant 
are down-regulated in both groups; symbols in the upper-left quadrant resemble DEPS down-regulated 
in the AL groups and up-regulated in the fasting groups; the lower-right quadrant resemble DEPS that are 
up-regulated in the AL groups and down-regulated in the fasting groups.
135
Chapter 7 | Mechanistic effects of fasting on irinotecan
7
Table 2. Overview of the top overrepresented canonical pathways in tumor following each comparison 
ranked by their –log P-value
TUMOR
(A) AL vehicle – AL irinotecan
Canonical Pathway P-value Genes Ratio Z-score
Glioma Signaling 1.39E-03 8/95 (8.4%) -2.121
Neuropathic Pain Signaling in Dorsal Horn Neurons 1.93E-03 8/100 (8.0%) -2.121
CREB Signaling in Neurons 5.60E-03 10/171 (5.8%) -2.333
PTEN Signaling 1.77E-02 7/118 (5.9%) +2.449
Nitric Oxide Signaling in the Cardiovascular System 2.48E-02 6/99 (6.1%) -2.000
Thrombin Signaling 2.99E-02 9/191 (4.7%) -1.000
eNOS Signaling 4.12E-02 7/141 (5.0%) -1.342
(A) Fasting vehicle – Fasting irinotecan
Canonical Pathway P-value Genes Ratio Z-score
CD40 Signaling 9.76E-04 14/65 (21.5%) +2.138
TNFR2 Signaling 9.45E-03 7/29 (24.1%) +2.646
ATM Signaling 9.30E-05 15/59 (25.4%) -1.604
Angiopoietin Signaling 9.22E-03 12/66 (18.2%) -1.265
Colorectal Cancer Metastasis Signaling 8.96E-04 35/236 (14.8%) +1.826
4-IBB Signaling in T-lymphocytes 8.31E-04 9/31 (29.0%) +1.414
B Cell Activating Factor Signaling 8.23E-05 12/40 (30.0%) +2.111
UVC-induced MAPK Signaling 7.85E-03 9/42 (21.4%) -1.000
IL-6 Signaling 7.45E-04 21/116 (18.1%) +1.528
PDGF Signaling 6.65E-04 16/77 (20.8%) +1.000
Estrogen-dependent Breast Cancer Signaling 5.92E-04 14/62 (22.6%) +1.069
Signaling by Rho Family GTPases 5.23E-03 32/234 (13.7%) +2.887
Androgen Signaling 5.19E-05 23/111 (20.7%) +1.667
ILK Signaling 5.07E-04 30/186 (16.1%) +1.512
Aryl Hydrocarbon Receptor Signaling 4.62E-05 27/140 (19.3%) +2.200
P2Y Purigenice Receptor Signaling pathway 4.62E-05 27/140 (19.3%) +2.200
Ephrin B Signaling 4.43E-02 11/73 (15.1%) +1.633
Prolactin Signaling 4.43E-02 11/73 (15.1%) +1.000
EGF Signaling 3.51E-03 27/183 (14.8%) +1.633
IL-8 Signaling 3.51E-03 27/183 (14.8%) +1.633
Ga12/13 Signaling 3.27E-04 22/117 (18.8%) +1.091
iNOS Signaling 3.06E-02 8/44 (18.2%) +1.890
Acute Phase Response Signaling 3.02E-02 22/169 (13.0%) +1.091
Rac Signaling 2.88E-03 18/104 (17.3%) +1.213
PPARa/RXRa Activation 2.70E-06 35/179 (19.6%) -1.569
TGF-B Signaling 2.57E-03 16/87 (18.4%) -1.941
Death Receptor Signaling 2.35E-02 14/92 (15.2%) +1.069
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comparison in the fasting groups, the caspase group was more activated in the fasted 
animals treated with irinotecan than in the fasting vehicle group (z-score 1.387). Specific 
targets of the caspase group that were up-regulated in the fasting irinotecan group, 
were CCND3, CDKN1A and CDKN1B, CDK4 and CKD6, and APP.
Discussion
Fasting is known to reduce the adverse side effects of chemotherapy treatment, while 
it preserves or even enhances its anti-tumor activity. To unravel the mechanism behind 
this remarkable effect, we performed transcriptome analysis on liver and tumor tissue of 
fasted and fed mice carrying subcutaneous colorectal carcinoma. We found that 3-days 
of fasting prior to irinotecan treatment reduces the side effects of irinotecan via down-
regulation of the gene expression profiles in the liver and activation of a cellular stress 
response, thereby possibly decreasing the accessibility of irinotecan in extra-tumor tis-
sue. Specific sets of genes involved in liver damage and toxicity were decreased due to 
fasting, indicating that metabolism from irinotecan to SN-38 is decreased and that SN-38 
is not able to exert its toxic actions in the liver. These effects were not present in tumor 
tissue, where the anti-tumor activity of irinotecan was not compromised by fasting. Even 
Table 2 (continued)
Canonical Pathway P-value Genes Ratio Z-score
NF-kB Signaling 2.32E-05 32/173 (18.5%) +1.768
Pancreatic Adenocarcinoma Signaling 2.32E-04 23/122 (18.9%) +1.528
RhoA Signaling 2.32E-04 23/122 (18.9%) +1.528
PPAR Signaling 2.31E-03 17/94 (18.1%) -1.213
Toll-like Receptor Signaling 2.20E-02 12/74 (16.2%) +1.134
AMPK Signaling 2.12E-03 22/134 (16.4%) +1.213
April Mediated Signaling 2.12E-03 22/134 (16.4%) +1.213
TNFR1 Signaling 2.12E-02 9/49 (18.4%) +1.000
FcyRIIB Signaling in B-lymphocytes 2.07E-02 8/41 (19.5%) -1.414
WNT/Ca+ pathway 1.88E-02 10/56 (17.9%) +2.333
Inhibition of Angiogenesis by TSP1 1.71E-03 9/34 (26.5%) -1.134
Wnt/B-catenin Signaling 1.70E-02 23/169 (13.6%) +1.414
Acute Myeloid Leukemia Signaling 1.58E-04 23/119 (19.3%) +1.091
Remodeling of Epithelial Adherens Junctions 1.17E-02 12/68 (17.6%) +1.134
PKCθ Signaling in T Lymphocytes 1.10E-02 18/118 (15.3%) +1.414
All canonical pathways with a z-score of ≤-1.000 or ≥+1.000 are listed. Pathways with a significant z-score of 
≤-2.000 or ≥+2.000 are depicted in bold. Genes ratio= the number and percentage of genes differentially 
expressed in ratio to the total number of genes involved in the pathway.
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so, expression analyses hinted towards increased sensibility for the chemotherapy in the 
tumor. These results increase our knowledge about the mechanistic processes underly-
ing dietary restriction (DR), making it a possible to facilitate translational research into 
the clinical setting, and may help us to develop DR mimetics that induce similar effects 
without the disadvantages of fasting.
The topoisomerase-I inhibitor irinotecan is a frequently used chemotherapeutic 
agent and recognized as first and second line treatment for colorectal carcinoma, which 
contributes to increased survival rates and the chance of a potential curative approach 
in patients with colorectal liver metastases (3, 4). The use of irinotecan is limited by 
the frequent occurrence of severe side effects, including hepatotoxicity (5). In a recent 
publication, we showed that fasting is a strong protector against side effects induced 
by irinotecan in a mouse model, while leaving its anti-tumor activity unaffected (9, 
21). In the present study, we examined the mechanistic actions of irinotecan in both 
healthy liver and colorectal tumor tissue, and confirmed above-mentioned findings on 
gene expression level. Irinotecan resulted in increased liver and kidney injury, and bone 
marrow depression, as indicated by increased AST, LDH and urea levels, and a significant 
leukocyte depletion 12 hours after one high dose of irinotecan. These changes were not 
seen in fasted mice, demonstrating that, in this study, irinotecan induced toxicity in AL 
fed animals was reduced by fasting. Indeed, over 3 fold fewer gene expression changes 
occurred in healthy liver tissue when mice were fasted prior to injection of irinotecan. 
The gene profiles between the AL and fasting comparisons overlapped only partially as 
evidenced by the genes and pathways in common. In the AL irinotecan treated mice, the 
majority of pathways indicated activation of chemokine and cytokine signaling as well 
as DNA damage response, indicating the induction of cell damage and inflammation. 
Both failed to appear after 3 days of fasting or were of lower magnitude. Also, fasting 
mostly inhibited pathways, and down-graded most actions involved in irinotecan treat-
ment. More interestingly, fasting induced an additional independent response, medi-
ated by stress pathways such as Nrf2 and Aryl Hydrocarbon Receptor, which are known 
to induce differential stress sensitization (DSS) (11, 22). Especially activation of Nrf2 plays 
a key role in induction of DSS, and has come up in previous gene expression analyses in 
fasting and DR mouse models (23, 24). A possible underlying mechanism of DSS is the 
inability of irinotecan to enter the healthy liver cells via activation of these pathways. 
An extra indication for this decreased permeability of the cells is the failure to activate 
genes involved in the irinotecan metabolism, such as topoisomerase-I (TOP1). Several 
studies showed the correlation between the TOP1 expression levels and the sensitivity 
to SN-38, the active metabolite of irinotecan (25-27). Further down the cascade of irino-
tecan is NF-κβ, a nuclear factor initiated by Nrf2 and involved in the effects of the drug. 
An increase in NF-κβ may lead to an extra suppression of cell growth and an increase in 
apoptosis in addition to that induced by irinotecan (16). This effect stopped out in the 
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AL groups, while even an inhibition of NF-κβ occurred in the fasted groups, including 
family member v-rel avian reticuloendotheliosis viral oncogene homolog A (RELA) (28).
Side effects of chemotherapy are difficult to measure at the transcriptional level, since 
efficacy and toxicity are closely correlated (29). Nevertheless, the list of genes possibly 
involved in toxicity of specific chemotherapeutic agents continues to lengthen. Genes 
that have been examined recurrently are dihydropyrimidine-dehydrogenase (DPYD) 
and methylenetetrahydrofolate dehydrogenase (MTHFD1) (30). Partial deficiencies of 
DPYD occur in 3-5% of the cancer patients, and are related to decreased drug clearance 
and prolonged exposure to toxicity (30, 31). The role of MTHFD1 deficiencies remains 
controversial with studies showing decreased toxicity, while others document no ef-
fect or even worsening of side effects of different chemotherapeutic agents (30). Both 
genes, normally highly expressed in the liver, were down-regulated in the AL irinotecan 
treated mice while these changes were nullified by fasting. Other genes associated with 
side effects of different chemotherapeutic agents, such as TYMS, GSTM1 and CDA, were 
not regulated in any of the treated groups (20, 30). However, expression levels of these 
genes in the liver are usually low. Taken together, our data suggest that fasting is able 
to decrease the metabolization of irinotecan to SN-38 in healthy liver tissue, thereby 
preventing the drug to exert its toxic effects.
On the contrary, the protective effect of fasting as seen in healthy tissue was absent in 
tumor tissue preconditioned by 3 days of fasting. The majority of differentially regulated 
pathways found in the liver of fasted irinotecan treated mice, were either oppositely 
regulated in fasted tumor tissue or to a lesser extent. Interestingly, the analysis of the 
AL tumor groups revealed less regulation due to irinotecan than in the mice that were 
fasted. Although the phenotypical results as well as the presence of TOP1 expres-
sion in tumor indicate that irinotecan is metabolized and active. The higher number 
of regulated genes as well as detailed analyses demonstrate an additional effect in 
tumor due to fasting. This effect might be dual, with a role for increased induction of 
chemotherapy-mediated apoptosis as well as sensitization to the actions of irinotecan. 
For example, the higher expression of genes such as NF-κβ (16), JUN (32) and MYC (33) 
as well as genes involved in the caspase cascade (34), i.e. caspase 9, p21 and p27, points 
towards an increase in chemotherapy-mediated apoptosis, and even hint towards 
higher sensitivity to chemotherapeutical agents (35, 36). Also, fasting might increase 
sensitivity to irinotecan by modulating the expression of tumor-specific genes. Several 
p53 knockout-models showed an increase in sensitivity to different chemotherapeutic 
agents (37, 38). Further research is needed to elucidate the role of these findings in the 
DSS.
Since pharmacokinetic studies showed that the half-life of the active metabolite SN-
38 is approximately 12 hours (21), we choose to explore the transcriptional changes 
in the therapeutic window in which the effects of both irinotecan and fasting would 
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be maximal. Analyses on multiple time points and with different dosages would likely 
improve our understanding of the results obtained in our study.
In conclusion, we showed that 3-days of fasting results in protection against the side 
effects of irinotecan treatment in healthy liver tissue, possibly via decreased metaboliza-
tion from irinotecan to SN-38 in the liver, together with the activation of a protective 
stress response in healthy, but not tumor tissue. Although fasting leads to an increase in 
differentially regulated pathways in tumor tissue following irinotecan treatment, it does 
not abrogate its antitumor efficacy but possibly increases its sensitivity to irinotecan. 
These data give insight in the mechanisms involved in the protective effects of fasting 
on the side effects of irinotecan, and may pave the way to develop dietary restriction 
mimetics which may induce similar effects without the disadvantages of fasting.
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Summary and discussion
According to the latest numbers colorectal cancer remains the third most common can-
cer diagnosis in men and the second in women worldwide (1). In approximately 20% of 
patients distant metastases are present at the time of diagnosis (2). The liver is by far the 
most common site for metastases, and approximately 50% of patients with early-stage 
disease will develop colorectal liver metastases (CRLM) (3, 4). Over the past 30 years, 
the treatment of CRLM has undergone major changes. Patients who were considered to 
be terminal and incurable, started to show promising improvements using the modern 
multi-modality approach. At the time of introduction of systemic treatment, 5-fluoruracil 
based regimens were standard of care in CRLM and already improved the overall survival 
from 6 to 10 months. Subsequently, the development of chemotherapeutic agents like 
irinotecan improved this overall survival to a median up to 24 months. However, the 
associated toxicity of chemotherapeutic agents is a major limitation to their use. There 
are several severe adverse side-effects seen during irinotecan treatment which may 
lead to early discontinuation of treatment. There is an urgent need for further optimiza-
tion of chemotherapeutic treatment to diminish the adverse side-effects, to tolerate 
higher doses and subsequently improve its efficacy. The overall aim of this thesis was to 
examine the role of the circadian clock and of fasting in improving chemotherapeutic 
treatment in CRLM.
In chapter 2 we reviewed the literature on the role of the circadian clock machinery and 
circadian gene expression levels in relation to human abdominal cancer types. We con-
cluded that the expression levels of multiple circadian genes are disturbed in malignant 
tissue in comparison to healthy tissues. Circadian output genes like PER1, PER2, and PER3 
are consistently downregulated in tumors of different types of cancer. Because of the 
aberrant expression of multiple circadian, and circadian regulated genes in cancer, novel 
therapies were conducted to exploit these aberrations as means to improve chemother-
apeutic treatment of patients. An important therapy in this field is chronotherapy (5, 6). 
Chronotherapy consists of administrating chemotherapeutical agents according to the 
biological rhythm. The perfect time of administration would be when the tumor tissue 
is most active and the surrounding healthy tissues are not. It is often seen that tumors 
show a disrupted or altered circadian function in contrast to the circadian entrainment 
of healthy tissues. In this case, improved efficacy is also seen when chemotherapeutic 
agents are given near their respective times of best tolerability. In a recent clinical study 
it has been shown that chronotherapeutic administration of irinotecan, oxaliplatin, and 
5-fluorouracil via highly toxic hepatic arterial infusion in heavily pretreated patients is 
feasible, well tolerated and resulted in a doubling of secondary resection rate in patients 
with otherwise unresectable colorectal liver metastases (7, 8). We conclude that many 
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circadian (regulated) genes are down regulated in tumor tissue of different types of 
abdominal cancer, and it is therefore suggested that these genes could help to improve 
chemotherapy treatment.
In chapter 3 we compared the 24-hour expression levels of key circadian clock genes 
in liver and kidney of healthy control mice with those of mice bearing C26 colorectal 
tumor metastases in the liver. Metastases in the liver were induced in these mice by 
injection of C26 colorectal carcinoma cells into the spleen. To prevent intrasplenic tumor 
growth, the spleen was removed after 10 minutes of injection. Tumors were grown for 
three weeks, and subsequently tumor, liver, and kidney tissue was collected around the 
clock to compare circadian rhythmicity. qRT-PCR expression levels of important clock 
genes revealed normal 24-hour oscillations of all measured clock- and clock-controlled 
genes in liver and kidney tissue. However, in colorectal liver metastases 24-hour oscilla-
tions were absent for all clock- and clock-controlled genes except for Cry1. In addition, 
we observed a phase shift of the circadian clock in healthy liver and in kidney tissue of 
tumor bearing animals. In the liver a phase advance was observed whereas in the kidney 
a phase delay was found, suggesting that this is a systemic effect. We conclude that the 
core clock machinery is severely disrupted in murine colorectal liver metastases which 
results in altered expression levels of output genes such as Dbp. It would be of interest to 
investigate how this phase shift between healthy liver and kidney tissue can be caused. 
It is known that tumor cells secrete a plethora of mediators such as TGF-β that is able to 
modulate the circadian clockwork by activating the ALK-SMAD3-DEC1 pathway. Varia-
tion in TGF-β levels in peripheral tissues can induce phase shifts in peripheral clocks (9).
Next, we were interested to determine whether these clock gene expression levels were 
also disrupted in human colorectal liver metastases. In chapter 4 we studied surgi-
cal resection specimens of 15 patients with primary colorectal carcinoma (CRC) and 
metachronous CRLM. We compared the expression levels of 10 clock genes in primary 
CRC, CRLM, and liver tissue within the same patient. Clock genes that were studied in-
cluded CLOCK, BMAL1, PER1, PER2, PER3, CRY1, CRY2, CSNK1E, Timeless (TIM), and timeless 
interacting-protein (TIPIN). Seven of the clock genes showed a down-regulation of mRNA 
levels in CRLM, while in CRC five clock genes were down-regulated. One clock gene was 
upregulated in in CRC, namely CSNK1E. This gene encodes the CKIε protein whose main 
function is to regulate circadian rhythmicity by phosphorylation and degradation of Pe-
riod genes (10). Upregulation of CSNK1E expression may lead to enhanced phosphoryla-
tion of the PER2 protein which is known to destabilize the PER2 protein and target it for 
ubiquitination and subsequent proteosomal degradation. Furthermore, CKIε plays an 
essential role in the early development of CRC (11-13). We also studied possible relations 
between gene expression levels and clinical and pathological factors of the included 
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patients. We found a significant correlation between gender and the and the expres-
sion of CRY1 in CRLM. Lowest levels of CRY1 mRNA expression were found in female 
patients. We also found that low expression of PER3 correlates with a high number of 
metastases. In other studies, circadian gene expression levels were also correlated with 
clinicopathological factors. Mazzoccoli et al. showed a significant association between 
low CRY1 expression levels in tumor tissue and a higher tumor grade, advanced age, 
and female sex. However, survival was better in CRC patients expressing lower CRY1 and 
CRY2 levels in tumor tissue (14, 15). These results are in line with another study which 
showed that high CRY1 expression in the tumor corresponded with poor overall survival 
in CRC patients (16).
In chapter 5 we started to examine the potential beneficial effects of dietary restric-
tion (DR) on chemotherapy induced adverse side effects. There is emerging evidence 
that DR, if well timed and titrated may improve a patients resistance to stress. Thus, we 
speculated that a dietary intervention may protect cancer patients against drug toxici-
ties. Reduction of food intake of approximately 30% (calorie restriction, CR) during life is 
a powerful means to increase resistance to multiple stressors, reduce inflammation, and 
increase lifespan in a variety of model organisms (17-22). We have previously extended 
these observations and showed that short-term CR and periods of fasting also improve 
acute stress resistance and protect against acute oxidative damage in the kidney and 
liver (23-26). This protection was associated with increased baseline levels of cytopro-
tective and anti-oxidant genes, and robust reduction of inflammation. In the present 
study we have examined the effects of fasting prior to irinotecan treatment on toxicity 
and anti-tumor activity in FabplCre;Apc15lox/+ mice, which spontaneously develop 
intestinal tumors. We showed that 3-days of fasting protects against irinotecan induced 
side-effects, and we observed a similar reduction of tumor size in fasted and ad libitum 
fed treated groups compared to controls. In addition, we found a significant decrease 
in cell cycle activity, proliferation, and angiogenesis, while senescence was increased in 
both fasted and ad libitum fed irinotecan treated groups, indicating that fasting does 
not affect the anti-tumor activity of irinotecan. Previous research from our lab showed 
that 3-days of fasting increases stress-resistance, including upregulation of the Nrf2 
pathway, which is involved in the protection against oxidative stress (23, 27). In contrast 
to the up-regulation of protective pathways by normal cells, it is thought that cancer 
cells are unable to obtain a protected state by dietary restriction. This phenomenon is 
called differential stress sensitization (DSS) and is based on the fact that cancer cells 
have acquired a number of mutations that progressively decrease their ability to adapt 
to dietary restriction (28, 29).
150
To extend and verify our findings and include a more mechanistic approach, we de-
signed the experiments as shown in chapter 6. Again, we examined the effects of fast-
ing prior to a high dose of irinotecan on the occurrence of side-effects and anti-tumor 
activity. In this model we made use of an ectopic model, C26 colon carcinoma cells were 
grown as subcutaneous tumors in the flank of BALB/c mice. In addition, to elucidate the 
mechanisms behind the fasting-induced protection to irinotecan induced side-effects 
we studied its pharmacokinetics in fasted and fed mice in plasma, liver, and tumor. These 
experiments showed again that 3 days of fasting prior to treatment with irinotecan 
prevents the occurrence of drug-related side-effects while anti-tumor efficacy was not 
affected. As in the previous study, we showed that fasted BALB/c animals did not show 
any signs of toxicity at all in response to high dose irinotecan. We demonstrated that lev-
els of the active and toxic metabolite of irinotecan, SN-38, were lower in plasma and liver 
tissue of fasted mice. In contrast, intratumoral SN-38 values in fasted mice compared to 
ad libitum fed mice remained unchanged. These data indicate that fasting induces im-
portant changes in irinotecan metabolism, and lowers the systemic exposure to SN-38.
Evidence from in vitro and in vivo research suggests that fasting has a great potential 
to be implemented in clinical cancer patients (28-34). Nonetheless, introduction of fast-
ing to the clinic remains challenging. A better understanding of different pathways and 
genes involved in the theory of fasting is necessary, and will help us to extend ideas 
translating this method to cancer patients.
Therefore, in chapter 7 we investigated transcriptional responses using microarray 
analysis after fasting and irinotecan treatment in CRLM and liver tissue in mice. BALB/c 
mice were subcutaneously injected with C26 colorectal carcinoma cells. After 12 days of 
tumor growth, two groups were fasted for 3 days and two groups were fed ad libitum. 
One group of each received irinotecan treatment, the other groups received vehicle. 
12 hours after injection mice were sacrificed and blood, liver, and tumor tissue were 
collected. Microarray analyses on tumor and liver tissue were performed. We found that 
3 days of fasting prior to irinotecan treatment reduces the side-effects of irinotecan via 
down-regulation of the gene expression profiles in the liver and activation of a cellular 
stress response. Several specific sets of genes involved in liver damage and toxicity were 
decreased due to fasting. However, the effects of irinotecan were preserved in the fasted 
tumor group, with a hint towards increased sensitivity for irinotecan. These findings sup-
port the differential stress resistance theory, stating that cancer cells are unable to adapt 
to a protected state by dietary restriction (29). We conclude that these results increase 
our knowledge about the mechanistic processes underlying DR, and may pave the way 
to find a DR mimetic. We believe that short-term fasting can improve both the quality of 
life as well as the sensitivity to chemotherapy in colorectal cancer patients.
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Future perspectives
The studies described in this thesis showed that circadian regulated genes are signifi-
cantly down-regulated compared to non-cancerous tissues in abdominal cancer types 
in animal experiments as well as in human studies. It is suggested that circadian genes 
could serve as biomarkers for development, treatment, and prognosis of human cancer 
patients. In mice bearing C26 colorectal tumor metastases in the liver, we showed that 
there was an absence of circadian rhythm in CRLM. Furthermore, we observed a phase 
shift of the circadian clock in healthy liver and in kidney tissue of tumor bearing animals. 
It would be of interest for future research to investigate how this phase shift between 
healthy liver and kidney tissue can be caused. It is suggested that the tumor can af-
fect the circadian rhythm of surrounding healthy tissue by excreting e.g. TGF-β. Future 
experiments need to focus on how the tumor can affect circadian rhythms in distant 
organs like kidney tissue. In cancer patients, this would also be an interesting research 
question. In our study with mice bearing C26 colorectal tumors, we concluded that oscil-
lations were absent in tumor tissue. However, it could also be that all cancer cells are 
ticking in a different phase. More research on single cell level could elucidate this topic.
In general, circadian clock research in human tissues suffers from serious drawbacks 
that may contribute to the failure to successfully understand human circadian rhythms 
in tumor tissue. For instance, in the clinical setting we are dependent on the time of 
collection of tissues, and we usually only have one time point to measure the expression 
of circadian genes. In an ideal situation we would like to have several time points over 
the day to obtain a 24-hour circadian rhythm, and future research needs to focus on 
a way to display circadian rhythm in patients without the need for surgical resection 
specimen. Chronotherapy consists of the administration of drugs at a specific moment 
of the day in order to minimize the side-effects and cause damage predominantly to the 
malignant cells (35). Over the last years it has been shown that treatment at a specific cir-
cadian time might improve drug tolerance, the activity of anti-cancer drugs, and inhibit 
cancer progression (36, 37). More randomized controlled trials should be conducted to 
investigate the added value of chronomodulated therapy for cancer patients.
The data described in this thesis demonstrate that a short term fasting regimen of 3 
days protects against irinotecan induced side-effects, while a similar reduction of tumor 
size was found in fasted and ad libitum fed treated groups. Irinotecan was used in these 
studies, because it is known for its severe toxicity also in non-cancerous cells. However, it 
remains unknown if fasting also protects against the adverse effects of other anticancer 
drugs. Therefore, further research is needed.
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Translation of the results of fasting prior to chemotherapy from animal studies to the 
clinical setting poses a challenge. We showed that 3 days of fasting protected against 
the side-effects of irinotecan. Mice, however, have a metabolic rate that is approximately 
7 times higher than that of humans (38). This suggests that the fasting period in hu-
mans should be prolonged by 7 times to obtain the same results. A fasting period of 3 
weeks seems impossible. DR of 3 days 30% restriction and 1 day fasting pre-operatively 
has been shown to be feasible and safe in humans undergoing surgery (39). A fasting 
regimen is found to be more difficult and controversial. However, in a case reported 
study of 10 patients who voluntarily fasted prior to different chemotherapy regimens, 
less side-effects were reported, and subjective wellbeing improved (31). Recently, we 
started a pilot study to investigate the feasibility, pharmacokinetics, and effects of a 
short-term dietary restriction regimen given before second line irinotecan treatment in 
CRLM patients. More clinical trials are required to explore the possible beneficial effects 
of dietary interventions. We should keep in mind that cancer patients are often malnour-
ished and already lost a substantial amount of weight before the start of chemotherapy. 
Restricting these patients from a balanced diet may cause morbidity and mortality. To 
overcome the problem of undernutrition in cancer patients, pharmacological mimetics 
that induce the beneficial effects of fasting without the disadvantages of fasting should 
be developed. Our microarray analysis data may be used to identify more differences in 
gene expression patterns and may reveal additional pathways that are involved in the 
beneficial effects of fasting, which may aid in finding a DR mimetic.
In the final part of this thesis we attempted to unravel some of the underlying mecha-
nisms of the beneficial effects of fasting, and therefore we investigated transcriptional 
responses using microarray technology of fasting and irinotecan treatment in CRLM and 
liver tissue in mice. We found that fasting reduced toxicity of irinotecan and it induced 
a protective stress response in healthy liver tissue. Furthermore, fasting preserved the 
anti-tumor activity on a transcriptional level. It is thought that the up-regulation of 
protective pathways by normal cells e.g. the Nrf2 pathway, is involved in the protection 
against oxidative stress (23, 27). However, Nrf2 knock-out mice still exhibited the protec-
tive effects after DR, therefore more research need to be conducted on the role of Nrf2 
in the protective effects of DR (40). Raffaghello et al. introduced the phenomenon that 
cancer cells are unable to obtain a protected state by DR, which he coined differential 
stress sensitization. It is based on the fact that cancer cells have acquired a number of 
mutations that decrease their opportunities to adapt to DR (28, 29). Although some 
of the mechanisms by which DR induces its protective effects are now known, further 
studies are warranted to fully understand the complex molecular response to dietary 
restriction.
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In conclusion, the use of differential circadian gene expression between cancerous 
tissue and host tissue, and the beneficial effects of fasting prior to chemotherapy are 
promising strategies to optimize chemotherapeutic treatment in CRLM patients. Future 
research is needed to fully clarify the role of the circadian clock and dietary interventions 
in cancer patients.
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Colorectaal carcinoom (CRC) is volgens recente cijfers de op twee na meest voorko-
mende kankersoort bij mannen en de op één na meest voorkomende soort bij vrouwen 
wereldwijd (1). Bij ongeveer 20% van de patiënten zijn reeds metastasen op afstand aan-
wezig tijdens het stellen van de diagnose (2). De lever is veruit de meest voorkomende 
plaats voor metastasen, en ongeveer 50% van de patiënten met CRC zal colorectale le-
vermetastasen (CRLM) ontwikkelen (3, 4). In de afgelopen 30 jaar heeft de behandeling 
van CRLM grote veranderingen ondergaan. Patiënten die in het verleden ongeneeslijk 
ziek werden verklaard, zijn nu beter te behandelen met de multimodaliteit aanpak. Deze 
aanpak bestaat uit het combineren van verschillende chemotherapeutische middelen 
om zo voorheen niet operabele tumoren te verkleinen en alsnog chirurgisch te ver-
wijderen. Op het moment dat chemotherapie werd geïntroduceerd voor CRLM was de 
behandeling gebaseerd op toediening van 5-fluorouracil en was de totale overleving 6 
tot 10 maanden. De ontwikkeling van chemotherapeutische middelen zoals irinotecan 
in combinatie met de multimodaliteit aanpak verbeterde de algemene overleving tot 
maximaal 24 maanden. De extreme toxiciteit van chemotherapeutische middelen is een 
belangrijke beperking voor het gebruik. Er zijn verschillende ernstige bijwerkingen van 
irinotecan die vaak leiden tot het vroegtijdig beëindigen van de behandeling. Zodoende 
is er een dringende behoefte aan verdere optimalisatie van de chemotherapeutische 
behandeling om bijwerkingen te verminderen en om hogere doseringen te tolereren. 
In dit proefschrift is de rol van de circadiane klok en van vasten onderzocht met als 
uitgangspunt de chemotherapeutische behandeling van CRLM te verbeteren.
Hoofdstuk 2 biedt de uitkomsten van een literatuurstudie naar de rol van de circadiane 
klok in abdominale kankersoorten. mRNA expressieniveaus van meerdere circadiaan ge-
reguleerde genen waren verstoord in tumor weefsel in vergelijking met gezond weefsel. 
Circadiane genen als PER1, PER2 en PER3 vertoonden consequent minder expressie in 
tumoren van verschillende soorten kanker. Er zijn nieuwe behandel schema’s ontwik-
keld om de afwijkende expressie van meerdere circadiane en circadiaan gereguleerde 
genen bij kanker te benutten. Chronotherapie is hier een voorbeeld van en bestaat uit 
het toedienen van chemotherapeutische middelen op basis van het biologische ritme 
(5, 6). Het perfecte tijdstip van toediening zou zijn wanneer de tumor het meest actief is 
en het omliggende gezonde weefsel het minst actief. In een recent klinisch onderzoek 
is aangetoond dat chronotherapeutische toediening van irinotecan, oxaliplatin en 5-flu-
orouracil via hepatische arteriële infusie bij zwaar voorbehandelde patiënten mogelijk 
is. De behandeling bleek goed te verdragen en leidde tot een verdubbeling van secun-
daire resectie bij patiënten met voorheen inoperabele CRLM (7, 8). We concludeerden 
dat veel circadiane (gereguleerde) genen verlaagd tot expressie komen in tumorweefsel 
van verschillende soorten abdominale kanker.
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In hoofdstuk 3 zijn 24-uurs mRNA expressieniveaus van essentiële circadiane-, en circa-
diaan gereguleerde genen in lever en nieren van gezonde controlemuizen vergeleken 
met die van muizen die C26 colorectale lever metastasen hadden. Metastasen in de lever 
werden geïnduceerd door injectie van C26 colorectaal carcinoom cellen in de milt. Om 
tumorgroei in de milt te voorkomen werd deze 10 minuten na injectie verwijderd. Tu-
moren kregen de kans om drie weken te groeien, waarna in een 24-uurs schema tumor, 
lever- en nierweefsel werd geoogst om expressie van circadiane genen te vergelijken. 
Met behulp van qRT-PCR werd een normaal 24-uurs ritme van alle klokgenen in lever 
en nierweefsel gevonden. In CRLM was het 24-uurs ritme afwezig voor alle klokgenen 
behalve voor Cry1. Tevens was er een significant verminderde expressie van output 
genen zoals Dbp. Daarnaast zagen we een faseverschuiving van de circadiane klok in 
gezond lever en nierweefsel van tumordragende dieren. In de lever zagen we een fase-
versnelling terwijl we in de nier een fasevertraging zagen. Dit wijst op een systemisch 
effect. We concludeerden dat de circadiane klok ernstig verstoord is in CRLM. Een nuttig 
vervolg onderzoek zou zijn om te onderzoeken hoe de faseverschuiving tussen lever en 
nierweefsel wordt veroorzaakt. Het is bekend dat tumorcellen verschillende mediatoren 
uitscheiden zoals TGF-β. Deze zijn in staat de circadiane klok te moduleren door active-
ring van de ALK-Smad3-DEC1 route (9).
Vervolgens hebben we onderzocht of deze verschillen in circadiaan ritme ook aanwezig 
waren in patiënten met CRLM. In hoofdstuk 4 hebben we chirurgische resectie pre-
paraten van 15 patiënten met primair CRC en CRLM onderzocht. Van 10 verschillende 
klokgenen is de mRNA expressie vergeleken in primair CRC, CRLM en leverweefsel van 
dezelfde patiënt. Klokgenen die onderzocht zijn CLOCK, BMAL1, PER1, PER2, PER3, CRY1, 
CRY2, CSNK1E, TIM en TIPIN. Zeven van deze klokgenen vertoonden een verminderde 
mRNA expressie in CRLM, terwijl in CRC vijf klokgenen verminderde mRNA expressie 
vertoonden. Alleen CSNK1E vertoonde een hogere mRNA expressie in CRC. CSNK1E 
codeert voor het eiwit CKIε en een van de belangrijkste functies is het reguleren van het 
circadiane ritme door fosforylering en afbraak van PERIOD genen (10). CKIε speelt een 
essentiële rol bij de vroege ontwikkeling van CRC (11-13). Ook is onderzocht of er rela-
ties bestaan tussen de genexpressie niveaus van CRC en CRLM patiënten en klinische en 
pathologische factoren. Er bestond een significante correlatie tussen het geslacht en de 
expressie van CRY1 in CRLM. Bij vrouwelijke patiënten werd een lager mRNA expressie 
niveau van CRY1 gevonden. Tevens vonden we dat een lage PER3 expressie correleerde 
met een groter aantal metastasen. In andere studies zijn ook correlaties aangetoond 
tussen circadiane genexpressie en klinische en pathologische factoren. Mazzoccoli et 
al. toonden een significant verband tussen lage CRY1 expressie in tumorweefsel en een 
hogere tumor gradering, oudere leeftijd en het vrouwelijk geslacht. De overleving was 
echter beter in CRC patiënten met een lagere CRY1 en CRY2 expressie in tumorweefsel 
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(14, 15). Deze resultaten zijn ook gevonden in een studie waaruit bleek dat een hoge 
CRY1 expressie in de tumor gecorreleerd was aan een slechtere overleving in CRC pati-
enten (16).
In hoofdstuk 5 is zijn we begonnen met het onderzoeken van de positieve effecten 
van calorische restrictie (DR) op de bijwerkingen van chemotherapie. Er zijn steeds 
meer aanwijzingen dat DR, mits goed getimed en gedoseerd, de weerstand tegen 
stress van patiënten kan verbeteren. Vermindering van de voedselinname van ongeveer 
30% tijdens het leven is een krachtig middel om resistentie tegen meerdere stressoren 
te verhogen en de levensduur van verschillende organismen te verlengen (17-22). In 
eerder onderzoek, uitgevoerd in ons laboratorium, is aangetoond dat kortdurende di-
eetinterventies en vasten beschermen tegen acute oxidatieve schade in nieren en lever 
(23-26). De bescherming werd in verband gebracht met een verhoogde aanwezigheid 
van cytoprotectieve en anti-oxidant genen. In deze studie is het effect van vasten op 
de bijwerkingen van irinotecan in een FabplCre;Apc15lox/+ muismodel onderzocht. Dit 
genetisch gemodificeerde muizenmodel zorgt ervoor dat de muizen spontaan tumoren 
in het darmstelsel krijgen. In dit model hebben wij gevonden dat dat 3 dagen vasten 
beschermt tegen het ontstaan van ernstige bijwerkingen bij het gebruik van irinotecan. 
In zowel gevaste als ad libitum gevoede dieren vonden we een gelijke tumorreductie. 
Daarnaast was er een significante afname in celcyclusactiviteit, proliferatie en angioge-
nese, terwijl markers voor senescence verhoogd waren in zowel gevaste als ad libitum 
gevoede groepen. Eerder onderzoek toonde aan dat 3 dagen vasten de stressbestendig-
heid verhoogd, onder andere door verhoogde expressie van Nrf2, welke betrokken is 
bij de bescherming tegen oxidatieve stress (23, 27). In tegenstelling tot de verhoogde 
expressie van beschermende routes in normale cellen, wordt gedacht dat kankercellen 
niet in een beschermende toestand kunnen komen door dieetrestrictie. Dit verschijnsel 
wordt ‘differential stress sensitization’ (DSS) genoemd en is gebaseerd op het feit dat 
kankercellen een aantal mutaties ondergaan waardoor ze zich niet meer kunnen aan-
passen aan dieetrestrictie (28, 29).
Om onze bevindingen verder uit te breiden en op zoek te gaan naar het mechanisme 
hierachter, zijn de experimenten in hoofdstuk 6 ontworpen. Nogmaals onderzochten 
we het effect van vasten op de bijwerkingen en anti-tumor effect van een hoge dosis 
irinotecan. In deze experimenten is ook de farmacokinetiek van irinotecan onderzocht. 
C26 coloncarcinoomcellen werden subcutaan geïnjecteerd in de flanken van BALB/c 
muizen en groeiden uit tot subcutane tumoren. De resultaten bevestigden dat 3 dagen 
vasten vóór behandeling met irinotecan bijwerkingen voorkomt, terwijl de anti-tumo-
ractiviteit niet werd beïnvloed. De actieve en toxische metaboliet van irinotecan, SN-38 
was significant lager aanwezig in plasma en lever weefsel van muizen die gevast hadden. 
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Daarentegen waren de concentraties van SN-38 in de tumor van gevaste in ad libitum 
gevoede dieren niet verschillend. Deze resultaten geven aan dat vasten een verandering 
teweeg brengt in het metabolisme van irinotecan en zo de systemische blootstelling 
aan SN-38 verminderd. Resultaten uit voorgaande studies suggereren dat het toepassen 
van vasten in de kliniek veel potentie heeft (28-34). Dit is echter een uitdagend proces. 
Om dit te bereiken zal een beter begrip nodig zijn van de verschillende pathways en 
genen die betrokken zijn bij de inductie van bescherming door vasten.
In hoofdstuk 7 is de transcriptionele respons na vasten van muizen die behandeld 
waren met irinotecan onderzocht met behulp van microarrays. BALB/c muizen werden 
subcutaan geïnjecteerd met C26 colorectale carcinoomcellen. Na 12 dagen tumorgroei 
werden twee groepen muizen gevast voor 3 dagen en twee groepen werden ad libitum 
gevoed. Vervolgens ontving één van deze groepen irinotecan behandeling, de andere 
groepen kregen vehiculum. Twaalf uur na injectie met chemotherapie werden de mui-
zen opgeofferd en werd bloed, lever en tumorweefsel verzameld. Microarray analyses 
van tumor en leverweefsel werden uitgevoerd. Resultaten toonden dat 3 dagen vasten 
voorafgaand aan irinotecan behandeling de bijwerkingen vermindert via downregulatie 
van genexpressieprofielen in de lever en activering van een cellulaire stressrespons. Een 
aantal specifieke sets van genen die betrokken zijn bij schade aan de lever en toxiciteit 
waren afgenomen als gevolg van het vasten. Deze bevindingen ondersteunen de DSS 
theorie, die stelt dat kankercellen zich niet kunnen aanpassen aan een beschermde 
toestand door calorische restrictie (29). We concludeerden dat de resultaten bijdragen 
om onze kennis over de mechanistische processen die ten grondslag liggen aan DR te 
vergroten. Met meer onderzoek naar de gunstige effecten van DR kunnen we uitein-
delijk op zoek gaan naar een mimeticum dat deze effecten kan induceren zonder te 
hoeven vasten.
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dankwoord
Dit proefschrift is tot stand gekomen dankzij de steun, hulp en inzet van velen. Een 
aantal mensen wil ik in het bijzonder noemen, omdat zij nóg meer dan anderen hebben 
bijgedragen aan de totstandkoming van dit proefschrift.
Mijn copromotor, dr. R.W.F. de Bruin, beste Ron, tijdens mijn co-schappen kreeg ik de tip 
met jou contact op te nemen voor het doen van onderzoek binnen de Heelkunde. Kijk 
eens wat daarvan terecht is gekomen. Jij bent het brein achter dit onderzoek. Dank voor 
al het geduld en de mooie tijd op het lab. Naast de basale wetenschap hebben we ook 
erg veel gelachen. De congressen waren legendarisch. Laten we binnenkort weer een 
whisky drinken samen.
Mijn promotor, professor J.N.M. IJzermans, beste Jan, ik kan me onze kennismaking 
nog goed herinneren. Toen bleek dat we beide op school hebben gezeten in Bergen op 
Zoom, was het ijs snel gebroken. Ik wil je voornamelijk bedanken voor de vrijheid die ik 
de afgelopen jaren van je kreeg. Tijdens overleg wist je altijd die ene vraag te stellen die 
mij weer extra alert en enthousiast maakte.
Professor A.H.J. Mathijssen, beste Ron, de samenwerking tussen de labs ontstond 2 jaar 
nadat ik begon met mijn onderzoek. Dit had vanaf het begin al zo moeten zijn. De frisse blik 
waarmee jij naar onderzoek kijkt is prachtig. Altijd heb je goede ideeën en ben je bereikbaar 
voor overleg. Ik weet zeker dat ook de klinische studie een succes zal worden! Ook bedankt 
voor het deelnemen aan de kleine commissie, jammer dat je er op 3 juni niet bij kunt zijn.
Professor G.T.J. van der Horst, beste Bert, je kennis over de klok is groot en heeft een 
belangrijke bijdrage aan mijn proefschrift geleverd. Ik heb veel van je mogen leren, dank 
hiervoor. Dank ook voor je laagdrempeligheid en de prettige samenwerking tussen de 
labs. Fijn dat je zitting wilt nemen in mijn promotie commissie.
Dr. M.J.M. Smits, beste Ron, dank voor de samenwerking en het gebruik maken van het 
Apc-model. Mooie experimenten hebben we gedaan en talloze tumoren samen geteld. 
Als derde Ron was je van onmiskenbare waarde.
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Overige leden van de kleine en grote commissie, hartelijk dank voor het beoordelen van 
mijn proefschrift en het zitting nemen in de commissie.
Dr. T.M. van Ginhoven, dr. JW. van den Berg, lieve Tessa en Jan Willem, jullie blijven mijn 
labouders. Van jullie heb ik de kneepjes van het labwerk mogen leren. Dank voor alles. Ik 
hoop nog eens met jullie samen in de kliniek te mogen werken.
Collega’s van het laboratorium voor experimentele chirurgie, laboratorium voor me-
dische oncologie en laboratorium voor genetica, jullie wil ik bedanken voor de mooie 
tijden en de hulp bij alle experimenten. Mariëlle, Juliette, Eva, Konstantinos, Shushimita, 
Simone, Ruth, Zhouqiao, Sandra, Gisela, Wendy, Henk, Filippo, Gosha, Peter, Inge en Erik, 
bedankt. Tanja en Eline, vanaf het begin waren wij labje #1, en wat hebben we gelachen. 
Ik zal nooit vergeten hoe jullie me in de maling namen met die ene brief. Artikel 9 certi-
ficaat moet ik trouwens nog steeds ophalen. Franny, Stef en Jeroen, de laatste fase was 
met jullie. Veel succes met het afronden van jullie proefschrift. Franny, veel dank voor de 
samenwerking en de gezelligheid tijdens o.a. het tumor array experiment. Beste Ali, wat 
fijn dat jij me zo goed geholpen hebt bij meerdere experimenten. Hopelijk zijn we je niet 
volledig kwijt aan het Amerikaanse onderzoek.
Alle mede-onderzoekers in de Z-flat en daarbuiten, dank voor de mooie momenten 
tijdens lunches, borrels en congressen. Als je het als onderzoeker even niet meer zag 
zitten, keek je gewoon even wanneer de volgende borrel was.
Graag wil ik alle chirurgen en arts-assistenten uit het Ikazia ziekenhuis bedanken voor 
de geweldige en leerzame tijd. Met name dr. P.T. den Hoed. Beste Ted, de daadwerkelijke 
bevestiging dat ik chirurg wilde worden kwam door jou.
Beste chirurgen en arts-assistenten uit het Franciscus ziekenhuis, enorm blij ben ik dat ik 
mag leren opereren in dit prachtige ziekenhuis. Er zullen de komende jaren veel mooie 
momenten volgen. Zo zal de skireis 2017 legendarisch worden!
Mijn paranimfen, Freek en Wouter. Freek, als studiegenoot, dispuutsgenoot, clubgenoot, 
maar vooral als heel goede vriend wist jij de afgelopen jaren precies waar ik mee bezig 
was. Dank dat je ook nog mijn paranimf wilt zijn. Wouter, grote broer en vriend, Kneeke, 
erg trots en dankbaar ben ik dat je mijn paranimf wilt zijn.
Arno, Thomas, Muis, Jordy, Geert, Freek, Jurriaan en Marijn, mijn beste vrienden. Dank 
voor de ondersteuning. Er komen nu nog meer pilsmomenten aan.
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Lieve Jolijn, mijn kleine zusje die ook geneeskunde is gaan studeren. Volgend jaar ben je 
klaar. Ik weet zeker dat je een erg goede en lieve dokter zal zijn. Ik ben trots op je.
Lieve papa en mama, door de kansen die ik van jullie heb gekregen kon ik gaan studeren 
en uiteindelijk promoveren. Altijd staan jullie voor me klaar. Alles wat we met elkaar 
doen is een feestje en altijd als ik thuis kom is het volop genieten. Ik heb veel bewonde-
ring voor jullie.
Tot slot, lieve Renate, wat ben ik ongelooflijk gelukkig met jou. Jouw steun en liefde 
hebben ervoor gezorgd dat er altijd iets leuks was om naar uit te kijken. Enorm bedankt 
voor het ontwerpen van de prachtige omslag, beter had het niet gekund. Het leven is 
prachtig met jou en we gaan er nog zó lang van genieten!!
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Sander Arjan Huisman was born on November the 18th of 1985 in Bergen op Zoom, The 
Netherlands. A large part of his youth, he grew up on the island Curaçao. After graduat-
ing from high school at R.S.G ‘t Rijks secondary school in Bergen op Zoom in June 2004, 
he started medical school at the Erasmus University Rotterdam. During medical school, 
he worked as a student assistant and tutor teaching surgical anatomy in extra-curricular 
classes to students. During his study, he did an internship at the department of Surgery 
at the St. Elisabeth Hospital in Curaçao. In 2010 he performed research at the Depart-
ment of Surgery, Laboratory of Experimental Surgery, Erasmus University Rotterdam 
(dr. R.W.F. de Bruin). In November 2010, he graduated from medical school, after which 
he started working as a PhD candidate at the Department of Surgery at the Erasmus 
University Medical Center in Rotterdam, under supervision of prof. dr. J.N.M. Ijzermans 
and dr. R.W.F. de Bruin. His studies focused on optimizing chemotherapy for colorectal 
liver metastases, which has resulted in this thesis. In November 2014 he started working 
as a surgical resident at the Department of Surgery at the Ikazia Hospital in Rotterdam 
(dr. P.T. den Hoed). In January 2016, he started his surgical training at the Franciscus 
Hospital (dr. T.M.A.L. Klem) and the Erasmus MC (dr. B.P. Wijnhoven).
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Summary of PhD training and teaching activities
Name PhD student: Sander A. Huisman PhD period: 01-11-2010 – 01-11-2014
Erasmus MC Department: Surgery Promotor(s): Prof.dr. J.N.M. IJzermans
Research School: Molecular Medicine Co-promotor: Dr. R.W.F. de Bruin
1. PhD training
Year Workload (ECTS)
General academic skills
- Biomedical English Writing (short) 2011 2.0 
- Biomedical English Writing and Communication 2013 5.7 
- Laboratory animal science 2011 5.7 
- Classical methods for data-analysis 2011 5.7 
Research skills
- Basic introduction course on SPSS 2011 1.0 
- Basis cursus oncologie (NVvO) 2013 3.0 
Presentations
- National conferences 2011 3.0 
 2012 4.0 
 2013 2.0 
   
- International conferences 2011 1.0 
2012 1.0 
2013 2.0 
2014 1.0 
Seminars and workshops
- Photoshop and Illustrator CS4 workshop 2011 0.3 
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2. Teaching activities
Year Workload (ECTS)
Supervising practicals and excursions, Tutoring
- Supervising first aid examinations (Medical students) 2012 0.2 
- Supervising first aid examinations (Medical students) 2013 0.2 
- Supervising first aid examinations (Medical students) 2014 0.2 
Supervising Master’s theses
- Supervising enthusiastic students in the lab 2012/2014 5.0 
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